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Abstract: 
 
 
As many tumours are poorly immunogenic, one approach for cancer therapy aims to improve 
natural anti-tumour immunity. Recently it has been shown that anthracycline-induced 
apoptosis in tumour cells results in the relocation of the ER resident chaperone calreticulin to 
the cell surface. Interestingly, this relocation directly stimulates T cell-mediated anti-tumour 
immunity following tumour cell phagocytosis by dendritic cells. In addition, evidence from 
medullary carcinoma of the breast patients shows a correlation between tumour-infiltrating B 
cells and a more favourable prognosis. Surprisingly, many of these infiltrating B cells recognise 
proteins relocated from their normal intracellular distribution to the tumour cell surface, also 
as a result of apoptosis. 
As B cells have recently been shown to be an important population of antigen presenting cells 
capable of extracting membrane antigens from target cells, these findings raise the possibility 
that tumour infiltrating B cells may be capable of presenting tumour antigens promoting the 
generation of anti-tumour immunity. In particularly, this thesis envisages that following 
apoptosis induction in tumour cells, antigen specific B cells will be able to acquire relocated 
tumour antigens, therefore directly promoting antigen-specific T cells.  
To provide a proof of principle I have characterized the processes involved in the extraction of 
membrane-tethered antigens by B cells from target cells using flow cytometry and a novel 
proliferation bio-assay. Unexpectedly, surface antigen acquisition by B cells has been 
demonstrated to be rapid, proceeding in times as short as 1 min. Furthermore, I have also 
characterised the processes involved in the relocation of antigens to the cell surface of dying 
target cells from various intracellular locations using anthracyclines and UVC as immunogenic 
apoptotic agents. This has allowed me to demonstrate that antigens from several intracellular 
compartments following apoptosis induction are acquired by antigen-specific B cells. 
Importantly, this antigen acquisition was sufficient to induce CD4+ T cell activation as 
confirmed by proliferation assay.  
These in vitro findings demonstrate that B cells are capable of activating CD4+ T cells following 
interaction with apoptotic target cells. Therefore, further investigations concerning the role of 
B cells in natural anti-tumour immunity may improve current anti-cancer therapies.  
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-  1. Introduction  - 
 
 
1.1. The role of immune system in tumour control  
 
1.1.1. Cancer as a global problem 
 
Until the late twentieth century, little progress had been made in understanding the 
mechanisms involved in the development of cancer. The death rate for cancer dropped by only 
5% between 1950 and 2005. In contrast, the death rate for heart disease dropped 64% at the 
same time, and for flu and pneumonia it fell by 58%. The World Health Organization predicts 
that by 2010 more than 12 million people will die due to cancer. Such a negative prognosis for 
patients is the result of the multi-complexity of cancer in comparison to other diseases. In 
particular, cancer is characterised by three malignant properties which change during the time 
of cancer growth.  
The first property is pro-tumourogenic alteration that starts to occur in a healthy tissue. This 
step can include the uncontrolled growth of cells due to various mutations in growth factor 
receptors or in signalling pathways and unresponsiveness for inhibitory signals. The second 
property of tumour development is characterised by the invasion of nearby tissue which 
results in tissue damage. Finally, tumour metastasis allows cancer to spread to other organs via 
lymph or blood.  
Therefore, there is a great need for better understanding of the complexity of cancer biology 
which will help to improve current anti-cancer therapies. This includes clinical treatment such 
as gene therapy, chemotherapy or surgery. The multiplicity of the biology of most cancers 
along with many deficiencies of current clinical practices still prevents this disease from being 
cured, although great improvements have been made by introducing many prevention 
screening programs.  
More recently, scientists have tried to understand the natural mechanisms by which the 
immune system can modulate tumour growth and have attempted to use these approaches to 
cure cancer. These methods are based on the natural function of the immune system to 
protect the body against invading pathogens. Importantly, such approaches are based on the 
fact that the immune system is also capable of recognising unhealthy or abnormal mammalian 
cells such as tumour cells leading to their elimination. Therefore, many recent studies have 
focused largely on how to improve natural mechanisms involved in anti-tumour immunity 
which hopefully will prove less harmful and more effective than current treatment.  
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1.1.2. The tumour microenvironment 
 
The microenvironment of a developing tumour is comprised of proliferating cells, the tumour 
stroma, blood vessels, infiltrating inflammatory cells and a variety of associated tissues. It is 
created and shaped by the tumour, but also by cellular events which take place in the 
surrounding tissues (Micalizzi and Ford, 2009).  
Immune cells that infiltrate the tumour site include effector cells of innate immunity such as 
dendritic cells (DC), macrophages, natural killer (NK) cells along with B and T lymphocytes. 
Inflammatory cells present in the tumour microenvironment can either contribute to tumour 
rejection or may paradoxically promote tumour growth. Specifically, many of these tumour-
promoting cells are directly modified by the tumour itself creating a tumour-favourable 
microenvironment. For example, tumour-associated macrophages or DC can either secrete 
special immunosuppressive reagents that inhibit T cell function or produce growth factors that 
promote tumour survival (Melief, 2008). These observations have clearly convinced scientists 
that tumours do not represent simple passive targets for host immunity. Instead, cancer cells 
actively downregulate or suppress many phases of anti-tumour immunity using a spectrum of 
different strategies consequently leading to poor immunogenicity and immunesurveillance of 
many tumours that will be discussed in Section 1.2.  
Another important aspect for understanding the biology of tumour development is the 
interaction between cancer cells and the surrounding stroma. There is a cross-talk between 
the tumour cells, the extracellular matrix, fibroblasts and other mesenchymal cells in the 
supporting stroma. This contact results in formation of a scaffold-supporting environment 
which is conducive with tumour expansion. Subsequently, tumours become vascularised as a 
result of secretion of angiogenesis growth factors such as fibroblast growth factor, vascular 
endothelial growth factor or platelet-derived growth factor by tumour-associated cells (Zhang 
et al., 2009b) (van Zijl et al., 2009). These factors also activate bystander endothelial cells to 
proliferate and to build channels further supporting tumour growth. Also, the proteolytic 
enzymes, which are present in this microenvironment, allow the degradation of components 
of the extracellular matrix (fibronectin, laminin or collagens) essential for tumour metastasis. 
For example, it has been shown in several types of tumour (skin, breast, lung and colon 
cancers) that the level of expression of various proteases such as plasminogen activator, 
cathepsin, collagenase, stromelysin is upregulated. In most of these cases, the upregulation of 
these enzymes correlates with a higher tumour grade to metastasis and invasion (De Wever 
and Mareel, 2003).  
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1.1.3. The immune recognition of tumour cells  
 
The mammalian immune system has evolved to protect against invading organisms ranging 
from viruses to multi-cellular organisms. However, it has been suggested that tumours have 
also played a role in defining immune recognition strategies (Seymour et al., 1999) (Pettit et 
al., 2000). As a consequence of adapted changes, immunological responses are mainly based 
on the identification and neutralisation of specific pathogen-encoded molecules and the 
destruction of malignant cells.  
In general, immune recognition is now known to consist of two distinct responses: innate and 
adaptive immunity based on antigen specificity and timing, which are discussed below. 
 
 Innate immunity 
Innate immunity is rapidly activated when pathogens try to invade the body. This non-specific 
response is the first line of defence that blocks the entry and spread of disease-causing agents. 
Innate immunity involves the release of soluble mediators such as cytokines, chemokines and 
reactive oxygen species (ROS). These bioactive mediators are produced mainly by DC, NK cells, 
macrophages, neutrophils, eosinophils, basophils and masts cells. In particular, when tissue 
homeostasis is perturbed or undergoes neoplasmatic modifications, tissue-resident 
macrophages and mast cells secrete cytokines, chemokinases that recruit leukocytes from the 
circulation into the affected tissue (de Visser and Coussens, 2006). In addition, recruited NK 
cells directly kill tumour cells in situ. They can eliminate tumour cells using two mechanisms 
that require direct cellular contact. Firstly, NK cells secrete granules that contain perforins - 
membrane disrupting molecules and granzymes - pro-apoptotic serine caspases involved in 
DNA fragmentation of target tumour cell (Chan and Housseau, 2008). The second pathway is 
mediated through pro-apoptotic members of the tumour necrosis factor (TNF) family. This 
family includes FasL and TNF-related apoptosis inducing ligand (TRAIL/Apo2L). The mechanism 
by which TRAIL and FasL induce cell death involves the recruitment of their receptors, TNFR 
and Fas respectively. Following binding to these receptors, downstream serine caspases are 
activated. Caspases (cysteine proteases) are involved in DNA fragmentation and participate in 
apoptotic cell death (Ames et al., 2009). This process will be described in more detail in Section 
1.5.  
Simultaneously, macrophages and DC, which are termed antigen-presenting cells (APC), are 
involved in the uptake of available antigen or the engulfment of apoptotic cells for 
presentation to T lymphocytes. Several subsets of DC have been defined, including myeloid-
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DC, plasmacytoid-DC and Langerhans cells. Not surprisingly, DC can also infiltrate several types 
of tumours and function as scavenger cells that contain tumour associated antigens (TAA). 
Following antigen encounter, DC migrate to specific sites within lymphoid organs where they 
interact with naive T cells providing the initial activation stimuli that leads to the induction of 
full anti-tumour immunity (Miller et al., 2004).  
It has been shown that tumour infiltration by DC results in a more favourable prognosis for 
brain and lung cancer patients via the activation of cytotoxic T cells (CTL) which then directly 
kill tumour cells. (Palamara et al., 2004). In particular, stimulation of Toll-like receptors (TLR) 
on DC by agonists leads to the upregulation of costimulatory molecules and to the production 
of anti-tumour cytokines such as interferon- (IFN-) and interleukin-12 (IL-12). Such pro-
inflammatory cytokines induce CTL activity leading to effective killing of tumour cells. 
Therefore, cytokines produced by TLR-activated DC stimulate effector cells and may represent 
a useful approach to developing a more effective immunotherapy (Mitchell and Sampson, 
2009). Furthermore, recent studies have demonstrated that following irradiation or 
anthracycline-treatment, dying tumour cells induce the maturation of DC and enhance antigen 
presentation to tumour-specific CTL. This mechanism will be described in more detail in 
Sections 1.3.4. and 1.3.5. Nevertheless, the role of DC is controversial because of their bivalent 
nature of DC in many tumour microenvironments. Although, DC can mediate efficient anti-
tumour immunity, there are many examples where DC actively promote tumour survival 
(Fricke and Gabrilovich, 2006). Therefore, more studies focusing on the role of DC in anti-
tumour immunity need to be carried out.   
 
 Adaptive immunity  
Upon exposure to a pathogen, the innate arm of the immune system is engaged non-
specifically. This is an important initial step in clearing the pathogen; however adaptive 
immunity is required to generate a more specific and efficient response that eliminates the 
pathogen. In particular, adaptive immunity has the capacity to recognise unique components 
of individual pathogens. This is achieved by expression of an array of unique antigen receptors 
on the surface of specialised immune cells termed lymphocytes. These receptors are 
generated by random gene rearrangements and allow a diverse flexible response to invading 
pathogens. In addition to the specific recognition of pathogen-derived antigens, these 
receptors are also capable of recognising antigens expressed by both normal mammalian cells 
as well as cells undergoing tumorogenesis which may result in the synthesises of novel or ‘neo’ 
antigens. Therefore, in healthy individuals there are several processes that ensure 
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lymphocytes expressing antigen receptors reactive with proteins expressed by normal healthy 
cell are either physically removed or inactivated. Furthermore, another defining feature of 
adaptive immunity is the generation of pathogen-specific memory lymphocytes. Following 
pathogen re-exposure, the presence of these cells allows a more robust and rapid immune 
response to take place. Lymphocytes are divided into two subsets (B and T lymphocytes) which 
differ in their response to antigen. Following antigen encounter and subsequent activation, B 
cells secrete their antigen-specific receptor as antibodies (immunoglobulin-Ig) that circulate in 
blood and lymph leading to antigen neutralisation or elimination. The role of B cells in anti-
tumour immunity will be described in Section 1.4. 
In contrast, following antigen encounter the receptor expressed by T cells mediates their 
cellular differentiation into various subsets that play a central role in cell-mediated immunity. 
By responding to fragments or small peptides derived from antigens which have either entered 
mammalian cells or are synthesised by intracellular pathogens, T cells provide homeostatic 
immunosurveillance. Also in contrast to antigen recognition by B cells, these antigenic 
fragments are recognised in the context of molecules encoded by the major histocompatibility 
complex (MHC). Based on which class of MHC molecule is recognised, T cells can be divided 
into two subsets consisting of CD8+ CTL and CD4+ T helper (Th) cells. 
CD8+ T cells are the major effector cells which recognise altered cells including those infected 
with intracellular parasites, stressed cells producing altered proteins or tumour cells 
expressing neo antigens. MHC class I molecules are expressed on every nucleated cell and bind 
and present peptides of 8–10 amino acid residues in length, which are largely derived from the 
degradation of cytosolic proteins to CD8+ T cells. Recognition of these antigenic peptide-MHC 
complexes provides activation signals for the differentiation of these cells into CTL that 
consequently kill the peptide/MHC expressing target cells. For this reason, CTL are not limited 
to detection of abnormal protein synthesized in the cell, but can be greatly expanded for the 
range of tumour antigens expressed intact on the cell surface. Therefore, numerous reports 
have described the beneficial role of cytotoxic CD8+ T cells that induce anti-tumour immunity. 
For example, in many types of tumours including melanomas (Hirohashi et al., 2009), lung 
carcinomas (Mami-Chouaib et al., 2002), primary breast tumours (Liu et al., 2009) or prostate 
cancers (Kiessling et al., 2008), the occurrence of infiltrating CTLs was directly related to 
tumour shrinkage in patients. Furthermore, in vivo animal studies have shown that adoptive 
transfer of CTL to SCID/NOD mice, which were previously challenged with lung cancer cell 
lines, significantly reduced tumour growth, in comparison to those mice which did not receive 
CTL (Mami-Chouaib et al., 2002). The mechanism of CTL-mediated anti-tumour killing is largely 
 
17 
due to release of perforin and granzymes and the surface expression of FasL. These cytotoxic 
molecules induce cancer cell death via caspase activation. In addition, IFN- secretion by 
activated CTL at the tumour site promotes NK cells activity and increases tumour antigen 
presenting function of DC and macrophages. Moreover, IFN- also stimulates CD4+ T cells to 
clonal expansion (Mata-Espinosa and Hernandez-Pando, 2008).  
CD4+ T cells generally have a role of helper T cells (Th) for other types of cells. This is 
predominantly by the production of cytokines that affect other populations of cells. CD4+ T 
cells recognise MHC class II molecules displaying the peptides of approximately 20 amino acids 
long, which are derived from extracellular proteins, in contrast to the cytosolic proteins 
presented by MHC class I molecules. Therefore, MHC class II-dependent antigen presentation 
is termed endocytic or exogenous pathway. Th cells have been further divided into several 
subsets based on the cytokines that they secrete (pro- or anti-inflammatory) (Borghaei et al., 
2009). One major subset (Th1) is characterised by the secretion of pro-inflammatory cytokines 
such as IFN-, TNF- which function to activate and generate memory CTL. In addition, Th1 
cells activate APC maturation and enhance antigen uptake and presentation. CD4+ T cells also 
promote DC maturation through CD40 ligation which results in surface stabilisation of MHC I-
peptide complexes, upregulation of costimulatory molecules required in signal transduction 
and production of IL-12. Indeed, this advance interaction between CD4+ T cells and DC is 
required for maximal clonal expansion of effector CD8+ T cells, induction of primary responses 
and most memory responses (Wang and Livingstone, 2003). Therefore, cognate interaction 
between CD4+ T cells and DC has the capacity to drive the specific CD8+ T cell-response. This 
interaction determines whether CD8+ T cells move into a state of activation or tolerance. 
Several studies have shown that in the presence of pro-inflammatory cytokines stimulated 
CD4+ T cells are responsible for the delivery of a third signal essential to full activation of CTL 
cells, thereby increasing the efficiency of CTL-mediated anti-tumour immunity (Cools et al., 
2007). 
Th cells can also directly kill tumour cells via the release of cytokines that activate death 
receptors on the tumour cell surface. In particular, Th cells are able to induce the apoptosis of 
tumour cells through Fas/FasL pathway. This mechanism is induced by ligation of Th cell CD40L 
to CD40 expressed on the lymphoma cell surface and subsequently resulted in upregulation of 
Fas on tumour cells (Knutson and Disis, 2005). Furthermore, Nguyen et al. has shown that Th 
cells also mediate tumour killing via mechanisms involving TRAIL and granzyme–perforin-
dependent pathways (Nguyen et al., 2000).  
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These mechanisms demonstrate that as well as the previously described indirect effect of Th 
cells on the modulation of tumour cell death (CTL via activation), these cells are also capable of 
directly triggering multiple death pathways in cancer cells. In addition, Th cells play an 
important role in the generation of long-lived immunity and enhanced CTL-mediated response. 
Therefore, an effective anti-tumour response requires cooperation between APC, Th and CD8+ 
T cells. 
 
 Antigen cross-presentation 
As described, most cells, including tumour cells, express MHC class I molecules and present 
antigens allowing the monitoring of the endogenously synthesised antigens to CD8+ T cells. 
APC (DC, macrophages and B cells) also express MHC class II and have the ability to present 
exogenous antigens via the MHC class II pathway for the priming of CD4+ T cell-mediated 
immunity. In addition, many APC types also have the ability to prime CD8+ T cells by a process 
termed cross-presentation. This was first described in 1976 by M.J. Bevan. His experiments 
showed that mice immunized with cells expressing exogenous antigen, generated specific CTL-
responses as a consequence of antigen presentation by MHC class I molecule (Bevan, 1976). 
Groh at el., has also shown using an in vitro system that DC were able to cross-present tumour 
antigens to CD8+ T cells through MHC class I path resulting in their clonal expansion. Such 
cross-primed CD8+ T cells produced IFN- which led to growth inhibition of several tumour 
cells including breast, melanoma, or ovarian cell lines (Groh et al., 2005). 
It is now known that cross-presented antigens do not always trigger an inflammatory immune 
response (cross-priming) but may also induce tolerance to self-antigens (cross-tolerance). 
Recently, experiments performed by Dudziak and co-workers revealed that differences in the 
cytokine environment may lead to the generation of either tolerance or immunity. They 
showed that the presence of inflammatory cytokines and costimulatory signals, results in 
cross-presentation leading to priming of an inflammatory response. It has also been shown 
that murine CD8+ DC subset efficiently cross-present antigens for CD8+ T cell priming and 
also directly stimulate CD4+ T cells via MHC class II molecules (Dudziak et al., 2007).  
 
 Non-classical antigen recognition  
As well as tumour antigen presentation via classical MHC molecules, some tumour antigens 
are also presented by non-classical molecules representing a third lineage of antigen 
presenting molecules, including MHC class I-related chain A (MICA) and chain B (MICB) surface 
proteins. These unconventional MHC molecules interact with C-lectin activatory receptor 
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(NKG2D) expressed by NK cells,  and  CD8+ T cells. Fiona et al. demonstrated that using 
HSP-90 inhibitors in myeloma cells, the upregulation of MICA and MICB was observed, leading 
to NKG2D ligation that triggered NK cells degranulation and tumour killing (Fionda et al., 2009). 
Also Zhang reported that HeLa and HepG2 tumour cell lines treated with sodium butyrate 
upregulated the expression of MICA and MICB on the surface. This resulted in an enhanced 
susceptibility of tumour cells to NK cell lysis (Zhang et al., 2009a). In addition, other molecules 
such as CD1 proteins also belong to the family of non-MHC-encoded proteins specialized in the 
presentation of hydrophobic antigens including lipids and glicolipid to T cells or NKT cells. It 
has been shown that CD1 plays an important role in the presentation of tumour ganglioside 3 
(GD 3) expressed by melanoma and small-cell lung carcinoma to NKT cells, resulting in better 
anti-tumour immunity (Wu et al., 2003). In contrast, the increased expression of another non-
classical MHC molecule, HLA-G, on the surface of T-cell lymphomas, renal carcinomas (Ibrahim 
et al., 2001) and melanomas (Seliger et al., 2003a) favour their escape from anti-tumour 
immunity. In particular, binding of HLA-G with immunoglobulin-like inhibitory receptors such 
as ILT2, ILT4 and KIR2DL4 resulted in the inhibition of the cytotoxic activity of NK cells and T 
lymphocytes bearing these receptors. In addition, the HLA-G5 soluble protein has been shown 
to trigger apoptosis in activated CD8+ T lymphocytes (Fournel et al., 2000). Similarly to HLA-G, 
also HLA-E expressed on the surface of melanoma cells is correlated with a negative prognosis 
for patients. Because of their capacity to bind the inhibitory receptor NKG2A, expressed by NK 
cells and CTL, HLA-E molecules might favor tumor cell escape from CTL and NK 
immunosurveillance (Derre et al., 2006). 
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1.2.The mechanisms leading to tumour escape from immune recognition 
 
Despite the ability of the immune system to recognise, target and destroy abnormal cells, 
tumours frequently acquire mutations that allow them to avoid immuno-recognition. It is 
estimated that tumours typically accumulate 10 000 or more mutations due to genomic 
instability (Tomlinson et al., 2002). In addition, tumour cells are able to manipulate immune 
responses leading to either self-tolerance or to the local secretion of immunosuppressive 
cytokines. Paradoxically, the immune system can also promote tumour survival. The 
combination of these effects generally leads to poor anti-tumour immunity and prognosis. In 
particular, the poor immunogenicity of many tumours directly corresponds with:  
1. downregulation of tumour cell MHC I and costimulatory molecules  
2. alteration of DC and macrophage function in tumour tissue  
3. induction of regulatory T cells 
4. tumour-mediated immune cell death  
These mechanisms are described in more detail in subsequent sections. 
 
 
1.2.1. Downregulation of tumour cell MHC I and costimulatory molecules  
 
As described previously, CTL represent a major component of anti-tumour immunity by 
recognising antigenic peptides expressed by altered cells in the context of MHC class I 
molecules. However, one of the primary mechanisms underlying the failure of the immune 
system to control tumour progression is a general downregulation of many proteins involved 
in antigen processing and presentation by tumour cells. For example, reduced levels of MHC 
class I molecules has repeatedly been described in melanoma cells where approximately 50% 
of neoplasmatic human melanocytes have reduced class I expression as a result of various 
defects in the antigen-presenting machinery (Rees and Mian, 1999).  
Likewise, the loss of expression of large multifunctional proteases, such as LMP2 and LMP7 
reduces the generation of many tumour antigen derived peptides. In addition, the lack of 
peptide-transporter proteins: TAP-1 and TAP-2 lead to block a transport of peptide epitopes 
from the cytoplasmic compartment into the endoplasmic reticulum in many tumours (Ogino et 
al., 2007). Seliger and co-workers showed that murine tumour cell lines derived from 
spontaneous or chemical-induced tumours have a coordinated downregulation of expression 
of TAP-1 and LMP subunits, which led to reduced surface MHC class I molecule expression 
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(Seliger et al., 2003b). These observations strongly support the concept that tumours escape 
from immune surveillance as a result of sequential antigen loss and down-regulation of 
antigen-processing mechanisms over time. Similarly, Lou et al. have shown that mice 
challenged with murine lung carcinoma cell line (CMT.64) are characterized by a down-
regulation of surface MHC class I expression as a result of a deficiency in antigen-processing 
components such as tapasin (Tpn), growth of tumour was observed. In contrast, CMT.64-
bearing animals, which were additionally transfected with an adenovirus encoding human Tpn 
to restore surface MHC class I, showed increased tumor cell killing by antigen-specific CTL and 
a significant reduction in tumor growth was observed. These findings demonstate that Tpn can 
enhance survival and immunity against tumors and also suggests that Tpn may be used as a 
component of immunotherapeutic vaccine protocols to eradicate tumors (Lou et al., 2008) 
 
 
1.2.2. Alteration of DC and macrophages function  
 
 Dendritic cells 
A growing body of evidence reveals an ambivalent role for tumour-infiltrating DC (TID) that 
may participate in the regulation of either tumour regression or growth. It is becoming clear 
that modifications of DC, which are central regulators of immune responses, can induce anti-
tumour immunity or, in some cases, even promote tumour survival (Frumento et al., 2006). 
Chaux (Chaux et al., 1997) has reported that when compared to splenic DC, TID are poor 
stimulators of primary allogeneic T-cell proliferation and cytokine secretion (e.g. IL-2 and IFN-
. Indeed, when the cytokines secreted by TID were examined, they were shown to be similar 
to those previously tolerogenic DC (e.g. IL-10, transforming growth factor (TGF-) and vascular 
endothelial growth factor (VEGF)) along with reduced levels of costimulatory molecule 
expression (Ryan and Evavold, 1998).  
Some studies have also revealed that human TID, obtained from both melanomas and breast 
cancer have reduced expression of costimulatory molecules (Frumento et al., 2006). This 
failure of TID to effectively activate T cells may explain why in many cases tumour-infiltrating 
lymphocytes (TIL) fail to eliminate tumour cells. It is also possible that TID cells can promote 
the expansion of regulatory T cells (Treg), described in Section 1.2.3., in tumour environments. 
Another study, showing a pro-tumourogenic role for DC has been presented by Battaglia et al. 
They demonstrated that metastatic tumour cells produce VEGF, a natural ligand for Nrp1 
expressed by pDC, which induces a tolerogenic phenotype (Battaglia et al., 2009). Such tumour 
associated DC show decreased costimulatory molecule expression and produce 
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immunosuppressive cytokines including IL-10 or TGF-. Consequently, the uptake of tumour 
cells by DC in the presence of immune-suppressive cytokines tends to induce T cell 
differentiation into Treg leading to a lack of anti-tumour immunity.  
 
 Macrophages  
Similar to their specialised phenotypes (once located in many healthy tissues) macrophages 
present in many tumour environments (tumour associated macrophages (TAM)) appear to 
specifically inhibit T cell functions through the release of suppressive cytokines, including TGF-
, IL-10, and prostaglandins (Sica et al., 2007). Prostaglandins such as PGE2 can stimulate cell 
proliferation, induce angiogenesis and inhibit apoptosis of tumours by increasing expression of 
the anti-apoptotic Bcl-2 protein. Furthermore, secretion of TGF- and IL-10 has a negative 
impact on cytotoxic CD8+ T cells that infiltrate the tumour site again leading to 
immunosuppresion. In addition, TAM and tumour associated neutrophils produce reactive 
oxygen species (ROS) and nitric oxide (NO) that participate in the carcinogenic effect of a 
chronic inflammatory reaction. These reactive species directly induce DNA damage and are 
responsible for neoplastic transformation (Osinsky et al., 2009). In particular, oxidative 
products induce single or double-stranded breaks and DNA modifications such as alkylation 
adducts formation leading to increased mutations. It has also been shown that ROS activate 
the NF-B signaling pathway in infiltrating leukocytes leading to secretion of TNF- and other 
pro-inflammatory cytokines. NF-B activation results in expression of pro-inflammatory 
cytokines in stromal cells. These cells produce a variety of soluble mediators affecting both the 
matrix and blood vessel growth promoting tumour progression (Tobar et al., 2008). 
Furthermore, many tumours directly produce factors such as IL-10, VEGF, GM-CSF that 
promote the recruitment of macrophages and DC to the tumour site. Consequently, these 
infiltrating cells exhibit an immature phenotype leading to inhibition of tumour antigen 
presentation.  
 
 
1.2.3. Induction of regulatory T cells  
 
Treg are a subset of CD4+ T cells that are generated either intra or extra-thymically expressing 
high levels of the receptor for the T cell growth factor, IL-2 (CD25) and the transcription factor 
FoxP3 (Beyer and Schultze, 2009; Itoh et al., 1999). They inhibit the activity of other T cell 
populations by limiting the availability of IL-2 or by the secretion of anti-inflammatory 
cytokines such as IL-10 or TGF-. Thereby, Treg maintain immune system homeostasis and 
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tolerance. Paradoxically, Treg can also lead to tumour-antigen unresponsiveness and induce 
state of Immunosupression for tumour (Fig. 1.1.). 
 
 
Fig. 1.1. Induction of Treg cells within the tumour site. Tumour cells produce suppressive factors that 
directly act on Treg or license TAM and DC to expand Treg. Such expansion occurs through the 
proliferation of pre-existing Treg and the conversion of naive precursors into de novo inducible Treg. 
Tumour-associated Treg suppress both the innate and the adaptive immune response, including the 
priming and effector phase of both CD4 (green) and CD8 (brown) T cells. Adapted from Nature 
Reviews Cancer 7, 880-887 (November 2007). 
 
 
Bergman et al., revealed that there is a 5-15% increase in the proportion of Treg present in 
infiltrating neck and head carcinoma when compared to the frequency present in the blood 
(Bergmann et al., 2007). To address this high frequency of Treg present within the tumour 
environment, Borhaeti et al., proposed that Treg acquire their regulatory phenotype and 
suppressive function in situ. The authors also revealed that TGF-, produced by tumour cells 
and by Treg, is an important factor that drives conversion and clonal expansion of tumour 
infiltrating Treg (Borghaei et al., 2009). In addition, expression of the enzyme idoleamine 2,3-
dioxygenase (IDO), that participates in degradation of the essential amino acid tryptophan, by 
either tumour cells or tumour-altered-APC, also modulates conventional T cells into Treg 
within the tumour microenvironment. Furthermore, it has been shown that IDO expressed by 
DC also inhibits effector T-cell proliferation and survival through consumption of tryptophan 
leading to tolerance induction (Mellor and Munn, 2004).  
The impact on increased tumour survival as a result of Treg activity was confirmed by an in 
vivo model used by Tanaka and co-workers. They showed that depletion of Treg by the 
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administration of an anti-CD25 monoclonal antibody, led to the prolonged survival of animals 
previously administered the B16 melanoma or the methylcholanthrene (MCA)-induced 
fibrosarcoma (Tanaka et al., 2002). Furthermore, when Treg-depleted mice were repeatedly 
challenged with tumour cells, the animals still maintained long-lasting protective anti-tumour 
immunity. It has also been observed that elimination of Treg in mice enhances the cytotoxic 
function of tumour-specific CD8+ T cells resulting in delayed tumour growth (Steitz et al., 
2001). Therefore, elimination or inhibition of Treg function can help to induce potential cancer 
immunotherapy. 
 
 
1.2.4. Tumour-mediated cell death  
 
In addition to the mechanisms by which tumour cells avoid inducing immunity, experiments 
conducted by Esche et al. have shown that some tumours can upregulate Fas ligand 
(FasL/CD95L) expression, directly leading to the induction of immune effector cell apoptosis 
(Esche et al., 2001). They demonstrated that tumour cells can  induce TID to undergo apoptosis 
in vitro and in vivo after contact with different types of tumours. In addition, studies 
performed by Debatin and co-worker also described that TIL are dysfunctional or significantly 
apoptotic in many types of cancer such as neuroblastoma, melanoma, breast carcinoma, head 
and neck cancers (Debatin and Krammer, 2004).  
Tumour-induced death of DC was confirmed by the activation of caspase-3 along with an 
increased expression of pro-apoptotic Bax and the formation of apoptotic bodies. 
Furthermore, other studies have shown that NK cells also undergo apoptosis via the activation 
of natural cytotoxicity triggering receptor upon interaction with tumour cells (Zwirner et al., 
2007). Again, these mechanisms lead to poor, local immunogenicity of tumour-tissue as a 
result of the induction of apoptosis in infiltrating T, DC and NK cells.  
Due to the diverse mechanisms described above that allow cancer cells to avoid immune 
recognition, the induction of anti-tumour immunity in many animal models and patients is 
limited. Understanding these mechanisms, in particular the role of APC, may allow future 
strategies for the re-establishment of anti-tumour immunity.  
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1.3. Immunotherapeutic treatment of cancer cells 
 
 
1.3.1 Cytokine therapy 
 
Cytokines are proteins or glycoproteins secreted by immune cells which, by binding specific 
receptors, regulate both the adaptive and innate immune system. They have autocrine and 
paracrine functions, leading to either local or distal effects which may enhance or suppress 
immune responses. As well as their characterised role in the control of anti-pathogen 
immunity, cytokines are also involved either directly in the control of tumour growth or 
indirectly in regulation of anti-tumour immunity.  
In the early 1980’s, many promising results of various cytokine therapies in numerous animal 
tumour models were reported. In particular, IFN-, TNF-, IL-2, IL-3, IL-4 IL-6, IL-12 GM-CSF 
were studied with great expectation. Simultaneously, after the cloning of many cytokine genes 
large-scale clinical testing of the anti-tumour properties of many cytokines became achievable.  
Some of the most promising anti-tumour cytokines therapies are described below. 
 
IL-1: This interleukin has many functional activities as a costimulatory agent for T cells and has 
also been implicated as an inflammatory adjuvant. In particular, IL-1 administration was shown 
to mediate an adjuvant effect in mice vaccinated with lung cancer (McCune and Marquis, 
1990). IL-1 administration resulted in better infiltration of activated T cells into the vaccination 
site. In addition, experimental data have shown that mice injected with fibrosarcoma cells that 
were transfected with an IL-1 expressing plasmid, rapidly rejected the transfectants when 
compared to mice injected with un-transfected tumour cells. This experiment clearly indicates 
that recruitment of anti-tumour immunity results from the secretion of IL-1 by tumour cells 
(Douvdevani et al., 1991).  
 
IL-2: Since the early 1980’s, IL-2 has been used to treat a variety of cancers including renal cell 
carcinoma, leukaemia and lymphoma. Degrate et al., have shown that patients with pancreatic 
adenocarcinoma who receive recombinant IL-2 have an improved prognosis. Following IL-2 
administration higher levels of NK cells and eosinophils have been observed in these patients. 
This indicates that IL-2 administration stimulates innate anti-tumour immunity (Degrate et al., 
2009). Numerous studies have also shown that IL-2 treatment increase anti-tumour CTL-
mediated immunity (Hawkins, 1993) (Ge et al., 2002). Although interleukins have moderate 
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success in some types of tumours, significant toxicity and side effect in patients are also 
apparent. Therefore other mediators are also currently used in the clinic as described below.  
 
IFN: The anti-proliferative actions of the three major types of interferons on tumour growth 
have been well documented for over the last thirty years. The role of IFN-, -b and – was first 
described by Priestman showing anti-tumour activity in patients with advanced melanoma 
(Priestman, 1979). This treatment resulted in anti-proliferative and immunomodulatory effects 
and is still in limited use today in clinics treating hematologic malignancies and solid tumours. 
In particular, IFN- have been approved for the treatment of renal and kidney carcinoma and 
chronic myelogenus leukaemia. This class of cytokine has highly pleiotropic effects acting on 
tumour cells both in a direct and indirect manner. It has been shown both in vivo and in vitro 
models that anti-neoplastic functions of IFNs can be mediated by direct cytostatic activity 
(characterised by reduced proliferation), modulation of oncogenes expression and also in cell 
lysis. In addition, IFNs have many anti-tumour effects including the induction of anti-tumour 
antibody responses and the enhancement of tumour cytotoxcity by macrophages, NK cells or 
CTL. For example, genetically modified mice lacking the interferon-receptor show enhanced 
development of many types of tumours (Kaplan et al., 1998). Also, it has been shown that the 
introduction of tumour cells that were transfected with the IFN- gene into animals generated 
enhanced anti-tumour immunity (Viret and Lindemann, 1997). Another study has 
demonstrated that the upregulation of a tumour antigen expression by IFN-leads to 
enhanced anti-tumour monoclonal antibody production. Santini et al. have also demonstrated 
that IFN- and IFN- can promote the differentiation of ex vivo human DC towards an 
immunosuppressive phenotype that lead to the priming and expansion of protective anti-
tumour immune responses. (Santini et al., 2009).  
In animal models it has been observed that IFN-in combination with IL-12 can activate NK 
cells and CTL. Unfortunately, there is limited use of IFN- in the clinic due to its modest 
therapeutic benefits and cytotoxic side effects that include fever, hypotension and multi-organ 
malfunction (Eriksen et al., 2009) (Santini et al., 2009). 
 
TNF-: Tumour necrosis factor-alpha was originally identified in the late 1970’s as a mediator 
of necrosis for various murine and human tumours and cell lines. TNF-is a potent pro-
inflammatory, pleiotropic cytokine that is produced by macrophages, neutrophils, fibroblasts, 
keratinocytes, NK, T, B cells and also by tumour cells themselves. TNF- binds to the receptors 
TNF-RI and TNF-RII, which are expressed on most mammalian cells. There is evidence that the 
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binding of TNF- to these receptors induces a cytolytic cascade of events characterised by 
generation of ROS, DNA fragmentation and apoptosis (Kirkwood, 2002). Therefore, a 
significant effort has been made to efficiently deliver TNF to many tumour sites. In 1995 
liposome-encapsulated recombinant human TNF- was reported to be anti-tumorogenic in 
patients with sarcomas or melanomas whilst showing reduced cytotoxic side effects. This 
reagent is currently still used to treat patients with stage IIB/III melanoma (Kirkwood et al., 
2001). Unexpectedly, some evidence suggests that endogenously secreted TNF- by tumour 
cells has a different effect on tumour pathophysiology. Paradoxically, TNF- may also act as a 
tumour promoting factor by the induction of immunosuppressive macrophages. Such 
tolerogenic TAM secrete angiogenic factors including VEGF and SDF-1which are important in 
tumour invasion and metastasis (Green et al., 2009a). In contrast, exogenous high levels of 
TNF-induce the recruitment and activation of cytotoxic NK and T cells, subsequently leading 
to tumour killing. Li et al., have also shown that soluble TNF- significantly promotes 
lymphocyte infiltration attracting both CD4+ and CD8+ T cells to the tumour site in murine cell 
line H22-induced hepatic carcinoma. In addition to a secreted form, TNF- can also be 
expressed as a trans-membrane variant (TM-TNF-). Expression of TM-TNF-stimulates 
induction of Fas expression on tumour cells surface implying that the involvement of Fas/FasL 
signaling pathway in TM-TNF- –induced death of H22 tumour cells. These results suggest that 
secreted and trans-membrane forms of TNF induce killing of cancer cells in vivo through 
different mechanisms (Li et al., 2006). Thus the pharmacological administration of TNF-has 
both promising anti-tumour effects, as well as severe cytotoxicity which will limit its use as an 
anti-tumour therapeutic (Leist and Jaattela, 2002). 
 
 
1.3.2. Adoptive immunotherapy  
 
In addition to the non specific immune-based therapies previously described, another major 
focus in current anti-tumour immunity is the generation of specific immune responses 
targeted towards distinct tumour antigens. This can involve either the adoptive transfer of ex 
vivo tumour-specific effector cells or active immunisation strategies (cancer vaccination).  
Encouragingly, initial clinical trials following administration of adoptive therapy are beginning 
to show some promising results in several types of cancer (Zhang and Herlyn, 2009). This type 
of therapy involves the removal of lymphocytes from individual patients followed by their ex 
vivo manipulation before re-introduction. In particular, T cells isolated from fresh tumour 
biopsies or PBMC are cultured with IL-2 and both anti-CD3 and CD28 leading to progressive 
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selection and clonal explanation of various subsets of T cells. Currently, adoptive therapy 
focuses not only on TIL, but also on transfer of ex vivo manipulated APC (Fig. 1.2.). 
 
 
 
Fig. 1.2. General approaches for ex vivo generated tumour-specific T cells. Following lymphocytes 
isolation from either peripheral blood (PBMC) or the tumour itself (TIL), antigen-specific CTL can be 
selected and expanded by repeated stimulation with antigen pulsed APC or inactivated tumour cells. 
This process requires several rounds of stimulation (left). Alternatively, the T cell population can be 
numerically expanded by polyclonal stimulation by cyclic stimulation with anti-CD3 and CD28 
antibodies leading to depletion Treg and selection CTL which maintaining the tumour specific TCR 
(right). Adapted from the J. Clin, Invest. 117:1204-1212 (2007).  
 
 
Several studies have shown that T cells isolated from tumour-draining lymph nodes (TDLN), 
followed by ex vivo activation and then re-infusion into tumour bearing mice led to tumour 
rejection. According to Cohen, T cells from TDLN were able to inhibit tumour growth due to 
interaction with APC. Host APC constantly migrate from tumour site to draining lymph nodes 
where they present tumour antigens to T cells (Cohen et al., 2001). In addition to the studies 
described that have focused on ex vivo activation and expansion of the effector T cell 
populations, a few recent reports have also demonstrated that down regulation of Treg 
function prior to adoptive therapy treatment has beneficial results (Muranski and Restifo, 
2009) (Antony et al., 2005; Gattinoni et al., 2005). It has been shown that Treg appear to be 
more sensitive to a common chemotherapeutic agent cyclophosphamide (Cy). Apart from its 
antineoplastic properties in the treatment of Hodgkin's disease, lymphoma and breast cancer, 
Cy may also have immunostimulatory function when used in low doses. In particular, it has 
been shown that a low dose of Cy leads to decreased expression of GITR and FoxP3 resulting in 
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attenuation of suppressive activity of Treg (Motoyoshi et al., 2006). This allowed more 
effective killing of B16/F10 melanoma cells by ex vivo generated TIL.  
Therefore, more advanced studies on drugs which selectively depletes Treg, may lead to 
reduced Treg-mediated suppression. This will improve the efficiency of adoptively transferred 
effector cells in tumour elimination.  
Another approach for cancer immunotherapy is the ‘cancer vaccination’ strategy. Currently, 
many studies have been made in identification of tumour antigens. These peptides can 
become the targets of tumour-specific T cell response because they are not displayed on the 
surface of normal/healthy cells or can be displayed in an abnormal manner. In general, tumour 
antigens can be broadly categorized into six types – unique, differentiation, over-expressed, 
cancer-testis, universal and oncoviral antigens. The examples of each group of tumour 
antigens are given in Table 1.  
The first category consists of unique antigens that are the result of point mutations or gene 
rearrangements leading to ontogenesis. Typical examples include proto-oncogenes (e.g. ras, -
raf) that are involved in cell division and differentiation. Mutations of these proto-oncogenes 
have been seen in 15% of patients with colorectal or pancreatic cancer. Furthermore, 
mutations resulted in inactivation of tumour suppressor genes such as CDK4, p53 observed in 
50% of human malignancies are also part of this group. In addition, mutated form of -actinin-
4 causing uncontrolled actin binding is also classified as a unique tumour antigen. 
Accumulation of -actinin-4 in the cytoplasm induces cellular motility and contributes to 
metastasis in patients with breast cancer (Honda et al., 1998).  
The second category comprises of peptides encoded by genes normally expressed only in 
particular types of tissue. The best examples of differentiation tumour antigens are peptides 
expressed in melanocytes and melanoma tumour cells such as tyrosine (gp75) which 
participate in melanin biosynthesis. The strong correlation between the level of IgG antibodies 
against the gp75 present in serum and cancer progression has been seen in melanoma 
patients. Also gangliosides (GM2, GM3, GD2, GD3) belong to the group of differentiation 
antigen. In particular, it has been shown that mice vaccinated with GM2 and then challenged 
with lung or breast cancer cells induce strong NK cells activation leading to anti-tumour 
immunity and consequently tumour rejection. In contrast, unvaccinated mice developed 
previously injected tumour and died (Labrada et al.).  
The third group of tumour antigens is over-expressed antigens which are stronger expressed in 
neoplasmatic cells than normal cells. The example is Human Epidermal growth factor Receptor 
2 (HER2), the glycoprotein which is over-expressed in 30% of breast cancer patients and 
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correlated with poor prognosis. The antibody against HER2 is currently a valuable tool in ADCC-
mediated tumour cells death. Also epidermal growth factor (EGFR) and CD20 belong to this 
class of tumour antigen as they significantly over-expressed on colorectal and lymphomas, 
respectively.  
Cancer-testis is a group of antigens that have been originally found on healthy male germ cells 
as silent antigens, but many types of tumorus including melanomas (Fratta et al.), lung cancer 
(Kim et al., 2009c) and brain tumour (Jacobs et al., 2008) also express these antigens. Due to 
their presence in various cancers and their limited expression in normal tissues, cancer-testis 
antigens, therefore, are ideal vaccine targets for tumor immunotherapy. Indeed, newly 
detected, NY-ESO-1 antigen is regarded as one of the most immunogenic antigens ever 
isolated, inducing spontaneous host immune responses in 50% of patients with NY-ESO-1-
expressing in various neoplasms. 
The fifth class, which is universal antigens, is comprised of proteins which are expressed in 
most neoplasmatic cells, but not in normal, differentiated tissues such as survivin and 
telomerase. Anderson et. al. has shown that survivin (regulator and cell death inhibitor) may 
be an important and widely applicable target for anti-cancer immunotherapeutic strategies 
(Andersen and thor, 2002).  
The final group of tumour antigens comprises of proteins encoded by viral oncogenes which 
are involved in ontogenesis such as E6 and E7 proteins expressed by the human papilloma 
virus type 16 (HPV16). As oncoviral proteins have foreign origins they are able to be 
unrecognisably by immune-effector cell. However, Yan et. al., showed that mice vaccinated 
with HPV16-E6E7-DNA, construct expressing in mammalian cells, were able to induce HPV-16-
specific antibody production and CTL response in tumour bearing animals (Yan et al., 2007).   
 
 
Table 1. General classification of tumour antigens. Adapted and modified from Journal of 
Translational Medicine 2004, 2:12. 
 
ANTIGEN EXAMPLES TYPE OF TUMOUR 
unique b-raf, ras, CDK4, p53, α actinin-4 colorectal, pancreatic, breast 
differentiation tyrosinase/gp75, gangliosides, melanoma, lung, breast 
over-expressed HER2, EGFR, CD20 breast, colorectal, lymphoma 
cancer-testis MAGE, NY-ESO-1 melanoma, lung, brain 
universal telomerase, survivin many types 
oncoviral HPV type 16, E6, E7 cervical 
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Based on these findings, it was possible to generate protein-based-vaccines that were able to 
treat many types of cancers, however some promising results have been also observed in 
patients who received ex vivo loaded autologous DC with tumour apoptotic bodies, tumour 
lysates or tumour mRNA/DNA as an alternative approach to induce tumour-antigen 
recognition. 
Although the identification of various tumour antigens has significantly advanced our 
understanding of anti-tumour immunity (Rosenberg, 2001), the discovery that many cancers 
do not express MHC class II molecules on their surface, experiments have focused on the 
modulation of antigen processing and presentation pathways, as a valuable tool for cancer 
immunotherapy. In particular, genes that encode molecules enhancing the immune response 
are introduced into tumour cells. Furthermore, CD8+ cytotoxic T cells are able to induce lysis of 
tumour cells exclusively upon recognition of tumours antigen presented in context of MHC 
class I. It has been shown that even one round of in vitro stimulated CTL cells allows inhibition 
of tumour growth. Also, using pulsed DC cells with MHC class I restricted peptides enhanced 
CTL cells anti-tumour function in melanoma patients (Oh et al., 2006) (Santin et al., 2002).  
Overall, clinical trials using MHC class I restricted antigens elicited only modest or transient 
immune response in most immunised patients (Bonehill et al., 2005). The reason of explaining 
the partial failure of this therapy is the lack of tumour specific CD4+ T cells that help to expand 
an effective CTL response. Since the 1980’s, the importance of CD4+ T cells in protection 
against tumour growth has been widely reported. However, insufficient progress has been 
made to understand the role of CD4+ T cells recognising MHC class II-restricted tumour 
antigens, mostly due to technical difficulties.  
 
 
1.3.3. Chemotherapy  
 
Chemotherapy is one of the principal approaches for the treatment for cancer patients by 
causing damage to rapidly dividing tumour cells. There are more than 90 different drugs 
available to the clinic, which have vastly improved since middle 1940’s when Louis S. Goodman 
for the first time treated lymphoma-bearing mice using mustine.  
The choice of specific chemotherapies depends on tumour type, histologic grade (how 
aggressive the tumour is) but also on tolerance to side effects resulting from the 
chemotherapeutic agent. It has been shown that cytotoxic drugs that can lead to complete 
remissions of some form of cancers such as lymphoma, are also effective in decreasing tumour 
size, and may prolong life even in metastatic cancers, such as osteosarcoma. Unfortunately, 
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chemotherapeutic multidrug resistance of many tumours is still a major obstacle in cancer 
therapy. Therefore, the different chemical structures and mechanisms of intracellular activity 
of chemotherapeutic agents need to be constantly developed. Interestingly, many studies have 
shown that a combination of chemotherapy and adoptive immunotherapy give better results 
than either therapy administrated separately. For example Dudley et al., have shown that 
patients with refractory metastatic (stage IV) melanoma given chemotherapeutic 
lymphodepletion with Cy administration, fludsrabine and 12 Gy irradiation, who were 
subsequently infused with lymphocytes previously isolated from their tumour site, had a high 
clinical response rate reaching 70%. However, patients who were administrated only one type 
of treatment (adoptive or chemotherapy) showed moderate anti-tumour responses (between 
10% and 34% clinical rates) (Dudley et al., 2005) (Dudley et al., 2008). Therefore, a 
combination of different strategies for anti-tumour immunity helps to minimise the side 
effects of chemotherapy including nephrotoxicity, hair loss, vomiting or nerve damage 
resulting in improved quality of life for patients.   
 
 
1.3.3.1. Anthracycline treatment and immunogenic cell death 
 
Anthracyclines including Aclarubicin, Daunorubicin, Doxorubicin and Mitoxantrone are an 
effective anti-neoplastic group of drugs derived from Streptomyces bacteria widely used in 
clinics. Although they are active against a variety of solid tumours such as sarcomas, breast 
and prostate cancers and haematological malignancie including leukemias or Hodgkin’s 
disease, their clinical use is not ideal due to tumour resistance and toxicity to healthy adjacent 
tissue. In particular, myocardial tissue is susceptible to free radical damage, therefore 
anthracycline-treatment might be an important risk factor resulting in cardiomyopathy 
(Lebrecht et al., 2009). Currently, scientists are focusing on the modification of the general 
anthracycline ring structure that allows reduction of the side effect but maintains a strong 
anti-tumour profile. 
The biological activity of anthracyclines is related to topoisomerase II inhibition (which is 
involved in DNA repair mechanisms), intercalation between DNA base pairs causing double 
and single strand break, inhibition of DNA/RNA synthesis and cell cycle arrest at the G(2)/M 
phase (Kim et al., 2009b). Production of hydroxyl free radicals and damage to the plasma 
membrane is also associated with the anti-tumour effects of anthracyclines (Mizutani, 2007). 
Furthermore, it has been described that doxorubicin treatment induces disruption of inner 
mitochondrial membrane potential resulting in apoptotic cell death (Kohler et al., 2008). 
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Recently another important aspect of anthracycline-therapy has been investigated by the 
Kroemer laboratory group (Panaretakis et al., 2009). They demonstrated that 
chemotherapeutic agents such as anthracyclines not only participate in selective killing of 
tumour cells but additionally stimulate anti-tumour immunity leading to more vigorous 
elimination of neoplasmatic tissue. This was shown in several mouse cancer cell lines including 
CT26 colon cancer, EL4 thymoma, GOS osteosarcoma, MCA-induced fibrosarcoma or the TS/A 
mammary tumour cell line. Following anthracycline treatment or -irradiation, tumours were 
shown to undergo apoptosis and to induce anti-tumour responses. Other classical apoptotic 
stimuli such as staurosporine or mitomycin C failed to induce anti-tumour immunity (Obeid et 
al., 2007b) (Apetoh et al., 2007b), (Casares et al., 2005). This ‘immunogenic’ cell death 
following anthracycline treatment was shown to be dependent on the surface exposure of the 
chaperone proteins calreticulin and ERp57. These proteins are relocated from the ER lumen to 
the plasma membrane and constitute an ‘eat me signal’ which is required for the phagocytosis 
of the dying tumour cells by DC. Antigens released from engulfed immunogenic tumour cells 
are then processed via the cross-presentation pathway for the activation of MHC class I-
restricted CTL. Thus anthracycline-treatment not only induces cell death, but also stimulates 
tumour antigen-specific immune responses.  
 
 
Fig. 1.4. A schematic representation of immunogenic cell death. Following anthracycline treatment 
apoptotic tumour cells relocate CRT and chaperone proteins to the cell surface. Additionally, by 
releasing HMGB1, dying tumour cells activate DC. In particular, CRT and HMGB1 interacting with CD91 
and RAGE/TLR4/TLR2, respectively can facilitate the uptake of the dying cells and induce cross-
presentation of tumour antigens that consequently elicit anti-tumour immunity. Adapted from Nature 
Reviews Immunology 9, 353-363 (May 2009).  
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In particular, Apetoch et al. injected CT26 colon cancer cells that had been treated with 
anthracyclines, mitomycin C or etoposide into the foot pad of BALB/c mice or CRT negative 
mice. Following lymph node isolation they assessed IFN- production by draining T cells. Only T 
cells isolated from CRT sufficient mice significantly secreted IFN- and rejected the 
anthracycline-treated tumour cells. In contrast, CRT sufficient mice that were challenged with 
CT26 tumour cell line previously treated with etoposide or mitomycin, failed to control tumour 
growth. As etoposide and mitomycin were shown to be non-immunogenic agents which do not 
trigger CRT relocation, this confirmed the role of CRT in the induction of anti-tumour 
immunity. Similarly, CRT negative mice challenged with anthracycline-treated CT26 cells had 
significant tumour growth, again indicating that anti-tumour immunity was CRT mediated.  
 
 
1.3.4. Radiotherapy 
 
Since the discovery by Roentgen in 1895, the X-ray has played one of the major roles in 
modern medicine. Radiotherapy (x-ray therapy or irradiation) is the use of a certain type of 
energy (ionizing radiation) to kill cancer cells and reduce tumour size. Although radiation 
damages both cancer cells and normal cells, most normal cells can recover from the effects of 
radiation and regain proper function. Currently radiotherapy has been improved by providing 
more specific mechanisms delivering energy to neoplastic tissue. In particular, using tumour-
specific antibodies conjugated with radioisotopes (Y90-trytium or I131-iodine) nearby healthy 
tissues receive limited damage (Borghaei et al., 2009). 
Many key biochemical processes in irradiated cells including DNA, RNA or protein synthesis, 
respiration or other metabolic pathways are inhibited or even completely eradicated by 
irradiation. However, the mechanisms by which irradiation triggers these biochemical changes 
including the induction of apoptosis in normal and neoplastic cells has not been completely 
understood until recently.  
It is now known that the p53 tumour suppressor gene is key in this process (Therrien et al., 
1999). In particular, it has been suggested that the product of the p53 gene is involved in 
monitoring the integrity of the genome. If DNA is damaged, the p53 product accumulates 
through a post-translational stabilisation mechanism and arrests the cell cycle at G1 to 
facilitate DNA repair. If repair fails, p53 then may trigger apoptosis. To address the role of p53 
in cell death following irradiation, Kerr et al. has showed that thymocytes lacking p53 are 
resistant to lethal effects of ionizing radiation. However following exposure to glucocorticoids 
as an alternative apoptotic stimulus, p53 deficient thymocytes undergo apoptosis (Kerr et al., 
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1994). Furthermore, DNA mutations that occur as a result of UV irradiation can lead to cell 
lethality. It has been shown by Ward that small doses of irradiation causes significant single or 
double-strand DNA breakage (Ward, 1994). In addition, a moderate dose of UV light induces 
apoptosis demonstrated in several in vivo and in vitro studies (Kimura et al., 2009) (Chathoth 
et al., 2009), (Reich et al., 2009). According to Kim et al., following UVB and UVC irradiation the 
colorectal cancer cell line (CX-1) exhibited morphological changes characteristic of apoptosis 
including the appearance of apoptotic bodies, the activation of caspases 8, 3, 1 as well as 
cytochrome c release (Kim et al., 2008b). Furthermore, whilst the CX-1 cell line was originally 
resistant to TNF-related apoptosis-inducing ligand (TRAIL) stimuli, following UV exposure CX-1 
cells were sensitive for TRAIL induced cell death. These studies may help to improve cancer 
therapy for certain TRAIL-resistant tumours such as lung, colorectal or prostate cancers by 
using UVC treatment to increase the sensitivity of these tumours to TRAIL –induce death.  
 
 
1.3.4.1.irradiation or UVC exposure also leads to immunogenic cancer cell death  
 
In addition to anthracycline-treatment (described in Section 1.3.3.) several studies have also 
shown that UVC and -irradiation are capable of inducing immunogenic cancer cell death 
(Panaretakis et al., 2009), (Tufi et al., 2008). Studies carried out by Brusa and co-workers 
revealed that UVC treated renal carcinoma cells (RCC) induce an accelerated maturation of TID 
enabling efficient tumour antigen CTL cross-priming (Brusa et al., 2008). Notably, they showed 
that post-apoptotic RCC (20 h following UVC exposure) release high mobility group box 1 
(HMGB1) protein that activates DC. HMGB1 is a non-histone protein which is bound to DNA 
and induces maturation and migration of DC via upregulation of costimulatory molecules and 
the induction of IFN- production by DC (Dumitriu et al., 2007) (Yang et al., 2007). 
Consequently, following incubation with apoptotic RCC cells, matured DC were shown to 
upregulate CD80, CD83 and CD86 along with the chemokine receptor CCR7 as well as 
increasing production of IL-1, IL-6 and TNF-. Pre-treatment of immature DC (iDC) with 
antibodies blocking the HMGB1 receptor, confirmed that DC maturation was HMGB1-
mediated. Furthermore, they also revealed that iDC incubated with UVC-treated RCC had 
elevated levels of inflammatory cytokine gene expression. More importantly they also showed 
that incubation with RCC induced an upregulation of molecules involved in the antigen-
processing machinery including the TAP subunits as well as inducing increased the expression 
of MHC class II genes. These findings clearly showed that selective apoptotic stimuli induce the 
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release of HMGB1 from various carcinomas during the later stages of apoptosis leading to DC 
activation and improved T cell stimulation.  
Similar mechanisms leading to immunogenic cell death following UVC treatment was observed 
by Brusa et al. They showed that following UVC treatment or exposure to raised temperature 
(56oC) the human prostate cancer cell line (LNCaP) was more effectively engulfed by DC (Brusa 
et al., 2009). Brusa et at. additionally showed that dying tumour cells also release HMGB1, 
which interacts with TLR4 or the receptor for advanced glycation end products expressed by 
DC. Ligation of these receptors was subsequently shown to induce enhanced targeting and 
processing of engulfed antigens. Indeed, DC from patients with deficient TLR4 alleles were also 
shown to be inefficient at presenting antigens from dying tumour cells (Apetoh et al., 2007a). 
Furthermore, using an ELISPOT assay, Brusa also demonstrated that UVC treatment of the 
tumour cells before DC loading induced MHC I-restricted IFN- release by autologus T cells as a 
result of tumour antigen cross-presentation. In contrast, live LNCaP cells inhibited DC 
maturation resulting in the attenuation of autologous responses.  
Another study demonstrated that DC incubated with -irradiated B-cell lymphoma (B-CLL) 
were 300 times more efficient in their ability to present B-CLL antigens than DC incubated with 
non-treated B-CLL. Using proliferation assays they revealed that autologus T cells isolated from 
B-CLL patients, after stimulation with apoptotic B-CLL loaded DC, produced five times more 
IFN- than T cells activated by DC pulsed with live B-CCL leukaemia. It was suggested that 
apoptotic B-CLL display ‘novel’ intracellular proteins which induce the anti-tumour response 
(Kokhaei et al., 2003). 
Therefore, there now exist many examples where radiotherapy not only is effective at inducing 
tumour death, but also induces a type of cell death that directly activates interacting APC 
leading to efficient T cell stimulation. Thus either -irradiation or UVC-treatment along with 
anthracycline treatment could induce a break in ‘classical’ apoptotic cell-induced tolerance to 
novel or ‘neo’ antigens leading to the initiation of improved anti-tumour immunity.  
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Concluding remarks for current cancer therapy  
 
Cancer is recognised as a lethal disease that is rarely controlled by host immune responses 
sometimes even in the presence of high frequencies of tumour-specific T cells. In order to 
overcome this apparent ‘weak immunogenicity’ of tumours, scientists have focused on 
methods that increase anti-tumour immunity including combinations of both specific cytotoxic 
T cell-mediated responses and humoral immunity. In principle, any therapy that delivers higher 
levels of presented or cross-presented tumour antigens to the draining lymph nodes could 
synergize with immunotherapy. Thus, immunogenic apoptotic tumour cell death following 
anthracycline chemotherapy or UVC radiotherapy treatment could be a valuable approach 
boosting natural anti-tumour immunity. In addition, inducing this kind of cell death in 
conjunction with cancer vaccination therapy should prove more efficient in terms of both 
priming an anti-tumour response and in the generation of tumour antigen-specific memory. 
Therefore, future treatments will require a multidisciplinary approach integrating surgical, 
radiation, chemotherapeutic and especially immunotherapy options to improve the quality of 
life of cancer patients, rather than just focusing on survival endpoints. 
 
38 
1.4. B cells and anti-tumour immunity 
 
 
1.4.1. Antigen recognition and B cell activation 
 
As previously described, B cells represent an important arm of the adaptive immune response. 
They specifically neutralize pathogens by production and secretion of antibodies. More 
recently, it is now known that B cells also play an important role as APC activating CD4+ T cells 
(Batista and Harwood, 2009; Clark et al., 2003; Rivera et al., 2001). Furthermore, some studies 
indicate that B cells which infiltrate tumour tissue play an important role as APC in tumour 
antigen presentation to specific T cells (Kotlan et al., 2005). However, little is known about the 
origin and specificity of B cells infiltrating the tumour microenvironment. Also anti-tumour 
recognition and elimination, based on specific antibodies binding to tumour antigens, has not 
been thoroughly explored and still needs to be developed. Therefore, a better understanding 
of the role and nature of B cells in anti-tumour immunity might be a powerful approach in 
further clinical practice for the treatment of many cancer patients. 
 
B cells express a membrane-bound antigen receptor (BCR) that binds and internalizes antigen 
into the endocytic compartment (Hou et al., 2006). In this environment the antigen-BCR 
complex forms a substrate for the action of proteolytic enzymes generating peptide fragments 
which associate with MHC class II molecules and are subsequently displayed on the B cell 
surface (Shlomchik, 2009). These complexes are consequently recognised by CD4+ T cells. 
Antigen presentation by B cells was until recently thought to be predominantly responsible for 
the activation of T cells that would provide helper signals for B cell activation and 
differentiation leading to the eventual secretion of the BCR as soluble antibody. However, 
recent data has shown that in several different situations, B cell APC-function is also crucial for 
full activation of T cell-mediated immunity (Crawford et al., 2006). In particular, Whitmire et al. 
showed that mice lacking B cells rapidly lost antigen-specific CD4+ T cells, but not CD8+ T cells 
memory after acute infection by lymphocytic choriomeningitis virus (LCMV). Consequently, the 
lack of CD4+ T cell memory led to incomplete recovery from chronic virus infection in B cell-
deficient mice. These data implicate a B cell function other than antibody production that 
induces long-term protective immunity (Whitmire et al., 2009). Similarly, Linton et al., 
demonstrated that mice lacking B cells were able to develop memory T cells, but such animals 
had significantly lower frequencies of both primary and memory antigen-specific T cells. 
However, in vitro when IL-4 and antigen activated B cells were provided, antigen-specific T 
cells were completely reconstituted (Linton et al., 2000). These results provide direct evidence 
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that B cells can have an essential role in determining the T cells expansion in response to 
antigen and generation the size of the memory antigen-specific T cells. Furthermore, in 
autoimmune disorders such as rheumatoid arthritis (RA), B cells also play a crucial role as APC. 
O’Neill showed using a mouse model of RA, proteoglycan (PG)-induced arthritis (PGIA), that B 
cells were a major source of APC which activated autoreactive PG-specific T cells via CD80/86-
CD28 costimulatory signals (O'Neill et al., 2007). In contract, mice with CD80/86 deficient B 
cells phenotype did not develop PG-specific T cells in this PGIA model, indicating that APC 
function of B cells in RA is essential. Therefore, understanding the mechanisms involved in the 
acquisition of antigen by B cells may be the key feature in this unique APC role. It may allow 
the evaluation of these mechanisms in the development of anti-tumour immunity.  
 
For the initiation of B cell responses peripheral antigens are transported via afferent 
lymphatics to the secondary lymph organs where they are ‘displayed’ as native proteins, either 
complexed with antibody, or complement components on the surface of specialized cells 
termed follicular dendritic cells (FDC) (Szakal and Tew, 1992). FDC are stromal cells located in 
specialised areas involved in B cell maturation. By providing native antigen and activation 
signals, FDC/B cell interactions are essential for B cell survival and consequently induce class 
switching and differentiation (Szakal et al., 1992). While it was shown more than twenty five 
years ago that antigen displayed by FDC is subsequently internalised into the B cell endocytic 
compartment (Schnizlein et al., 1984) the mechanisms involved in B cell antigen acquisition 
from these cells was only recently described. In pioneering experiments, Batista has shown 
that B cells can physically extract native antigens which are tethered to non-internalisable 
surface (Batista and Neuberger, 2000). Subsequently, it was also demonstrated that B cells can 
acquire tethered antigens displayed by target cells resulting in an immunological synapse (IS) 
formation. 
As well as FDC, both DC and macrophages have also been demonstrated to display antigens for 
B cell acquisition. Wykes et. al. showed that non-immunized rats, challenged with DC 
previously pulsed with antigen, could elicit antigen-specific IgM and IgG responses (Wykes et 
al., 1998). Furthermore in vivo studies performed by Bergtold, Desai et al. demonstrated that 
DC capture naive antigens that subsequently are endocytosed by the Fc receptor. Such FcR-
antigen complexes access a nondegradative intracellular vesicular compartment and recycle to 
the cell surface of DC allowing interaction of native antigen with the BCR. This interaction 
consequently leads to B cell activation and class switching (Bergtold et al., 2005). These 
findings show that DC maintain intact native antigen that is capable of initiating a primary B 
cell response. Furthermore, more recent studies identified subcapsular sinus CD11b+ CD169+ 
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MHC II+ macrophages in the marginal zones of lymph nodes as a cell type displaying native 
antigens for B cell acquisition during the first few hours following antigen administration 
(Carrasco and Batista, 2007) (Junt et al., 2007).  
Central to the acquisition of antigen by B cells is the expression of BCR. The BCR is a molecular 
complex consisting of a membrane anchored pre-cursor of the subsequently secreted antibody 
along with the Ig/Igheterodimer. In addition to BCR/antigen binding, interactions between 
adhesion molecules expressed by the B and target cell including leukocyte function-associated 
molecule-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) are essential for antigen 
acquisition and IS formation (Carrasco and Batista, 2006b). Koopman et. al. have shown that 
binding between CD49d/CD29 (VLA-4), an integrin expressed on leucocytes and its ligand: 
vascular adhesion molecule-1 (VCAM-1) which is expressed on FDC facilitates this interaction 
(Koopman et al., 1994). Carrasco and Batista suggest that B cell antigen acquisition consists of 
four steps (Carrasco and Batista, 2006b). Firstly, initial interaction between VLA-4 and VCAM-4 
promotes adhesion of B cells to the membrane bearing native antigen. Secondly, binding of 
LFA-1 to ICAM-1 activates signaling pathways that lead to cytoskeletal changes in the B cell. 
Next a supramolecular structure (cSMAC) is formed consisting of a docking structure with the 
BCR and antigen at the centre, whilst LFA-1 and VLA-4 remain in the periphery of the SMAC 
(pSMAC). Finally, the BCR/antigen complex is internalized inside the B cell endocytic pathway 
completing the process of antigen acquisition.  
Furthermore, Arana et. al. demonstrated that prior to IS formation, phosphoinositide 3-kinases 
(PI3K) and the small GTP-ase protein, Rac2, play a crucial role in the process of antigen 
recognition. In particular, they showed that Rac2 is involved in both early cytoskeleton 
rearrangement and in the up-regulation of LFA-1 essential for IS formation (Arana et al., 2008). 
To confirm the role of Rac2 in the adhesion process, the authors showed that B cells isolated 
from Rac2 deficient (Rac2-/-) mice had a defect in the adhesion process as a consequence of 
down-regulation of LFA-1 molecule, compared to wild-type mice. Surprisingly, B cells from 
Rac1-/- mice did not show any significant differences in adhesion. They also examined the role 
of PI3K in B cell adhesion and IS formation. In the presence of the PI3K inhibitor, wortmannin, 
they observed a lack of Rac2 activation which led to reduction of IS formation. This data 
confirmed the essential role of Rac2 in the promotion of B cell adhesion. Consistent with this 
they also demonstrated that overexpression of a constitutively active form of Rac2 led to 
enhanced antigen aggregation and integrin expression. Interestingly, these experiments were 
performed using an artificial bilayer membrane system, allowing controllable antigen dose 
availability. Thus, for the first time they demonstrated the complex interplay involved in 
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antigen mediated intracellular signaling events and cytoskeleton rearrangements results in the 
IS formation (Treanor et al.).  
Following antigen acquisition, B cells are selected in specialised areas of secondary lymphoid 
tissues termed germinal centres, based on a combination of their efficiency to bind, internalize 
and present peptide fragments generated from these extracted antigens to CD4+ T cells. This 
B-T interaction is crucial for the mutual activation of both cells. Contact between B and T cells 
helps to develop a fully maturated antibody response involving class switching and memory 
cell formation. Furthermore, B-T interaction also leads to full T cell activation. In some cases, 
such activation of CD4+ T cells by B cells may also lead to either the generation of functional 
CTL that directly eliminate tumour cells or to the development of long-term tumour specific-
CTL (Ho et al., 2002).  
 
 
1.4.2. The role of B cells in anti-tumour immunity   
 
According to several reports the role of B cells in anti-tumour immunity is controversial. 
Indeed, Shah et al. suggests that role of B cells in tumour biology maybe immunosuppressive, 
resulting in the inhibition of tumour rejection (Shah et al., 2005). It has been shown that B cell 
depleted mice, (using anti-CD20 antibody) that were vaccinated with adenovirus expressing 
the virus-E7 gene (Ad.E7) in mice bearing TC1 tumors (murine lung cancer cells expressing 
human papilloma virus-E7), have enhanced anti-tumour immunity compared to non-depleted 
mice. Therefore, these studies demonstrate that B cell depletion may be a useful adjunct in 
anti-tumour treatment (Kim et al., 2008a). In addition, it has been shown that long-term B cell-
mediated inflammatory response can influence tumour development. This results in the 
activation of signaling pathways regulating tumour progression. In particular, chronic 
production of Th2 cytokines such us IL-10, IL-4 or immunoglobulin complexes may lead to 
tumour expansion (Howell and Rose-Zerilli, 2006) (Tan and Coussens, 2007). Indeed, increased 
level of IL-10 in patients with gastric cancer was correlated with poor prognosis as a result of 
tumour angiogenesis and inhibition of CTL infiltration (Sakamoto et al., 2006). Another study 
has demonstrated that anti-tumour antibodies were involved in the recruitment of 
macrophages and granulocytes via FcR into the tumour site. Such activated macrophages and 
granulocytes produce VEGF which stimulate tumour angiogenesis and promote metastasis 
(Barbera-Guillem et al., 1999). 
Further studies need to be done to determine which type of anti-tumour immunity will be 
most effective in certain types of human cancers. Although these selected papers demonstrate 
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pro-tumourogenic function of B cells in tumour sites, the vast majority of studies have shown 
the beneficial role on B cells in anti-tumour immunity. Some examples of these beneficial roles 
will be described below. 
 
 
1.4.2.1. The role of antibodies as adjuvant in cancer therapy 
 
Several mechanisms have been described to explain the anti-tumour activity of tumour-
antigen-specific antibodies. In particular, the immunomodulatory mechanisms of antibody-
mediated anti-tumour immunity are based on mediation of the cellular cytotoxicity of tumour 
cells by ADCC mechanism. In addition, by cross-linking FcR expressed on DC or macrophages 
this also promotes antigen presentation leading to activation adaptive CD4+T cell-mediated 
immunity.  
 
 Tumour vaccination enhances antibody production 
Li et al. have highlighted the important role of antibodies in anti-tumour immunity where CTL-
mediated response was either difficult to detect or absent (Li et al., 2008). They demonstrated 
that breast tumour (TUBO)-bearing mice vaccinated with chaperon-rich TUBO-cell lysates 
(CRCL) induced strong anti-tumour antibody production and delayed tumour growth, in 
contrast to tumour-bearing mice which were not vaccinated. To prove that vaccination 
enhanced antibody production and consequently led to improved anti-tumour immunity, they 
also vaccinated JH knockout mice lacking B cells and antibodies (Ig-/-). Vaccination of these Ig-/- 
tumour-bearing mice with CRCL lysates did not lead to protection and tumour growth kinetics 
was significantly faster than in vaccinated B cell sufficient tumour-bearing mice. This 
experiment clearly indicates that B cell responses generated by CRCL vaccination plays an 
important role against tumour growth. In addition, they tested the possibility that anti-tumour 
immunity could be transferred with immune sera. They pooled sera from mice deficient in T 
cells but not with B cells and immunised with TUBO-CRCL lysates. Following transfer of sera, 
mice were challenged with TUBO cells and anti-tumour activity was measured. They showed 
that in these mice, tumour growth was significantly delayed. Interestingly when TUBO 
challenged mice received sera raised against lysates from different types of tumour cells, these 
mice did not induce protection against their tumours. This provides additional evidence that 
CRCL vaccination induces specific antibody responses which enhance anti-tumour immunity. 
They proposed that these antibodies functioned in ADCC mediating tumour lysis. In particular, 
IgG1, IgG2a, IgG3 iso-types were observed in the sera 1 week after the first CRCL-immunization 
and these antibodies persisted for at least 3 weeks, suggesting that long-term immunity can be 
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elicited. Also they examined the role of CD4+ and CD8+ T cells in TUBO-bearing mice. Using 
mice depleted of either CD8+ or CD4+ T cells before and after vaccination they assessed which 
population of T cells is involved in tumour regression. In this type of cancer, CD8+ T cells did 
not play a role in anti-tumour immunity in TUBO-bearing mice followed CRCL administration. 
In contrast, in mice depleted of CD4+ T cells, the tumours grew significantly faster than in 
control mice with intact CD4+ T cells. This suggests that tumour-reactive CD4+ T cells are 
crucial for the induction of this antibody-mediated anti-tumour immunity.  
 
 ADCC in tumour therapy 
The majority of antibodies, which have been used for anti-tumour therapy, act by 
simultaneously binding to tumour antigens and to FcR stimulating tumour-specific ADCC. This 
antigen/FcR cross-linking induces the release of cytokines including IFN-γ and also cytotoxic 
granules by NK cells, CTL and neutrophils. These granules contain perforin and granzymes and 
actively lyse target tumour cells displaying antigens. In addition, antibody/FcR cross-linking on 
macrophages stimulates enhanced phagocytosis of antibody-coated tumour cells and 
simultaneous release of ROS, NO, a variety of proteases and FasL (Iannello and Ahmad, 2005). 
Due to the relative efficiency of this process, substantial effort in the development of 
monoclonal antibodies that effectively promote ADCC through improved FcR interactions has 
been made. The most common antibody used in clinics is an anti-HER2/neu monoclonal 
(trastuzumab) that has been approved to treat patients suffering for breast cancer. For 
example a clinical study performed by Kute and co-workers has shown that administration of 
trastuzumab leads to significant activation of granulocytes or mononuclear cells in patients 
with breast cancer (Kute et al., 2009). They revealed that these effector cells showed enhanced 
tumour killing properties. In addition, in vitro experiments confirmed that the natural killer cell 
line (NK-92) showed enhanced tumour killing in the presence of trastuzumab.  
Similar to treatment with trastuzumab, the use of the anti-CD20 monoclonal antibody 
(rituximab) has been very effective for a number of years in the treatment of various types of B 
cell lymphoma (Weiner et al., 2009). For example, Weitzman et al. demonstrated the 
activation of NK cells following treatment with rituximab in patients with chronic lymphocytic 
leukemia (Weitzman et al., 2009). Interestingly, Jazirehi, Bonavida showed another function of 
rituximab as an agent that negatively regulates survival pathways in lymphoma cells. In 
particular, they demonstrated downregulation of the p38MAPK signaling pathway resulting in 
the inhibition of constitutive STAT-3 activity and subsequent downregulation of pro-apoptotic 
Bcl-2 expression following rituximab treatment. Furthermore, they showed rituximab is 
involved in the upregulation of Raf-1 kinase inhibitor protein (RKIP). Activated RKIP leads to 
 
44 
inhibition of pro-survival ERK1/2 and NF-B pathways and therefore chemosensitizes tumour 
cells for apoptotic cell death (Jazirehi and Bonavida, 2005).  
It is noteworthy that Green et al. have shown the administration of an anti-E-cadherin 
antibody prior to the administration of pools of various anti-tumour antibodies disrupts multi-
cellular tumour aggregates and increases tumour antigen availability and hence increases the 
efficiency of ADCC (Green et al., 2002).  
 
 Monoclonal antibodies as adjuvants for DC 
As described previously, monoclonal antibodies are a valuable tool for treatment of many 
malignant diseases. In the last decade, monoclonal antibodies are the most common classes of 
new generation drugs for cancer treatment. More than 20 therapeutic antibodies have been 
approved for clinical use and many others are now at the clinical and preclinical stage of 
development (Kubota et al., 2009). 
Many tumours do not express MHC class I or II molecules and therefore the uptake of 
opsonised tumour cells by DC via Fc receptor leads to cross presentation and efficient 
generation of both antigen-specific CD4+ and CD8+ T cell-mediated responses. However, 
during the steady state DC cells exhibit immature phenotype which can promote tolerance. 
Therefore to induce effective anti-tumour recognition by DC the maturation stimulus need to 
be applied. Importantly, FcRIIa and FcRIIIa receptors not only mediate antigen uptake, but 
also affect the DC maturation in contrary to inhibitory receptor FcRIIb. It has been shown that 
opsonised tumour cells that bind to activating receptors FcRIIa or FcRIIIa on DC are engulfed 
via interferon pathway and therefore antigen uptake and cross-presentation were enhanced. 
For those reasons, monoclonal antibodies, which selectively bind to activating receptors and 
block inhibitory, could be a valuable tool delivering maturation stimulus to DC cells. This 
mechanism might be one of the most potent determinants boosting adaptive immunity.  
 
 
1.4.2.2. Tumour infiltrating B cells  
 
Recent evidence from medullary carcinoma of the breast (MCB) patients has shown that there 
is a correlation between TIB and a more favourable prognosis (Kotlan et al., 2005). Moreover 
some studies have shown increased numbers of plasma cells in patients with different types of 
breast cancer (Coronella-Wood and Hersh, 2003). One important finding from these studies 
was the identification of the antigens recognised by many of these B cells. Surprisingly, many B 
cells recognised antigens normally located in intracellular compartments in healthy cells. In 
addition these studies also demonstrated that a significant proportion of the tumour cells that 
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were associated with B cells were undergoing apoptosis. Therefore this study demonstrated 
that during apoptosis normal protein trafficking is somehow altered in MCB cells leading to the 
display of novel or ‘neo’ antigens on the cell surface that could be recognised by B cells.  
Similar studies showing the important role of infiltrating B cells that helps to evaluate tumour 
bio-markers were performed by Shigematsu et al. They revealed that tumour-specific 
antibodies, mostly IgG class, obtained from B cells infiltrate isolated from malignant 
mesothelia could be used to serological identify of tumour neo-biomarkers by recombinant 
expression cloning method (SEREX). In particular, they identified 22 antigens that correlated 
with the clinical course of patients including mutated p53 and thrombospondin-2 (Shigematsu 
et al., 2009). These promising results demonstrated that TIB could be used as a valuable tool 
for tumour diagnosis. 
The same correlation between strong lymphoplasmatic infiltration by B cells in tumour site and 
improved prognosis for patients with MCB was shown by Pavoni and co-workers (Pavoni et al., 
2007). They demonstrated that local humoral immune response within the tumour site of 
breast cancer patients had an oligoclonal character. They found that antibody genes derived 
from tumour infiltrating B cells are predominantly oligoclonal and specific for neo-antigens 
expressed within the tumour site. Using phage-display libraries isolated from MCB tumours 
they tested the functional binding of antibodies from TIB. In particular, they examined 
reactivity against a common tumour associated antigen CEA (carcinoembryonic antigen) but 
also against the MUC1 antigen associated with colon cancer or against the Ed-B domain of 
fibronectin, a marker of angiogenesis in many types of cancers. These results clearly imply that 
oligoclonal antibody selection (mostly IgG as opposed to IgA seen in healthy individuals) takes 
place at the tumour site. Using primary tumours as a source of genes encoding anti-tumour 
antibodies, they described a useful technique for tumour antigen screening that may prove to 
be a valuable tool for future diagnostic and therapeutic anti-tumour approaches.  
It has been also shown that tumour infiltrating human B cells are involved in direct killing of 
tumour cells. Kemp et al., demonstrated that following CpG-A containing 
oligodeoxynucleotides (CpG ODN) stimulation of periphery isolated B cells, the level of 
TRAIL/Apo2 ligand was unregulated. Surprisingly these CD14+, CD19+, and CD56+ B cells were 
able to kill tumour cells in a TRAIL/Apo-2L-dependent manner (Kemp et al., 2004). 
 
 
1.4.2.3. Use of B cells as APC in anti-tumour treatment  
 
Since Lanzavecchia in the middle 1980s clearly showed that antigen-specific B cells efficiently 
present antigen to T cells (Lanzavecchia, 1985) (Lanzavecchia and Bove, 1985), the use of B 
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cells as APC when designing effective tumour vaccines for weak tumour antigens has been 
explored. Indeed, Lapointe et al. tested the capacity of human peripheral B cell to simulate T 
cells against poorly immunogenic tumour melanoma antigens (gp100) or melanoma cell 
lysates. The authors demonstrated that resting B cells, which were activated via CD40 ligation 
and IL-4 treatment and then pulsed with tumour antigens, efficiently processed and presented 
MHC class II restricted peptides to specific CD4+ T cells (Lapointe et al., 2003). This was 
inhibited by the inclusion of anti-MHC class II antibodies. In addition, they also showed B cell 
presentation was sensitive to treatment with chloroquine, which inhibits the processing of 
exogenous antigens by raising the pH of the endocytic pathway. In contrast, CD8+ specific-T 
cells were able to recognise cross-presented antigen from B cells in the presence of 
chloroquine. However, cross-presentation of antigens to CD8+ T cells was five times less 
efficient then canonical MHC class II restricted antigen presentation to CD4+ T cells. 
Importantly, they also demonstrated that compared to DC, B cells have an additional 
advantage in that their proliferation was substantial, thus generating increased numbers of 
effective APC from a reduced volume of patient blood which could also be cryopreserved 
(Coughlin et al., 2004) (Schultze et al., 1997). Consequently, these authors argue that using 
primary B cells as APC, following appropriate stimulation and expansion, has a great potential 
for effective anti-tumour CD4+ T cell generation.  
 
 
1.4.3. Apoptotic antigens as a trigger for anti-tumour immunity  
 
Substantial evidence supports the concept that antigens displayed on cancer cells upon 
apoptosis are able to trigger the local immune-response initiated by B cells. Such infiltrating B 
cells uptake apoptotic antigens from tumour tissue and present to CD4+ T cells, which mediate 
anti-tumour immunity. This state is atypical where apoptosis is usually poorly immunogenic or 
even tolerogenic, with only necrosis resulting in immunity. Understanding the mechanism of 
this process is currently limited and forms the basis of my studies.  
For example, it has been shown that the cytoskeletal protein -actin was exposed on the 
surface of medullary breast carcinoma (MBC) cells treated by TNF, cycloheximide (CHX) or 
granzyme B as an early apoptotic event. Hansen et. al. (Hansen et al., 2002) indicated an 18% 
increase in actin display on the surface compared with non-treated MBC cells. They also 
observed that B cells and plasma cells infiltrating MBC are specific for actin and induce an 
oligoclonal response.  
Similar evidence has been provided by Obeid et al. (Obeid et al., 2007b) who have shown that 
calreticulin, a ER resident chaperon, can be exposed on the surface of cancer cells upon 
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apoptosis and can stimulate immunogenicity. Furthermore, they classified differences 
between several apoptotic-inducing stimuli. Most cytotoxic agents that target the ER 
(brefeldin, tunicamycin), the mitochondria (arsenite, C2 ceramide) or DNA (etoposide, 
mitomycin C) failed to induce immunogenic cell death. However, treatment with anthracyclins 
(doxorubicin, idarubicin and mitoxantrone) did lead to specific calreticulin-induced 
immunogenicity (Obeid et al., 2007b). Another study by Koltan et al. (Kotlan et al., 2005) has 
described the importance and immunogenic capacity of gangliosides, particularly GD3 in 
breast carcinomas. The authors postulated that tumour infiltrating B cells have specific 
tumour-recognizing capacity against GD3. Moreover they indicated that in the other types of 
cancers like neuroblastoma or melanoma, GD2 is overexpressed and stimulates a local 
oligoclonal B cell response against this antigen.  
Another example of the apoptotic induction of protein relocation resulting in ‘neo’ antigen 
recognition by B cells can be seen in the autoimmune disorder primary biliary cirrhosis (PBC). 
Patients with this disorder are characterized by the presence of high levels of auto-antibodies 
specific for several components of inner mitochondria membrane proteins. Interestingly, one 
of these auto-antigens, pyruvate dehydogenase complex (PDC) was shown to be redistributed 
to the cell surface upon apoptotic induction (Robe et al., 2005) (Jones et al., 2002). Following 
this relocation, it is therefore possible that the PDC specific auto-reactive B cells can bind, 
internalize and present this normally intracellular antigen to activate auto-reactive, PDC 
specific CD4+ T cells and initiate disease.  
All together these findings imply that several distinct intracellular proteins such as actin, 
gangliosides and PDC, can become targets for B cell recognition following relocation induced 
by apoptosis. 
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1.5. Changes in intracellular protein organization during apoptosis  
 
 
1.5.1. Apoptosis as a type of cell death 
 
Apoptosis is a physiological, gene-directed form of cell death causing controlled cell 
proliferation in several biological conditions and maintenance of tissue homeostasis. It plays a 
crucial role in modulating tissue growth during embryonic development and cell turnover in 
adult life. Moreover, apoptosis plays an important role in the immune system and represents a 
highly efficient mechanism for the destruction of infected cells as well as removing excess 
lymphocytes both during immune cell development as well as a way of controlling 
lymphocytes life span following immune responses. Programmed cell death was first described 
in 1972 by Currie, Kerr and Wyllie. The term was used to describe a common type of 
programmed cell death that the authors repeatedly observed in various tissues and cell types. 
The authors noticed that these dying cells shared many morphological features, which were 
distinct from the features observed in cells undergoing pathological, necrotic cell death. 
Unregulated necrotic cell death is the result of sudden, massive destruction of organelles such 
as mitochondria or lysosomes. According to Savill et al., (Savill et al., 2003) a crucial feature of 
necrosis in vivo is that dying cells disintegrate and release cell contents before the debris is 
ingested by phagocytes. Moreover, necrosis is difficult to prevent, whereas the apoptotic 
pathway can potentially be modulated to maintain cell viability. These two processes are 
temporally dislocated and represent two extremes of a continuum: the necrosis process can 
start only and exclusively when the cell dies and is an irreversible process, a ‘no return’ way in 
the cell life, while apoptosis is a ‘special’ form of cell death with the characteristics of an active 
process. On the other hand, mild perturbation of different cellular compartments can trigger a 
coordinated sequence of biochemical events. The culmination of this process is apoptotic 
cellular demise that is regulated at the organellar or cellular levels. Characteristic features of 
apoptosis mostly concern: cell shrinkage, chromatin condensation, nucleosomal DNA 
degradation and fragmentation of the cell into ‘apoptotic bodies’ (Gozuacik and Kimchi, 2004) 
which are phagocytosed by neighbour cells.  
This chapter has documented many recent findings that the consensus on apoptotic cell death 
largely result in immunosupression appears no longer valid. Indeed, in the study of anti-
tumour immunity the certain cytotoxic agents may have been shown to induce 
immunostimulatory apoptosis. A key feature of this apoptotic immnunoactivation is 
intracellular protein relocation to the cell surface from dying cells resulted in effector cells 
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stimulation. Therefore, understanding how proteins from different cellular compartments are 
reorganized during apoptosis is of considerable importance. In this way, cellular components 
might reflect novel markers either as a signal for phagocytosis or for the induction of immune 
recognition. Moreover, each organelle can sense a stressful and pathogenic alteration, which 
either leads to adaptation or reaches a critical threshold of damage.  
 
 
1.5.2. The major pathways of apoptosis 
 
The initiation of apoptosis in mammalian cells is broadly divisible into two separate pathways 
(Putcha et al., 2002). One pathway known as the intrinsic pathway is initiated by several 
stimuli, including cell-cycle or metabolic perturbations, oxidative stress, DNA damage or the 
lack of growth-factor signalling, treatment with corticosteroids or staurosporine. This causes 
the induction of apoptotic protease activating factor 1 (Apaf-1), cytochrome c and activated 
proteolytic enzymes termed caspases which are the core of the apoptotic machinery caspases. 
In particular caspases-9 plays a pivotal role in the intrinsic pathway. Currently, about 14 
caspases have been identified and they are synthesized as inactive zymogens containing a pro-
domain, a p20 large domain and a p10 small domain (Lamkanfi et al., 2007). These zymogens 
can be cleaved to their active form following the induction of apoptosis. A characteristic 
feature of caspases is substrate cleavage at the C-terminal region. 
Most physiological cell death in mammals occurs through apoptosis, mainly proceeding via the 
intrinsic mitochondrial pathway. The metabolic consequences of mitochondrial outer 
membrane permeabilization (MOMP), as well as the leakage of apoptotic factors normally 
confined to mitochondria determine the catabolic features of cell death. Regulation of the 
mitochondrial apoptotic pathway is mainly controlled by B cell lymphoma-2 (Bcl-2) family 
members located within mitochondria, ER and nucleus (Patel et al., 2009). All isolated Bcl-2 
family members (about 20 proteins in mammals) are characterised by one of the four relatively 
conserved Bcl-2 Homology Domains (BH). Some of the family members (including Bcl-2 and 
Bcl-XL)
 are apoptosis-inhibitory proteins, others (such as Bax, Bad, and Bid) are promoters of 
apoptosis. Normally, Bax and Bak reside in the cytosol, however upon receipt of the apoptotic 
signal, these proteins migrate and bind to the mitochondrial membrane in the place called 
’permeability transition pore’. This state induces loss of selective ion permeability. The loss of 
mitochondrial membrane integrity and permeability is the result of releasing many proteins 
from lumen of mitochondria for example: cytochrome c, Smac/DIABLO (second mitochondrial 
activator of caspases), HtrA2/Omi (high-temperature requirement serine protease A2), 
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adenylate kinase 2, AIF (apoptosis-inducing factor), pro-caspases-2, -3, and 9. The 
consequences of this process are the loss of mitochondrial functions essential for cell survival 
(Ferri and Kroemer, 2001a). As a result of the membrane changes, there is release into the 
cytosol of the contents of the intermembrane space, including cytochrome c and AIF. AIF 
moves directly to the nucleus, where it produces chromatin condensation and nuclear 
fragmentation. Cytochrome c is the only known activator of the cytoplasmic protein Apaf-1 but 
binding to Apaf-1 which is necessary for the subsequent activation of procaspase-9. Caspase-9 
activates downstream caspases, including procaspase-3, responsible for the cytological 
changes (Burz et al., 2009).  
The second type of apoptotic pathway (the extrinsic pathway) is initiated by the binding of 
extracellular ligands (e.g. Fas ligand and granzyme B) to tumour necrosis factor (TNF) family 
receptors such as Fas that finally activate executor caspases that mediate DNA fragmentation 
(Duiker et al.). Initial activation of the extrinsic pathway requires Fas-associating death domain 
(FADD), caspase 8. The link in intrinsic and extrinsic mechanism is carried by a Bcl-2 family 
member (BID). When BID connects the receptor-initiated (extrinsic) and stress-signal (intrinsic) 
pathways through caspase-8 cleavage of BID into truncated BID (tBID), then tBID translocates 
to the mitochondria resulted in the release of cytochrome c and activation of Apaf-1 and 
caspases (Ashkenazi, 2008). The binding of cytochrome c to Apaf-1 causes Apaf-1 to adopt a 
more open conformation. This state facilitates the further binding of dATP/ATP, allowing Apaf-
1 multimerization and association of pro-caspase-9, thus generating the apoptosome. 
Activated caspase-9 in turn cleaves caspase-3, causing apoptotic cell death.  
 
 
1.5.3. Apoptosis regulation at the endoplasmic reticulum  
 
The proper functioning of the ER is crucial for numerous aspects of cell physiology. All 
eukaryotes react rapidly to ER dysfunction through a set of adaptive pathways know as ER 
stress (ERS). Although ERS has been implicated in numerous types of pathology, the regulation 
and execution of ERS-induced apoptosis in mammals is still not completely understood. ERS 
can be triggered by disparate perturbation in normal ER function, such as the accumulation of 
unfolded, misfolded or excessive proteins or by Ca2+ signaling (Ferri and Kroemer, 2001b). 
Moreover ER lipid or glycolipid imbalances, or changes in the redox or ionic conditions of the 
ER lumen can lead to ERS (Ferri and Kroemer, 2001b) (Granville et al., 2001). However, when a 
stress is so strong or persistent that ER dysfunction cannot be corrected, cells can initiate 
apoptosis, allowing the regulated destruction of cell rather than cause irreparable damage or a 
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risk to the organism as a whole. The mechanism by which ER stress is induced, results in the 
activation of caspases-12. According to Nakagawa et al., caspases-12 null mice and cells are 
partially resistant to apoptosis induced by ER stress but not by other stimuli (Nakagawa et al., 
2000). Caspase-12 is specifically located on the cytoplasmic side of ER. During releasing Ca2+ 
ion stores from the ER caspase-12 is proteolytically activated by m-calpain.  
 
 
1.5.4. Dynamics of nuclear proteins during apoptosis 
 
One of the biochemical hallmarks of apoptosis is genetic DNA fragmentation and disintegration 
of nuclear envelope that precede the nuclear breakdown phase. Proteins of the nuclear 
envelope, which support the nuclear architecture, are directly cleaved by the effector caspases. 
Disintegration of the lamina proteins is a typical feature for cell death because the structural  
support of the nucleus depends on an intact lamina structure. The lamin B proteins are cleaved 
by caspase-3, whereas the lamin A/C proteins are cleaved by caspase-6 (Ruchaud et al., 2002). 
Moreover, it was suggested that chromatin condensation during apoptosis depends on 
degradation of lamin A (Ruchaud et al., 2002). 
According to Croft et al., 2005 (Croft et al., 2005) the cytoskeletal actin-myosin-based 
contraction is required for disruption of nuclear integrity during apoptosis. Thus, it is possible 
that activation of apoptosis affects first the cytoskeleton, which subsequently affects lamina 
organization and the formation of intra-nuclear structures. This process leads to massive 
degradation of the lamina and causes nuclear breakdown. Degradation of lamina proteins is 
not specific for caspase-8-induced apoptosis because the intrinsic pathway also triggers 
degradation of lamina proteins (Broers and Ramaekers, 2004). Thus, lamina degradation is a 
crucial event before DNA degradation and nuclear breakdown can take place. It has been 
shown that cleavage of lamin A by caspase-6 is required for chromatin condensation (Ruchaud 
et al., 2002). During the nuclear breakdown phase, cleavage of the lamina proteins precedes 
DNA condensation, which is subsequently fragmented. First the genome is cleaved into 50-300 
kbp DNA fragments, which possibly reflects structure of chromatin loops and hexametric loops 
structures. 
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1.5.5. Protein relocation upon apoptosis  
 
 from nuclei: 
In the past decade, there have been considerable improvements in the way of characterization 
auto-antigens in chronic autoimmune diseases. One of autoimmune disorder is Sjogren’s 
syndrome characterized by the abnormal production of antibodies in the blood that are 
directed against various tissues of the body. This particular autoimmune illness features 
inflammation in certain glands of the body as a result of recognition by auto-antibodies of 
nucleic acid or protein complexes relocated to the cell surface. However the mechanism of 
intracellular antigens relocation is still unclear. According to McArthur et al., one of the 
possibilities of distribution auto-antigens to the surface is process of apoptosis induced by 
TNF-in the salivary gland cells. They demonstrated that nuclear proteins like SS-A (Ro) and 
SS-B (La) and cytoplasmatic protein fodrin are translocated to the membrane of apoptotic cells 
leading in local secretion of auto-antibodies and finally tissue injury (McArthur et al., 2002). 
Using cell fractionation and immunofluorescence techniques they revealed that at increasing 
time after TNF- and cycloheximide treatment these proteins were relocated to the cell 
surface. These findings have been clearly implicated in salivary gland destruction in Sjogren’s 
syndrome as a potential auto-antigens acting autoantibody production that may allow in 
better understanding the mechanism of autoimmunity.  
 
 from cytoplasm: 
During the process of apoptosis, cells lose volume due to cytoplasm ‘boiling’ and plasma 
membrane blebbing, and form apoptotic bodies that initially remain surrounded by 
membranes. This increased membrane usage has to be substituted from internal sources. 
Recently, it has been indicated that ER and Golgi apparatus are candidates for substituting the 
membrane loss during the process of particle ingestion. Franz et al. (2007) (Franz et al., 2007) 
revealed that cells undergoing apoptosis change the glycosylation status of their membrane, 
for example at the surface exposure of the lectin-binding sites. Furthermore, they 
demonstrated that after shrinkage apoptotic cells displayed increased levels of ER-resident 
lipids, proteins and immature glycoproteins. They suspected that immature proteins are 
translocated via the actin network to the cell surface during the late phase of apoptosis. 
Particularly, it has been shown that ER-resident chaperon calnexin was observed on the 
surface of PI impermeable cells after shrinkage induced by UVB in Jurkat cells. Moreover, a 
small fraction of calnexin was also relocated to the surface of various cells such as 
mastocytoma cells, murine splenocytes, fibroblast cells and human HeLa cells. The same 
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observation was made using confocal microscopy. Viable and necrotic cells did not show 
surface staining for calnexin, while PI negative apoptotic cells exclusively displayed plasma 
membrane fluorescence. To support this hypothesis Franz et al. (2007) (Franz et al., 2007) used 
a HC immunoglobulin heavy chain that in viable cells should be retained in the ER and not 
reach the cell surface. Using fluorescence microscopy, they verified that vital HC transfected 
Ag.8 cells (mouse myeloma) did not show surface exposure of HC. In contrary, after UV-B 
irradiation, HC could be detected at the surface of apoptotic Ag.8 cells.  
Franz and coworkers (2007) (Franz et al., 2007) also demonstrated that: glycolipid gangliosid 
(GM1) and ER-Tracker are redistributed to the plasma membrane in late apoptotic cells. These 
two lipids are normally located in the ER membrane. The location of GM1 and the ER-Tracker 
showed that both molecules co-located inside viable cells and at the plasma membrane of 
apoptotic cells. Furthermore, Franz et al. (2007) (Franz et al., 2007) monitored the relocation 
of internal membranes to the surface using KDEL receptor-GFP transfected HeLa cells. In viable 
cells the KDEL receptor was located in ER/cis-Golgi compartment as an integral membrane 
protein. However, after UVB irradiation when the plasma membrane had started blebbing the 
ER-membranes and KDEL receptor were relocated to the cell surface. These results clearly 
show that during apoptosis the ER membrane is transported to the cell surface to replace 
plasma membrane that is lost during the blebbing process.  
 
 from ER: 
In order to prior belief, apoptotic cell death can be non-immunogenic. However Tufi et al. 
revealed that cancer cell lines HeLa and neuroblastoma (SH-SY5Y) treated with anthracyclines 
can elicit anticancer immune response. They show that anthracyclines lead to the exposure of 
intra-cellular protein calreticulin on the plasma membrane of dying tumour cells and hence 
stimulate the recognition and engulfment dying cells by DC or macrophages (Tufi et al., 2008).  
CRT was identified in 1974 as a soluble protein from the lumen of the ER which buffers Ca2+ 
level and also participates in the folding of newly synthesised glycoproteins, preventing their 
aggregation. Interestingly, translocation CRT to the surface occurred only when ER Ca2+ level 
was reduced. These results are in contrast to former study where in colon cancer and 
fibrosarcoma cell lines low level of ER Ca2+ did not play crucial role in the relocation CRT to the 
cell surface. For example, they indicated that only in anthracyclines-treated SH-SY5Y or HeLa 
cell lines that overexpressed Reticulon-1C (RTN-1C) or treated with thapsigardin, translocation 
of CRT to the surface is observed. Both RTN-1C and thapsigardin are involved in the decrease 
of ER Ca2+ level. To regulate Ca2+ level by overexpession RTN-1C they used tetracycline-
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inducible model in doxycycline pre-treated SH-SY5Y cells (SH-SY5YRTN-1C). Interestingly, western 
blot analysis shows that 24h from anthracycline-treating in SH-SY5YRTN-1C the total level of CRT 
was comparable to SH-SY5Y cell. This observation suggests that ecto-CRT occurrence on the 
cell surface is due to translocation rather than de novo synthesis of CRT. In situ 
immunofluorescence images also revealed ecto-CRT surface staining and partially overlapping 
with ecto-RTN in non-permeabilized cells. Moreover, inhibition SERCA pomp by thapsigardin 
was also able to induce CRT relocation to the surface in SH-SY5Y cells. To summarize Tufi et al. 
suggest that ER Ca2+ homeostasis plays a major role in the regulation of CRT exposure, 
however many aspects are still unclear. For example this manipulation does not induce 
apoptotic features, suggesting that CRT exposure and apoptosis may be independent 
processes from each other. There is necessity for further investigation to answer this question. 
Also Brusa et al. has found that late stage of apoptosis have the ability to stimulate DC to 
phagocytosis of cancer cells. They demonstrated that renal carcinoma cells (RCC53), followed 
UVC irradiation undergo apoptotic changes like extracellular exposure of PS, surface relocation 
of CRT and releasing of HMGB1 (Brusa et al., 2008). In addition DC, incubated with apoptotic 
tumour cells, more efficiently cross-present tumour antigen to CTL cells. Surprisingly, UVC 
treated tumour cells are more likely phagocytised by DC cells than -irradiated RCC53 cells. 
According to Brusa et al. 3.6 J/cm2 of UVC dose within 4 h cause apoptotic changes in RCC53 
cells leading to PS externalization, translocation of CRL from the ER to the cell surface and 
occurrence of other molecules which are involved in the process of apoptotic cell uptake. 
Therefore, DC during 20 h incubation with apoptotic tumour cells endocytose them and 
produce pro-inflammatory cytokines such as TNF-, IL-1and IL-6. Furthermore, they show 
that isolated mRNA from DC, previously pulsed with UVC-treated RCC53 cells, expressed a 
large number of genes encoding IFN-, in particular IFNA2, IFNA5 but also genes encoding IL-
12. In protein level they also revealed upregulation in expression of costimulatory molecule 
CD80, CD83 and MHC class I complexes. 28 h later such maturated DC cells present tumour 
antigens in context MHC class I more efficiently to CD8+ T cells than DC cells loaded with 
untreated tumour cells. Using degranulation assay they demonstrated that expression of 
CD107 in CD8+ T cells, following stimulation with DC loaded with apoptotic tumour antigens, 
significantly increases. This experiment clearly indicates that cytolytic phenotype of T cells was 
correlated with type of tumour antigen presented by DC (Brusa et al., 2008).  
 
55 
1.6. Aim of the project 
 
As discussed in this chapter, there are various anti-tumour therapies including cytokine 
therapy, adoptive transfer, chemotherapy and radiotherapy. However, neither of these 
therapies in general results in complete eradication of tumours and has various side effects. 
Therefore, this project intended to explore a novel approach of anti-tumour immunotherapy. 
In particular, this thesis has focused on the hypothesis that following the induction of 
apoptosis by certain agents, intracellular tumour antigens will be relocated to the cell surface. 
Importantly, I also hypothesised that antigen-specific B cells would be capable of recognising 
these relocated antigens and directly activate antigen-specific T cells. Understanding novel 
mechanisms of tumour antigen recognition by B cells may consequently lead to improved 
tumour elimination and may find potential implementation in the clinics.  
In particular, to test this hypothesis I will attempt to: 
1. generate a panel of plasmids encoding a model antigen targeted to various subcellular 
compartments 
2. monitor the surface relocation of this intracellular antigen following treatment with 
different apoptotic stimuli  
3. establish an in vitro system to allow the detection of surface re-distributed antigen by 
antigen-specific B cells and its subsequent presentation to cognate T cells  
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-  2. Hen egg lysozyme as a model antigen  
to study antigen recognition  - 
 
2.1. Introduction 
 
Previous experiments from several laboratories have demonstrated that proteins can relocate 
to the cell surface following apoptosis from the mitochondria, the ER and from the cytosol 
(Lane et al., 2005; McArthur et al., 2002; Obeid et al., 2007b; Panaretakis et al., 2008). A 
number of these antigens can be termed ‘silent’ tumour antigens that following apoptosis may 
become immunogenic and consequently promote anti-tumour immunity. Therefore, we 
decided to establish an assay to allow the measurement of antigen extraction by B cells from 
the cell surface of a tumour cell line. These intracellular antigens following apoptotic stimuli 
should be relocated to the tumour cells surface, extracted and presented to T cells (Fig. 2.1.). 
This novel in vitro system of tumour antigen recognition by B cells following apoptosis may 
allow the understanding of the induction of improved anti-tumour immunity that could 
eventually be translated into the clinic.  
 
Fig. 2.1. A schematic representation of hypothesis for a novel role of B cells in the induction of anti-
tumour immunity. Tumour cell e.g. HeLa cells transfected with intracellular model antigen (1.) 
undergo apoptotic cell death. This specific type of cell death induces intracellular protein relocation to 
the surface (2.). B cells can activate T cell-mediated anti-tumour immunity in response to protein 
relocation from apoptotic tumour cells (3.).  
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To establish and study protein relocation following apoptosis induction, I decided to use a 
well defined model antigen - hen egg lysozyme (HEL). HEL is an enzyme with bacteriolytic 
properties that was first identified and named by Alexander Fleming almost ninety years 
ago. It is comprised of 129 amino acid residues and its molecular weight is 14.5 kDa. 
This antigen has many advantages. Firstly, HEL is a small easy to purify and commercially 
available soluble protein. The X-ray crystallography of HEL (Fig. 2.2.) complexed with several 
anti-HEL monoclonal antibodies is also well documented. One of these antibodies, HyHEL 10 
(Gerwing and Thompson, 1968) (Smith-Gill et al., 1984) can be used to detect HEL expression 
by immunofluorescence. Additionally, our laboratory has B cells expressing the HyHEL10 
antibody as a membrane bound BCR (Smith-Gill et al., 1984). To follow antigen 
presentation of HEL by these specific-B cells our laboratory also has a panel of HEL-
specific T cell hybridomas (Adorini et al., 1993). To this end, T cell hybridomas will be used 
as a read out of extracted antigen by B cells in this in vitro system. Following antigen 
relocation from various sub-cellular compartments and its subsequent extraction and 
presentation to HEL-specific CD4+ T cells, it is hoped that this system will allow to 
understand the role of B cells presenting novel antigen from apoptotic tumour cells.  
 
 
  
Fig. 2.2. Schematic representation of the structure of HEL (a.) (www.fodras.com). Panel b. shows the 
X-Ray of 3D structure of HEL with disulphate bonds highlighted on orange 
http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=69658. 
 
a. b. 
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2.2. Results 
 
 
2.2.1. Sub-cellular localization of HEL   
 
To localize HEL to a number of discrete sub-cellular compartments, I used a panel of plasmids 
(Fig. 2.3.) received as a kind gift from S. Ostrand-Rosenberg (Qi et al., 2000) and  
F. Batista (Batista and Neuberger, 2000) (Carrasco and Batista, 2006a).  
1. membrane–HEL (mem-HEL). This construct encodes a membrane anchored variant of HEL 
(using the transmembrane domain of the mouse MHC class I molecule, H2Kb ). The predicted 
molecular weight of the protein encoded by this construct is 21 kDa.  
2. mitochondria-HEL (mito-HEL). This construct contains cytochrome c oxidase subunit VIII that 
is expected to localize HEL within mitochondria. The predicted molecular weight of the protein 
encoded by this construct is 16 kDa.  
3. nucleus-HEL (nuc-HEL). This construct contains a triplicate nuclear localization sequence 
(NLS) from SV40 large T antigen which is expected to direct HEL expression into the nucleus. 
The predicted molecular weight of the protein encoded by this construct is 19 kDa.  
4. cytosol-HEL (cyto-HEL). This construct does not contain any targeting sequences and is 
therefore expected to retain HEL in the cytosol. The predicted molecular weight of the protein 
encoded by this construct is 15.5 kDa. 
 
Following bi-directional sequencing I transfected HeLa cells (epithelial cell line derived from 
cervical cancer) (Scherer et al., 1953) with each of the plasmids. I decided to use this type of 
tumour cells for two reasons. Firstly, HeLa cells are relatively easy to transfect by liposome 
compounds for the delivery of exogenous nucleic acids commonly used in laboratories. In 
particular, using Lipofectamine 2000TM (Invitrogen) transfection agent, HeLa cells could be 
transfected into 70-90%, according to the manufacturer’s protocols. Secondly, these adherent 
cells have a typical mammalian cell morphology which allows easy visualization of sub-cellular 
compartments. Also, HeLa cells are very easy to maintain in culture.  
Initially, I optimised conditions for the most efficient transfection. Then, I tested various time 
points of plasmid expression between 24 h and 72 h and I also examined different amounts of 
DNA used during transfection procedure ranging between 0.2 g to 2 g of DNA (data not 
shown). Optimal HeLa transfection was shown to be using 1 g of DNA with protein expression 
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being measured 24 h following transfection. Furthermore, transfection efficiency was routinely 
60 – 70% using Lipofectamine 2000.  
The expression pattern of HEL was characterised with either the HyHEL 10 monoclonal 
antibody or a polyclonal anti-HEL antibody using a combination of immunofluorescence 
microscopy and laser scanning microscopy (LSM). To confirm the correct localisation of nuc-
HEL, mito-HEL and cyto-HEL expression, the HeLa transfectants were co-stained with 
antibodies/reagents specific for the appropriate sub-cellular compartments. In particular, I 
used Hoechst, which binds to nuclei and the mitochondrial-specific dye MitoTracker Red. In 
addition, I also co-transfected control plasmids expressing either green fluorescent protein 
(GFP) in mitochondria (mito-GFP) or enhanced green fluorescent protein (EGFP) in the cytosol 
(cyto-EGFP). As these vectors also contain sequences encoding an additional 10 amino acid c-
Myc tag, protein expression was also detected either by polyclonal anti-HEL antibody or by 
anti-c-Myc (9E10) antibody using Western blotting. (Note: plasmid encoding mem-HEL did not 
contain c-Myc epitope and expression was detected only with a polyclonal anti-HEL antibody). 
 
 
 
Fig. 2.3. A schematic representation of the panel of HEL cDNA constructs used in this study. 
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2.2.2. Mem-HEL expression  
 
Initially, to confirm correct mem-HEL expression in HeLa transfectants, I performed Western 
blotting. Fig. 2.4. shows that the lysates from mem-HEL transfectants contain a protein which 
is reactive with a polyclonal anti-HEL antibody of the expected molecular weight (21kDa). 
Furthermore, as this plasmid represents a control for HEL expression on the cell surface my 
first aim was to confirm surface detection using fluorescence and confocal microscopy (Fig. 
2.5.). Following transfection, HeLa cells were stained with HyHEL 10 (anti-HEL) primary 
antibody and then an anti-mouse FITC labelled secondary antibody. After fixation, cells were 
either stained directly (Fig. 2.5., Fig. 2.6.) or permeabilized prior to staining (Fig. 2.7.). Direct 
staining with primary and secondary antibodies without permeabilization prevented 
intracellular binding of HEL and surface staining was able to be distinguished from intracellular 
staining (Fig. 2.5.). Using confocal microscopy single cells were also analysed in both vertical 
and horizontal planes to produce images such as those shown in Fig. 2.5. panel c., where the 
expression of HEL can be clearly seen as a circle around the edge of cell. Furthermore, results 
from immunofluorescence microscopy also revealed membrane staining as a diffused 
fluorescence without any discrete intracellular staining. When the transfectants were 
permeabilized prior to staining, both a diffused pattern and accumulation of HEL surrounding 
the nuclei was observed consistent with normal protein synthesis and exit from the ER (Fig. 
2.7.).  
 
 
 
              
 
 
Fig. 2.4. Western blot analysis of transiently transfected mem-HEL HeLa cells. Lysates form 
0.8x105cells per lane were separated on 14 % gel and following transfer were stained with primary 
anti-HEL and anti-rabbit-HRP. Numbers to the right represent the migration of standard molecular 
weight markers (kDa) (ProSieve). The western blot analysis is representative of 2 separate 
experiments.  
 
mem-HEL 
30kDa 
 
21kDa 
anti-HEL  
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                                                        mem-HEL without permeabilisation  
               
Fig. 2.5. Immunofluorescence analysis of mem-HEL expression in transiently transfected HeLa using 
confocal microscopy. After fixation cells were stained with anti-HEL mouse primary antibody (HyHEL 
10) and anti-mouse-FITC (panel a., b., c.). Panel b. and c. show cells incubated with Hoechst 33342 dye 
to visualise nuclear staining. Panel c. shows a 3D projection of single HeLa cell which was sectioned in 
vertical and horizontal plane to directly visualise cell membrane. The images are representative of 6 
separate experiments.  
 
                                                         mem-HEL without permeabilisation 
                 
Fig. 2.6. Immunofluorescence analysis of mem-HEL expression in transiently transfected HeLa using 
fluorescence microscopy. After fixation cells were stained with anti-HEL mouse primary antibody 
(HyHEL 10) and anti-mouse-FITC (panel a.). Then cells were incubated with Hoechst 33342 dye (panel 
b. and c.) to visualise nuclei. The images are representative of 6 separate experiments.  
 
                                                          mem-HEL with permeabilisation 
                    
Fig. 2.7. Immunofluorescence analysis of mem-HEL expression in transiently transfected HeLa using 
fluorescence microscopy. After fixation and permeabilisation cells were stained with anti-HEL mouse 
primary antibody (HyHEL 10) and anti-mouse-FITC (panel a. and c.). Panel b. and d. are representation 
of the same images from panel a. and c. respectively, but additionally including nuclei visualised by 
Hoechst 33342 dye. The images are representative of 6 separate experiments.  
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2.2.3. Mito-HEL expression  
 
The first plasmid designed to target intracellular antigen localisation contained a mitochondrial 
targeting sequence (mito-HEL). As previously, HeLa transfectants were analysed using a 
combination of Western blotting and fluorescence/confocal microscopy. Lysates from 
transfectants were separasted on SDS-PAGE gels and transferred to nitrocellulose. As the mito-
HEL plasmid contains the c-Myc tag, following transfer the membranes were incubated with 
the anti-c-Myc monoclonal antibody 9E10. In Fig. 2.8., it can be seen that 9E10 antibody 
recognises endogenous c-Myc seen in lysates from both untransfected and as well HeLa 
transfectants (upper band on the level of 32 kDa) (Ferre et al., 1986). In addition, it can be seen 
a band of approximately 16 kDa, that is consistent with the expected size of mito-HEL that also 
contains a c-Myc epitope.  
Furthermore, to establish that the mito-HEL plasmid was targeting HEL to the correct sub-
cellular compartment, I analysed transfectants using fluorescence and confocal microscopy. To 
identify mitochondrial staining, I co-transfected the cells with a control plasmid: mito-GFP 
(pShooter commercial plasmid from Invitrogen) and also incubated them with a mitochondrial 
specific dye MitoTracker Red. This dye passively diffuses across the plasma membrane and 
accumulates in the active mitochondria (see Material and Methods). Importantly, MitoTracker 
contains a mildly thiol-reactive chloromethyl moiety that maintains the dye associated with 
the mitochondria following fixation. Indeed, in Fig. 2.9. it can be clearly seen that the mito-GFP 
expression and the MitoTracker Red staining overlap and localise to many punctuate vesicles 
surrounding the nuclei. Furthermore, it was also confirmed using colocalisation analysis 
software that these two staining patterns show significant overlap (data not shown). These 
initial findings allowed the subsequent analysis of mito-HEL localisation to be examined. When 
I transfected HeLa cells with the pCMV-mito-HEL construct, punctuate vesicles surrounding the 
nuclei were also observed following staining with the HyHEL 10 antibody (Fig. 2.10.). However, 
this staining pattern was identical neither to that seen in cells transfected with the mito-GFP 
construct nor to these labelled with MitoTrackerRed. Therefore, I co-transfected HeLa cells 
with mito-HEL and mito-GFP to analyse colocalization. Fig. 2.11. panel b. (colocalisation chart) 
represents dual colour analysis of mito-GFP and mito-HEL expression that indicates that HEL 
and GFP proteins did not colocalise. It can be seen that both green and red fluorochromes are 
still distinct. If colocalisation was observed, orange should be seen in the middle of chart due 
to overlay red (mito-HEL) and green (mito-GFP) fluorochromes. Based on this and the data 
illustrated in Fig. 2.11., it appears that mito-HEL was not expressed in mitochondria.  
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                                                     anti-cMyc 
 
Fig. 2.8. Western blot analysis of transiently transfected mito-HEL HeLa cells. Cells lysates from 
different numbers of mito-HEL HeLa transfectants (lane 1: 1.6x105 of cells, lane 2: 3.2x105 of cells and 
lane 3: 0.8x105 of untransfected cells) were separated on 14 % SDS-PAGE gel and following transfer 
were stained with primary anti-cMyc (mouse 9E10) antibody and anti-mouse-HRP. Numbers to the 
right represent the migration of standard molecular weight markers (kDa) (ProSieve). The western 
blot analysis is representative of 2 separate experiments.  
 
 
 
        
Fig. 2.9. Fluorescence microscopy of HeLa cells transiently transfected with mito-GFP (panel a.). Panel 
b. represents HeLa cells stained with MitoTracker Red to visualise mitochondria. Additionally, both 
panels show Hoechst nuclear staining (blue). The images are representative of 6 separate 
experiments.  
 
 
    
Fig. 2.10. Fluorescence microscopy of HeLa cells transiently transfected with mito-HEL (panel a., b., c. 
and d.) to visualise mitochondria. Additionally, panel b. and d. show Hoechst nuclear staining (blue). 
These experiments used anti-HEL mouse antibody (HyHEL 10) and anti-mouse conjugated with TRITC 
(panel a. and b.) or FITC (panel c. and d). The images are representative of 6 separate experiments.  
 
b. a. c. d. 
a.  b. 
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Fig. 2.11. Transient co-transfection of HeLa cells with mito-HEL (red) and mito-GFP (green). Panel a. 
represents images captured from fluorescence microscopy, while panel b. represents images using 
confocal microscopy. Panel c. is a colocalization chart demonstrating the intensities of measured red 
(mito-HEL) and green (mito-GFP) pixels (on the y and x axes respectively) corresponding to the 
randomly selected field of 2 individual HeLa cells shown in panel b. Cells were stained with anti-HEL 
antibodies (HyHEL 10) and secondary anti-mouse-TRITC and Hoechst (blue). The images are 
representative of 6 separate experiments.  
 
 
 
2.2.4. Mito-GFP-HEL expression  
 
Consequently, as mito-HEL did not appear to localise to mitochondria, I constructed a new 
plasmid. This construct (mito-GFP-HEL) was engineered as a fusion protein to express both HEL 
and GFP in mitochondria. Having N’terminal inserted GFP as a marker of expression it was easy 
to detect whether the fusion protein is correctly translated and directed into mitochondria.  
Dual colour analysis from confocal microscopy shows (Fig. 2.12. panel b.) that the pattern of 
GFP expression was similar to that seen with mito-GFP construct (Fig. 2.9. panel a. and b.). 
However, this figure also shows (Fig. 2.12. panel c.) that no HEL expression can be detected by 
the HyHEL10 antibody. Thus, it appears that the failure to detect HEL in the mitochondria 
maybe as a result of incorrect HEL folding/structure. To test that this fusion construct is 
synthesised, I also examined lysates from mito-GFP-HEL transfectants. Protein extracts from 
transfectants were run on gels and transferred to nitrocellulose and probed with anti-c-Myc, 
anti-HEL and anti-GFP antibodies (Fig. 2.13. panel a. and b.). This confirmed that both anti-HEL 
antibodies as well as the C-terminal c-Myc tag antibody 9E10 were not reactive with this HEL 
fusion protein.  
a. b. . 
c. 
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Fig. 2.12. Visualisation of mitochondria in transiently transfected mito-GFP-HEL HeLa cells performed 
using confocal microscopy. In these experiments were used anti-HEL mouse antibody (HyHEL 10) and 
anti-mouse conjugated with TRITC (panel c.). Panel a. shows Hoechst nuclear staining, panel b. 
indicates GFP expression and panel d. represents overlap image from these three colours. The images 
are representative of 6 separate experiments.  
 
 
 
     a.                                                                                      b.        
                 pCMV-mito-GFP-HEL                                
                                            
     anti-c-Myc         anti-HEL        anti-GFP                                            anti-GFP  
 
Fig. 2.13. Western blot analysis of transiently transfected (a.: pCMV-mito-GFP-HEL and b.: pCMV-mito-
GFP (lane 1), mito-GFP-HEL (lane 2)) HeLa cells. Cell lysates from 0.8x105 cells were separated on 14% 
SDS-PAGE gel and following transfer were stained with primary (a.) anti-c-Myc (mouse 9E10), anti-HEL 
and rabbit anti-GFP antibodies (followed by secondary anti-mouse-HRP, anti-rabbit-HRP, anti-rabbit-
HRR respectively), (b.) with primary anti-GFP (rabbit) antibody and secondary anti-rabbit-HRP. 
Numbers to the right represent the migration of standard molecular weight markers (kDa) (ProSieve). 
The western blot analysis is representative of 2 separate experiments.  
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2.2.5. Nuc-HEL expression 
 
To characterise the expression of the nuc-HEL construct, I performed Western blotting with 
lysates from pCMV-nuc-HEL transiently transfected HeLa cells following separation on SDS-
PAGE and transfer to nitrocellulose membrane. Using either anti-c-Myc or anti-HEL antibodies 
to detect HEL expression, it can be seen in Fig. 2.14. panel a. and b. that bands of the 
predicted molecular weight (19 kDa) were detected. 
As before, immunofluorescence analysis was used to visualise the expression pattern of HeLa 
cells transfected with nuc-HEL. HEL was visualised using HyHEL10 and anti-mouse-FITC 
antibodies. Immunofluorescence microscopy indicated that the pattern of nuc-HEL expression 
was heterogeneous (Fig. 2.15. panel a. and b.). It can be seen that HEL expression 
demonstrated either strong inter-nuclear staining (red arrows) or an atypical peri-nuclear 
pattern (blue arrows).  
To formally assess whether nuc-HEL expression is directed into the nucleus I performed co-
localisation studies with the DNA staining dye Hoechst using confocal microscopy. As can be 
seen in Fig. 2.15. panel c., the dual colour analysis chart generated from nuc-HEL transfectants 
shows that even though there is some co-localisation between Hoechst and nuc-HEL, the vast 
majority of nuc-HEL is localised extra-nuclear.  
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                             anti-c-Myc                                                      anti-HEL 
Fig. 2.14. Western blot analysis of transiently transfected nuc-HEL HeLa cells. Cell lysates from 0.8x105 
cells (lane 1: HeLa cells transfected with nuc-HEL and lane 2: untransfected HeLa cells) were separated 
on 14% gel and following transfer were stained with (a.) primary anti-c-Myc (mouse 9E10), and (b.) 
anti-HEL antibody (followed by secondary anti-mouse-HRP and anti-rabbit-HRP antibodies 
respectively). Numbers to the right represent the migration of standard molecular weight markers 
(kDa) (ProSieve). The western blot analysis is representative of 2 separate experiments.  
 
 
 
 
       
 
 
Fig. 2.15. Fluorescence (panel a., b.) and confocal microscopy analysis (panel c.) of HeLa cells 
transiently transfected with mito-GFP-HEL (all panel) to visualise nuclei. Red arrow represents inter-
nuclear staining, blue arrows indicate an atypical peri-nuclear pattern of nuc-HEL expression. In these 
experiments were used anti-HEL mouse antibody (HyHEL 10) and anti-mouse conjugated with FITC (all 
panel). Panel c. represents overlap image from Hoechst staining (blue) and nuc-HEL. Panel d. is a 
colocalization chart demonstrating the intensities of measured green (nuc-HEL) and blue (Hoechst) 
pixels (on the y and x axes respectively) corresponding to the randomly selected field of 20 individual 
HeLa cells shown in panel c. The images are representative of 6 separate experiments.  
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2.2.6. Cyto-HEL expression  
 
I also analysed HEL expression targeted to the cytosol. To this end, I have transfected a positive 
control cyto-EGFP plasmid (Clontech) to visualise the green cytoplasm. In Fig. 2.16. panel a., 
cyto-GFP expression can be seen as an evenly diffused pattern of fluorescence with a slightly 
stronger distribution in the nucleus. To analyse the expression of cyto-HEL, I therefore either 
compared the expression pattern of cyto-HEL to that of cyto-EGFP (Fig. 2.16. panel b. and c.) in 
co-transfected HeLa cells. In Fig. 2.16. panel b., clearly shows that the expression cyto-HEL was 
different to that seen with cyto-EGFP. The dual colour analysis chart generated from co-
transfectants confirmed this diversion (Fig. 2.16. panel c.).   
 
     
 
Fig. 2.16. Confocal microscopy analysis representing the expression pattern of cyto-EGFP HeLa 
transfectants. HeLa cells were transfected by cyto-EGFP plasmid (panel a.). Panel b. shows the 
transiently co-transfected HeLa cells with cyto-HEL (red) and cyto-EGFP (green). Cells were stained 
with anti-HEL antibodies (HyHEL10) and secondary anti-mouse-TRITC and nuclei were stained by 
Hoechst 33342 (5 g/ml). Panel c. is a colocalization chart demonstrating the intensities of measured 
red (cyto-HEL) and green (cyto-GFP) pixels (on the y and x axes respectively) corresponding to the 
randomly selected field of one individual HeLa cell shown in panel b. The images are representative of 
6 separate experiments.  
 
 
2.2.7. New constructs to target HEL to various sub-cellular compartments  
 
It is therefore clear that the constructs that I have used to target HEL either to the 
mitochondria, cytosol or nucleus do not lead to the correct localisation. This was not expected 
as these constructs were recently shown to correctly target HEL in transfected Sal/Ak cells (Qi 
et al., 2000) . Upon re-examination of the sequences contained in these plasmids, we observed 
that the HEL signal sequence was still present. It is therefore possible that this sequence may 
interfere with additional sub-cellular localisation sequence in HeLa cells.  
a. b. c. c. 
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Consequently, I designed new constructs lacking the HEL signal sequence to target HEL to 
either the mitochondria (mito-HEL(-SS) data not shown) or to the cytosol (cyto-HEL(-SS)).  
These constructs were generated using PCR (Materials and Methods). Following restriction 
enzyme digestion (Fig. 2.17.) and sequencing cyto-HEL(-SS) construct was transiently 
transfected into HeLa cells.  
 
     
Fig. 2.17. DNA gel analysis (lane 1: marker, lane 2. X174NoeIII-size marker, lane 3 cyto-HEL). 
Digestion of 2g cyto-HEL cloned to pShooter vector (cyto-pCMV) by NcoI and NotI restriction 
enzymes. This DNA gel analysis is representation of 1 experiment.  
 
 
Transfectants were analysed by Western blotting. It can be clearly seen in both Fig. 2.18., 
panels a. and b. that HEL expression was not observed in cells transfected with cyto-HEL(-SS) 
(lane 2), in contrast to previously tested cyto-HEL construct that apparently expresses HEL 
(lane 3) but with incorrect localisation.  
 
              1                                    2             3                   1                                  2            3       
             
                        anti-c-Myc antibody                                               anti- HEL antibody 
 
Fig. 2.18. Western blot analysis of transiently transfected (lane 1: lysates from untransfected HeLa 
cells, lane 2: lysates of new cyto-HEL(-SS), lane 3: lysates from cyto-HEL HeLa cells. Cell lysates from 
0.8x105 cells were separated on 14% gel and following transfer were stained with primary anti-cMyc 
(mouse 9E10) antibody and anti-mouse-HRP (a.), primary anti-HEL antibody and anti-rabbit-HRP (b.). 
Numbers to the right represent the migration of standard molecular weight markers (kDa) (ProSieve). 
The western blot analysis is representative of 1 separate experiment.  
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2.3. Discussion 
 
In this chapter, I have attempted to express HEL in various sub-cellular compartments of HeLa 
cells to allow me to study the localisation of this model antigen following apoptotic-induced 
relocation. Western blotting analysis confirmed that the plasmid encoding mem-HEL produced 
protein of the correct molecular weight in HeLa cells (Fig. 2.4.). In addition, 
immunofluorescence analysis of non-permeabilized HeLa cells also revealed as expected that 
this protein was expressed on the cell surface (Fig. 2.5.).  
Whilst using the pShooter-based constructs from Dr. S. Ostrand-Rosenberg to target HEL to the 
mitochondria (Fig. 2.10), nucleus (Fig. 2.15.) and cytosol (Fig. 2.16., panel b.), led to the 
expression of proteins of the correct molecular weight, the expected sub-cellular localisations 
were not observed. This was performed using both fluorescence microscopy and Western 
blotting. Furthermore, dual colour analysis of both mito-HEL and cyto-HEL transfectants 
demonstrated atypical localisation. Transfectants expressing the nuc-HEL construct showed a 
heterogeneous pattern that reflected both atypical, extra-nuclear staining as well as correct 
nuclear expression. This was not expected as these constructs were recently shown to 
correctly target HEL in transfected Sal/Ak cells (Qi et al., 2000). Upon re-examination of the 
sequences contained in these plasmids, we observed that the HEL signal sequence was still 
present. It is therefore possible that this sequence may interfere with additional sub-cellular 
localisation sequence in HeLa cells or may even have a dominant effect on the targeting 
sequence leading to mislocalisation that was observed. This moved me to design new HEL 
constructs without the signal sequence (Fig. 2.17.). Unfortunately, none of the new plasmids 
lacking the signal sequence (cyto-HEL(-SS) and mito-HEL(-SS)) led to HEL synthesis, even 
though restriction enzyme digestion, sequencing and PCR confirmed that cDNAs were correct. 
In addition, I fused HEL with a correctly targeted GFP positive control plasmid (mito-GFP-HEL) 
which resulted in only GFP expression in the mitochondria (Fig. 2.12.).  
I speculate that the various sub-cellular conditions, to which I have attempted to target HEL, 
abrogate proper folding of this protein. This may be due to the presence of four disulphide 
bonds in the HEL secondary structure (Fig. 2.2. panel a.). These disulphide bridges form 
between the eight cysteine residues and are essential for HEL activity and contribute to its 
rigidity (Fischer et al., 1993). This fact may explain why the plasmid encoding the fusion protein 
(mito-GFP-HEL) was expressed only partially. Indeed, Fig. 2.12. demonstrates that GFP was 
synthesised but HEL was not. These findings indicated that posttranslational modification and 
redox potential of each compartment might abrogate HEL expression and need to be taken 
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into account when designing future experiments. Therefore, as an alternative to using the HEL 
antigen for B cell recognition and presentation, we decided to use different model antigen 
system that should not suffer from the same structural sensitivity as the disulphide bonds of 
HEL. This new model of antigen, used in further experiments, will be described in  
Chapter 3.  
 
In conclusion: 
HeLa cells transfected with a panel of plasmids were examined by Western blotting using  
anti-HEL or anti-c-Myc antibodies. I tested the transfectants expressed: mem-HEL, nuc-HEL, 
mito-HEL and cyto-HEL plasmids. In addition, the expression pattern of each plasmid was 
visualised using a combination of immunofluorescence and confocal microscopy. Plasmids 
expressing nuc-HEL, mito-HEL and cyto-HEL did not show correct co-localisation when 
compared to several standard markers (Hoechst and MitoTrackerRed) for each cellular 
compartment and only the mem-HEL plasmid led to the correct plasma membrane localisation 
of HEL.  
I originally speculated that this atypical localisation of HEL may be caused by the presence of 
the HEL signal sequence (SS), in each pShooter constructs. For that reason, I generated three 
constructs that lacked the HEL signal sequence (-SS). Nevertheless, the deletion of the signal 
sequence from, mito-HEL(-SS), mito-GFP-HEL and cyto-HEL(-SS) plasmids, unexpectedly lead to 
complete inhibition of HEL expression. I envisage that the presence of a signal sequence allows 
limited disulphide bound formation within the ER and protein detection.  
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-  3. EGFP-TTCF as a model antigen  - 
 
 
3.1. Introduction 
 
In the previous chapter, I chose to use hen egg lysozyme (HEL) as a model antigen. However, as 
documented, the correct intracellular localisation of HEL was problematic, probably resulting 
from incorrect folding of HEL. Therefore, I decided to use another model antigen tetanus toxin 
C fragment (TTCF). Our laboratory has previously generated TTCF-specific B cells (Antoniou 
et al., 2000). These cells will be used to detect the surface antigen expression and its 
presentation to TTCF-specific T cell hybridomas.  
Importantly, TTCF has been well described as a model antigen to study the MHC class II -
restricted antigen processing pathway and also frequently used to provide T help 
determinants in vaccine formulations (Manoury et al., 1998).  
Furthermore, TTCF was N’ terminal fused to enhanced green fluorescent protein EGFP allowing 
easy monitoring of EGFP-TTCF (E/T) model antigen. This E/T construct was previously 
successfully expressed in bacteria by Dr A. Knight (unpublished data). In Fig. 3.1., this model 
antigen can be seen as a crystal structure of EGFP linked with TTCF. Using the E/T fusion 
protein as a model antigen has several advantages that will be discussed later in this section. 
Firstly, fusing EGFP to TTCF will allow the direct visualization of the fusion protein using 
fluorescence or confocal microscopy due to the natural autofluorescent properties of EGFP.  
EGFP is a modified version of the Green Florescent Protein (GFP) originally generated from the 
jellyfish Aequorea victoria (Cormack et al., 1996). EGFP is a one of a series of GFP mutants, 
which has a shifted excitation peak of 490 nm. Changes in excitation spectra of EGFP result 
from the replacement of amino acids (64 phenylalanine to leucine and in position 65 is 
threonine instead of serine that is observed in the original GFP protein).  
EGFP is a 27 kDa amino acid monomer which emits green light the maximum emission at 509 
nm wavelength when excited by either blue light or UV. Importantly, the -barrel of EGFP 
crystal structure is thought to be essential for preserving the chromophore for exposure of 
oxygen species damaging structure and consequently causing bleaching of EGFP fluorescence. 
It has been shown that EGFP is a stable fluorescent protein that is resistant to certain 
denaturating conditions. Surprisingly, Saeed has found that SDS, urea or heat, did not have any 
significant effect on the fluorescence of EGFP at pH 7.5 or 8.5 (Saeed and Ashraf, 2009). In 
addition there are many commercially available vectors which target GFP or EGFP to 
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various intracellular compartments (see control mito-GFP plasmid in Fig. 2.9. panel a.) 
demonstrating that GFP is not sensitive to intracellular variations in redox potential. 
Therefore, fusing EGFP with TTCF (E/T) was predicted to allow simple monitoring of antigen 
relocation to the surface following apoptosis and extraction by readily available TTCF-
specific B cells.  
Due to EGFP presence as a reporter gene that naturally exhibits bright green fluorescence 
when exposed to blue light, assessing the expression of desired proteins, in this case 
TTCF, in microscopy was fast and relatively easy. Noteworthy,  this fusion protein E/T was 
predicted not to suffer from the same structural sensitivity as the disulphide bonded HEL, 
initially used as a model antigen, as described in Chapter 2.  
All these advantages suggest that E/T may be a useful model to study antigen extraction 
and presentation by B cells to specific CD4+ T cells. More importantly, this antigen may be 
a valuable tool in establishing an in vitro assay allowing the generation and monitoring of 
anti-tumour immunity by B cells. 
 
 
 
 
Fig.3.1. A schematic representation of the 3D structure of the fusion protein EGFP-TTCF (E/T). Green 
represents structure of EGFP fused with TTCF (illustrated by blue and purple colours reflecting two 
different domains of TTCF). Structure of E/T obtained and adapted from: www.pubmed.com.  
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3.2. Results  
 
 
3.2.1. Construction of a model fusion antigen EGFP-TTCF (E/T) for the study of 
protein relocation from different intracellular compartments 
 
In order to generate a panel of plasmids expressing a model antigen in the desired sub-
cellular compartments the first step was to engineer the cDNA sequence of E/T flanked by 
5’PstI site and 3’NotI site. These restriction sites consequently allowed easy cloning of E/T 
into the expression vector pCMV targeting E/T to different subcellular compartments.  
Using 5’EGFP PstI as a forward external primer and 3’TTCF NotI as a reverse external primer 
(Table 2. blue primers), I analysed the E/T cDNA. This allowed me to generate a blunt-ended 
PCR product containing PstI and NotI restriction sites flanking the E/T cDNA. 
 
Table 3. The sequences of primers which have been used to generate and sequencing E/T. 
Name of primer Sequence Length 
5’EGFP Pst1 5’-CTG CAG ATG GTG AGC AAG GGC GAG GAG -3’ 27-mer 
3’TTCF Not1 5’-GCG GCC GCG TCG TTG GTC CAA CCT TCA TC -3’ 29-mer 
EGFP Seq 3F 667 5’-CTG AGC ACC CAG TCC GCC CTG-3’ 21-mer 
TTCF Seq 4F 967 5’-TCT GAA GTT ATC GTG CAC AAG -3’ 21-mer 
TTCF Seq 5F 1267 5’-TGG GTT TTC ATC ACT ATC ACT -3’ 21-mer 
TTCF Seq 6F 1567 5’-ATC CCG GTA GCT TCT AGC TCT -3’ 21-mer 
TTCF Seq 7F 1867 5’-GCT CCG GGT ATC CCG CTG TAC -3’ 21-mer 
 
 
As a template for E/T amplification, I used a previously constructed plasmid pET-16b-
EGFP-TTCF (Andrew Knight, unpublished data). This plasmid contains EGFP fused to the 
N’terminus of TTCF previously reported by Hewitt et al. (Hewitt et al., 1997). This plasmid also 
allowed bacterial expression and purification (using N-terminal His Tag sequence) of soluble 
E/T in E.coli cells. In Chapters 4 and 5, I will discuss further experiments analysing the soluble 
E/T protein. To amplify the E/T sequence from the pET-16b vector for mammalian 
expression, I used platinum PfX DNA polymerase to generate high-fidelity PCR application 
product. I then mixed the PCR product together with pCR-Blunt TOPO vector (Fig. 3.2.). Using 
this highly efficient cloning kit, I was able to generate E.coli colonies chemically transformed 
with the resulting plasmid.  
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As the pCR-Blunt vector contains the gene for kanamycin resistance, I selected E.coli cells on 
kanamycin supplemented LB.  
Following plasmid isolation the DNA was bi-directionally sequenced using internal primers 
(Table 2. green primers). Colonies containing plasmids with the correct sequence were used to 
transfer this cDNA into vectors for mammalian expression and sub-cellular targeting. Following 
digestion with PstI and NotI restriction enzymes, the 2052 bp cDNA was ligated into the 
pShooter serious of vectors: pCMV-cyto, pCMV-mito and pCMV-ER. For cell surface E/T 
expression, a plasmid was modified from the pCMV-ER vector by inserting an H-2Kb trans-
membrane domain (Fig. 3.4.). This domain was present in the previously described plasmid 
containing mem-HEL (Chapter 2, Fig. 2.3 ).  
DNA was isolated from selected E. coli colonies. Fig. 3.3. shows an example of agarose gel 
electrophoresis following restriction enzyme digestion of pCMV-cyto-E/T plasmid DNA with 
PstI and NotI. The plasmid sequence can be seen as a band that migrates consistent with an 
expected size of 4 kbp. In addition, the E/T cDNA is also seen with an apparent molecular 
weight of 2 kbp. Identical procedures were used for the generation of plasmids targeting E/T 
to the mitochondria, ER and plasma membrane (data not shown).  
 
 
    
Fig. 3.2. A schematic representation of pCR-Blunt II TOPO (Invitrogen) plasmid. This plasmid was used 
to clone the E/T fusion protein with blunt ends previously amplified by PCR procedure. This map 
shows also the restriction sites, in particular PstI and NotI cleavage sites which were used to clone PCR 
product. 
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Fig. 3.3. Agarose electrophoresis of E/T cloned into the pShooter pCMV-cyto vector as one example of 
correct cloning of this model antigen. Lane 1: digestion of 2 g EGFP- TTCF cloned to pShooter vector 
(cyto-pCMV) by PstI and NotI restriction enzymes, lane 2: X174NoeIII-size marker, lane 3: size 
marker. This DNA gel analysis is representation of 1 experiment. This experiment was done once.  
 
 
 
 
The following pCMV plasmids were generated;  
1. Cytosol-EGFP-TTCF (cyto-E/T). This construct does not contain any targeting sequences and 
is therefore expected to localise E/T in the cytosol. 75 kDa is its predicted molecular weight. 
2. Endoplasmatic reticulum-EGFP-TTCF (ER-E/T). This construct contains a SEKDEL-ER retention 
signal that is expected to direct E/T expression in the ER. 76 kDa is its predicted molecular 
weight. 
3. Mitochondria-EGFP-TTCF (mito-E/T). This construct contains a fragment of the cytochrome c 
oxidase subunit VIII that is expected to localise E/T within mitochondria. 76 kDa is its predicted 
molecular weight. 
4. Membrane-EGFP-TTCF. I also generated a control plasmid (mem-E /T)). This construct 
encodes a membrane anchored variant of E/T using the trans-membrane and cytoplasmatic 
domains of the mouse MHC class I molecule, H-2Kb. 79 kDa is the predicted molecular weight. 
pCMV-cyto (4 kb) 
 
E/T (2 kb) 
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Fig. 3.4. Diagrammatic representation of the panel of E/T cDNA constructs used in this study.  
 
 
3.2.2. Confirmation of E/T expression in HeLa cells by Western blotting  
 
As previously described, I engineered a panel of plasmids, which were tested for expression 
and sub-cellular localisation. 24 h following transfection (using TurboFect with a transfection 
efficiency of 60-70%) these plasmids targeting E/T to the mitochondria, cytoplasm, ER or 
plasma membrane were validated using Western blotting. HeLa transfectant lysates were 
separated by SDS-PAGE and transferred to nitrocellulose where they were probed with either 
anti-TTCF or anti-GFP antibodies.  
In Fig. 3.5., it can be seen that anti-GFP antibodies recognises the various E/T fusion proteins 
(lanes 2-5) as well as GFP from a positive control plasmid pCMV-ER-GFP (lanes 7, 8). The bands 
represent the expected sizes for all the fusion proteins: cyto-E/T, mito-E/T, mem-E/T, ER-E/T 
(approximately 76 kDa) and also the positive control ER-GFP (30 kDa). 
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Fig. 3.5. Western blot analysis of HeLa cells transfected with different constructs. Cell lysates from 
lane 1: untransfected 0.8 x105 cells HeLa, lane 2: cyto-E/T , lane 3: mito-E/T, lane 4: mem-E/T, lane 5: 
ER-E/T, lane 6: empty, lane 7: ER-GFP (as a positive control), lane 8: ER-GFP (HeLa transfectants with 
less number of cells) were separated on 12 % gel and following transfer were stained with primary 
anti-GFP (rabbit) antibody and anti-rabbit-HRP. Numbers to the right represent the migration of 
standard molecular weight markers (kDa) (ProSieve). The western blot analysis is representative of 2 
separate experiments.  
 
 
 
3.2.3. Confirmation of E/T expression and localisation in HeLa cells by 
immunofluorescence microscopy and confocal 
 
I then analysed the expression and localisation of the control mem-E/T construct. 24 h 
following transfection with TurboFect (Material and Methods), HeLa cells were fixed and 
analysed. Nuclei were visualised by incubation with Hoechst 33342. Finally, coverslips were 
mounted in anti-fading reagent and visualised using fluorescence and confocal microscopy. 
The expression pattern of mem-E/T plasmid can clearly be seen defining the edge of cell 
indicating correct surface expression of the fusion protein (Fig. 3.6.). 
 
   
Fig. 3.6. Surface expression of mem-E/T construct in transiently transfected HeLa using fluorescence 
microscopy. After fixation cells were directly examined on microscopy (panel a. and b.) or additionally 
incubated with 5 g/ml Hoechst 33342 dye (panel c.) to visualise nuclei. The images are 
representative of 6 separate experiments.  
b. a. 
76 kDa 
 
 
 
28 kDa 
c. a. b. 
c. 
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However, to confirm whether mem-E/T is exclusively expressed on the cell surface, I visualised 
mem-E/T HeLa transfectants additionally using confocal microscopy (Fig. 3.7.).  
Confocal microscopy offers several advantages over conventional optical microscopy. The 
major attribute of confocal microscopy is the ability to collect serial optical sections from thick 
specimens. Therefore, a series of images taken at a controllable depth of field may allow 
localisation of the desired protein. Following transfection of HeLa cells with the mem-E/T 
construct, slides were examined by confocal microscopy. In Fig. 3.7., the panel of serial images 
show EGFP fluorescence as green circles which are changing along the scanned cell depth. This 
is consistent with mem-E/T expression on the cell surface. 
 
 
       
       
Fig. 3.7. Serial optical section of mem-E/T HeLa transfectants generated using confocal microscopy. 
HeLa cells were transfected with mem-E/T construct and 24 h later fixed. Following intensive washing, 
cells were placed to coverslips. Such prepared slides were then analysed on confocal microscopy using 
an objective lenses with a magnification of 60 times. The surface of entire cell was scanned six times 
from a different cell depth as indicated by the collection of 6 images of HeLa transfectants. The images 
are representative of 2 independent experiments.  
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Subsequently, I transfected HeLa cells with other constructs (mito-E/T, cyto-E/T, and ER-E/T) 
and visualised them using confocal microscopy (Fig. 3.8.). HeLa transfectants were also stained 
with Hoechst 3342 (for visualising nuclei) and wheat germ agglutinin (WGA) for visualisation of 
the plasma membrane. WGA is a carbohydrate-binding protein of approximately 36 kDa that 
selectively binds sialic acid and N-acetylglucosaminyl sugar residues which are predominantly 
found on the plasma membrane. The expression pattern of each construct suggests the correct 
targeting of E/T to the desired intracellular compartment. In particular, cells transfected with a 
cyto-E/T construct exhibit diffused cytosolic pattern, cells transfected with a mito-E/T show 
fluorescent small punctuate vesicles. Also, cells transfected with an ER-E/T construct show a 
typical expression pattern for ER as tubular elements surrounding the nuclei and cells 
expressing mem-E/T are visualised as a ring on the edge of the cell. 
 
 
 
Fig. 3.8. Expression pattern of E/T constructs in transiently transfected HeLa cells. The images were 
captured using confocal microscopy and represent the expression of the green model antigen E/T) 
targeted to different subcellular compartments: cytosol (panel a.), ER (panel b.), mitochondria (panel 
c.), plasma cell membrane (panel d.). HeLa cells were transfected by cyto-E/T, ER-E/T, mito-E/T, mem-
E/T plasmids respectively. Cells were stained with wheat germ agglutinin (WGA) (5 g/ml) on red and 
nuclei were stained by Hoechst 33342 (5 g/ml) (blue). The images are representative of 2 
independent experiments.  
a. 
c. d. 
b. 
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Fig. 3.9. Images captured from confocal microscopy representing transiently transfected HeLa cells. 
Fusion antigen targeted to different cellular compartments (green). Red represents markers for each 
compartment. The third column shows a merge between fusion protein and marker (yellow). 
Following fixation, cells were examined using confocal microscopy. The images are representative of 2 
independent experiments.  
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Because these E/T constructs appear to demonstrate correct cellular localisation, I then 
performed a more detailed analysis by comparing their expression patterns to these of well 
characterised markers. To address that, I used markers determining cytosol, mitochondria and 
ER compartments: anti--tubulin antibody, MitoTracker Red dye and anti-IgG antibody 
respectively. In Fig. 3.9., it can be clearly seen that all constructs overlap with the markers 
characterising particular cellular compartments. Furthermore, dual colour analysis chart (Fig. 
3.10.) that converts the pixels on the axes from the overlying images of single HeLa 
transfectant seen in Fig. 3.9., also confirmed colocalization.  
 
 
Fig. 3.10. Colocalization chart demonstrating the intensities of measured red (marker) and green (E/T) 
pixels (on the y and x axes respectively) corresponding to the randomly selected field of one 
individual HeLa cell shown in Fig. 3.9 (last column). E/T fusion antigen targeted to different cellular 
compartments: mitochondria (panel a.), cytoplasm (panel b.), ER (panel c.) or membrane (panel d.) of 
single HeLa cell (shown in Fig. 3.9., first column) was converted on green pixels on the y axe. Red 
pixels on the x axe illustrate markers of the each compartment: MitoTracker Red (panel a.) and anti--
tubulin antibody directly conjugated with TRITC (panel b). Also in panel c. following co-transfection 
with plasmids expressing human heavy chain IgG and ER-E/T construct, the ER marker was 
determined. HeLa cells were stained primary with anti-human IgG antibody and secondary anti-rat 
TRITC conjugated antibody. In panel d., cells were stained with wheat germ agglutinin (WGA) for 
highly selective staining of the plasma membrane. Orange colours in the middle of the each chart 
indicate overlapping between fusion protein and marker. The images represent the experiment that 
was performed once. 
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3.3. Discussion 
 
In this chapter, I have generated four constructs (mem-E/T, cyto-E/T, ER-E/T and mito-E/T) 
containing targeting sequences that localise the recombinant green protein E/T into various 
intracellular compartment. The reason why I decided to use E/T as a model antigen was 
because of the simplicity in visualisation of green recombinant protein in microscopy. 
Importantly, EGFP as auto-florescent protein is also resistant to apoptotic conditions.  
Our laboratory has previously generated TTCF specific-B cells, which are able to recognise the 
relocated E/T antigen to the surface. Therefore, generating a panel of plasmids localising E/T in 
various sub-cellular compartments will find the ideal implementation in this project. 
 
The first step of this experiment was to generate four constructs which will be expressed in 
certain sub-cellular compartments of HeLa cells. To address that, I performed the standard 
cloning procedure. Using pCR-Blunt TOPO cloning vectors, I inserted E/T previously amplified 
with certain primers. Followed transformation to chemically competent E.coli cells, I selected 
the colonies that expressed the desired plasmid and performed DNA isolation. The next step 
was to ligate pCMV expression vector previously dephosporylated with insert encoding E/T 
and to transform to chemically competent E.coli cells. 24 h after transformation, the isolated 
DNA was verified by sequencing, restriction enzymes digestion and the PCR technique. These 
selection procedures allowed me to generate four constructs that were checked in terms of 
open frame reading (sequencing), molecular weight (gel electrophoresis), occurrence 
restriction enzymes sites (restriction enzyme digestion) and matching template with primers 
(PCR amplification). 
Relying on molecular techniques, which revealed positive results, I decided to examine E/T 
expression in HeLa cells by Western blotting and microscopy. Following optimisation of 
transfection conditions, HeLa cells were transfected by TurboFect and 24h later E/T expression 
was analysed. Transfected HeLa cells were lysed and proteins were extracted. Following SDS-
PAGE, proteins transferred to a membrane where they were probed with an anti-GFP 
antibody. In Fig. 3.5. I show an image of a probed filter demonstrating the bands of the 
predicted size (78 kDa) of all the E/T construct. Additionally, HeLa transfectants were visualised 
using fluorescence and confocal microscopy. Approximately 70-80 % HeLa cells were 
transfected. Each construct exhibited the expression pattern that expected to be localised in 
the correct intra-cellular compartment. In order to determine whether the expression pattern 
of E/T is exclusive for a certain compartment, I also performed additional staining of HeLa 
transfectants with markers determining cellular compartments. In particular, I compared cyto-
 
84 
E/T with -tubulin, mito-E/T with MitoTrackerRed and ER-E/T with plasmid encoding human-
heavy chain IgG in HeLa transfectants. Taken together, these results from Western blotting and 
confocal microscopy clearly indicate correct expression and correct localization of each E/T 
construct.  
Having correctly expressed all four constructs in a transient transfection system, I also 
attempted to generate stable cell lines expressing each E/T construct. Unfortunately, I could 
not select a stable cell lines, even though I tried to use different cell lines (HeLa or LTK (mouse 
fibroblasts)) and various transfection reagents (calcium phosphate, Lipofectamine, TurboFect). 
Because of these problems in generation of stable cell lines, the levels of antigen expression in 
the HeLa transient transfectants were taken into account in the interpretation of further 
experiments. This will be discussed in more detail Chapter 5.  
 
 
In conclusion: 
 
I successfully generated a panel of plasmids expressing a fusion protein E/T in various 
intracellular compartments and on the plasma cell surface of HeLa cells. The correct sequence 
of E/T was confirmed by sequencing, enzymatic digestion and PCR procedure. Next, I moved 
from DNA to protein level to confirm the correct expression of E/T fusion protein. To address 
this, E/T expression was firstly tested using Western blotting. As expected, anti-GFP antibody 
recognised E/T protein transferred from lysates of HeLa transfectants.  
Secondly, confocal microscopy confirmed the correct localisation of cyto-E/T, mito-E/T, ER-E/T 
and mem-E/T constructs in the cytosol, mitochondria, ER and on the plasma cell surface, 
respectively. Also, further experiments performed with markers characterising certain sub-
cellular compartments, undoubtedly showed the co-localisation between marker and E/T 
expression. This observation clearly confirmed correct E/T localisation in four different cellular 
compartments.  
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-  4. Optimization of conditions for the induction of intracellular 
antigen relocation in E/T transfected HeLa cells  - 
 
 
4.1. Introduction 
 
Classical inducers of apoptosis that target the ER (brefeldin, tunicamycin), the mitochondria 
(arsenite, C2 ceramide) or DNA (etoposide, mitomycin C) fail to induce immunogenic cell 
death. Treatment with anthracyclines including doxorubicin, idarubicin and mitoxantrone or 
with UVC exposure for example, has been shown to relocate the ER resident chaperone 
calreticulin (CRT) to the cell surface leading to a novel immunogenic form of cell death (Obeid 
et al., 2007b; Tufi et al., 2008; Zhang and Kaufman, 2008). Limited evidence also supports the 
concept that the induction of immunogenic cell death in various tumour cells leads to antigen 
relocation on the cell surface resulting in the induction of local anti-tumour immunity. The 
mechanism of intracellular antigen relocation is still unclear. McArthur et al. has shown that 
apoptosis induced by TNF- in salivary gland cells also results in auto-antigen relocation to the 
cell surface. Using cell fractionation and immunofluorescence techniques they revealed the 
nuclear proteins SS-A (Ro) and SS-B (La) and the cytoplasmatic protein fodrin were relocated to 
the cell surface after TNF- and cycloheximide treatment (McArthur et al., 2002).  
Based on the above findings, I decided to test whether the anthracyclines doxorubicin (DX), 
mitoxantrone (MX) and UVC exposure were also capable of causing E/T relocation from the ER 
as well as from the cytosol and mitochondria to the cell surface. Furthermore, I compared the 
effect of staurosporine (STS), a well-defined agent causing non-immunogenic apoptotic cell 
death (Obeid et al., 2007b). This natural alkaloid inhibits the protein kinases through the 
prevention of ATP binding to the active centre of the kinase. Therefore, this chapter 
documents the effects of E/T HeLa transfectants treated with various doses of anthracyclines, 
UVC and STS with a particular emphasis on the alteration of E/T cellular location.  
 
The biological effects of UVC exposure are multiple and include the release of soluble 
mediators, modification of the surface molecule expression, mitochondria alteration, cell 
shrinkage, surface membrane blebbing, chromatin condensation and DNA fragmentation. 
Takasawa et al., have described that in response to UVC exposure, cytochrome c is released 
from the mitochondrial inter-membrane space to the cytoplasm (Takasawa et al., 2005). In 
addition, the activation of death receptors CD95 on the cell surface induced by UVC and UVB 
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also triggered machinery apoptotic cell death (Kulms et al., 1999). These examples of UVC 
treatment have also been shown to induce immunogenic cell death by relocation of CRT from 
the ER to the cell surface.  
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4.2. Results 
 
 
4.2.1. Morphological changes in HeLa cells induced by anthracyclines and 
staurosporine (STS) treatment 
 
Firstly, I optimised the time and concentration of DX, MX and STS treatment of untreated HeLa 
cells based on a combination of morphological observations that were illustrated by light 
microscopy (Fig. 4.1.). Following drug treatment, HeLa cells start to exhibit morphological 
changes including cell detachment, cell shrinkage and the occurrence of apoptotic bodies.  
 
 
   
   
Fig. 4.1. Morphological changes of HeLa cells after drug treatment. Representative images from light 
microscopy using 40 times magnification of HeLa cells treated for 4 h with 100 M DX (panel b.),  
40 M MX (panel c.) or 1.5 M STS (panel d.). Panel a. shows untreated HeLa cells. The images are 
representative of 3 separate experiments.  
 
untreated  100M DX. 
40M MX. 1.5M STS 
a. b. 
c. d. 
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In addition, I also performed the colorimetric MTT ((3-(4,5-Dimethylthiazol -2-yl)-2,5-
diphenyltetrazolium bromide, a tetrazole) assay, as shown in Fig. 4.2. This assay measures cell 
viability through the colour density of the converted yellow MTT substrate to the purple 
product-formazan in the mitochondria of living cells. This reduction takes place only when 
mitochondrial reductase enzymes are active and therefore conversion of the substrate can be 
directly related to the number of viable cells. Expectedly, in each panel following drug 
treatment a dose dependent decrease in HeLa cell viability can be seen. In particular, after  
1.5 M STS or 200 M DX treatment, HeLa cells were only 25 % viable. However, following  
80 M MX treatment, approximately 30% of HeLa cells died (panel c.). Nevertheless, the 
disadvantage of this test is that the MTT assay does not distinguish whether the observed cell 
death is apoptotic or necrotic. 
3
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Fig. 4.2. Quantification of cell viability by MTT test. 4 h after addition of drugs treatment (panel a., b., 
c.) the activity of mitochondrial reductase enzymes was measured by production of formazan 
estimating cells viability. Treated cells (blue columns) were compared to vehicle treated cells (red 
columns) that were standardised to 100 % viability. Data is representative of three independent 
experiments where the mean optical density from triplicate wells was converted to % cell viability 
(using untreated cells as 100 %). 
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Therefore, I also performed the annexin V binding assay that characterises apoptotic cell 
death. One of the earlier features of apoptosis but not necrosis, is the translocation of 
phosphatidylserine (PS) from the internal to the external face of the plasma membrane. 
Annexin V is a 35.8 kDa, calcium-dependent phospholipid-binding protein with a high affinity 
for PS, which can be directly conjugated with desired fluorochrome. Therefore, annexin V 
binding to the cell surface is an indicator of the early stages of apoptosis. 
In Fig. 4.3. panel b., it can be seen that annexin V-Cy5 binds to the surface of apoptotic HeLa 
cells treated with STS. In Fig. 4.3. panel d., the circle rings reflect the annexin V binding which 
overlay with the surface of dying HeLa cells captured by light image. This method of annexin V 
binding visualised using confocal microscopy was not significantly reproducible and I 
encountered many technical problems. In particular, the location of apoptotic cell plasma 
membrane stained with Cy5 proved technically difficult. This was due to the fact that annexin 
V-Cy5 was the only commercially available conjugate (annexin V-FITC could not be used) and 
this dye is excited at 649 nm in the far red part of the spectra. This means that Cy5 staining 
could only be visualised once images had been acquired. Therefore, I decided to use a different 
dye and another technique for detecting annexin V binding to apoptotic HeLa cells, which is 
described in Section 4.3.3. 
    
 
    
Fig. 4.3. Annexin V-Cy5 staining of apoptotic HeLa cells. Apoptosis was induced with 1.5 M of STS 
(panel b.) for 4 h. After 4 h, cells were incubated for 20 min with 1 μg/ml of annexin V-Cy5 in binding 
buffer. Following fixation, HeLa cells were examined using confocal microscopy on the far-red 
fluorescence. Panel c. and d. represent overlay images from light microscopy reflecting cell 
morphology and confocal microscopy to visualise annexin-V-Cy5 staining. The images are 
representative of 4 independent experiments.  
1.5M STS untreated  a. b. 
d. c. untreated-overlay 1.5M STS-overlay 
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4.2.2. The effect of anthracyclines and STS on HeLa E/T transfectants 
 
As the process of transfection itself leads to limited HeLa cytotoxicity, I established that this 
was minimal (with optimal protein expression) after 24 h using TurboFect, compared to that 
seen with Lipofectamine used in Chapter 2. In addition, I determined the concentration of DX, 
MX and STS (100 M, 40 M, 1.5 M respectively) that induced apoptosis in HeLa cell 
transfectants at this time point while maintaining sufficient cell adherence for staining and 
microscopic analysis. I then examined the intracellular re-localisation of E/T expressed by the 
various plasmids following apoptosis induction in HeLa cells.  
Fig. 4.4. shows HeLa cells transfected with the ER-E/T construct (panels a. to c.) and treated 
for 4 h with anthracyclines undergo apoptotic changes. These changes include the appearance 
of apoptotic bodies on the surface of cells. It can be also seen that these apoptotic bodies 
contain relocated E/T antigen following DX and MX treatment (panel b. and c.). The 
intracellular distribution of cyto-E/T also appears to change following drug treatment and 
fluorescent apoptotic bodies are observed (panels e. to g.). HeLa cells transfected with mito-
E/T constructs, however, do appear to show changes in intracellular localization but 
fluorescent apoptotic bodies are not seen (panels i. to k.). Treatment of all E/T expressing 
transfectants with STS does not lead to E/T relocation into apoptotic bodies but rather induces 
changes in the cytoskeleton causing cell elongation (panel d., h. and l.). This data is consistent 
with previously described reports demonstrating that only certain drugs including 
anthracyclines have the ability to induce immunogenic cell death as reflected by CRT surface 
relocation. In contrast, STS or mitomycin C induced canonical programmed cell death which 
did not lead to protein redistribution (Obeid, Tesniere et al. 2007).  
 
Thus, this data showing relocation of E/T allowed me to test whether TTCF-specific B cells can 
acquire this antigen in a similar manner to that which has been reported for membrane 
tethered antigens.  
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Fig. 4.4. The effect of drug treatment on transiently transfected HeLa cells. After 4 h incubation with 
100 M of DX (panel b., f., j.), 40 M of MX (panel c., g., k.) or 1.5 M of STS (panel d., h., l.) HeLa 
transfectants were fixed and directly examined on fluorescence microscopy. Panel a., e. and i. 
represent untreated E/T transfectants expressing ER-E/T, cyto-E/T, and mito-E/T respectively. The 
images are representative of 3 independent experiments. 
a. 
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d. c. b. 
k. 
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Relying on the previously described observations using fluorescence microscopy and MTT 
tests, I decided to use the optimised concentration of 1.5 M STS, 100 M DX and 40 M MX 
to induce apoptosis in HeLa ER-E/T transfectants. 4 h following treatment, transfectants were 
washed to remove excess drug and graded numbers were incubated for 24 h with TTCF-
specific B and T cells. The generation of TTCF-specific B and T cells and a detailed description of 
the bio-assay will be described in Chapter 5.   
Paradoxically, in Fig. 4.5. it can be observed that IL-2 production from the TTCF-specific T cells 
decreases when they were incubated with antigen-specific B cells and increased numbers of 
apoptotic transfectants. In control experiments when specific B and T cells were incubated 
with soluble TTCF antigen, IL-2 production was measured with increased concentration of 
soluble TTCF (Fig 4.5. panel d.). To establish if this cytotoxic effect was due to drug carryover 
of anthracycline-treated HeLa cells on either the TTCF-specific B or T cells, I performed MTT 
tests. Indeed, TTCF-specific B and T cells were incubated for 24 h with 50, 500 or even 5000 
times less concentrated doses of MX (2 M, 0.2 M and 0.02 M of MX) than that used in the 
bio-assay. As shown in Fig. 4.6. and Fig. 4.7., B cell hybridomas were relatively insensitive to 
these low doses of anthracyclines and were therefore not likely to be affected following the 
extensive washing of the treated HeLa transfectants in the antigen presentation assay shown 
in Fig. 4.5. panel a., b., c. In contrast, however, Fig. 4.6. and Fig. 4.7. show that the T cell 
hybridomas appeared to be extremely sensitive to doses as low as 0.02 M MX which 
represents 0.05% of the dose used in the antigen presentation assay.  
Thus, this test indicated that the standard antigen presentation assay with T cell hybridomas, 
which were incubated for 24 h with anthracycline-treated (and extensively washed) HeLa 
transfectants, was not a viable assay for measuring antigen presentation.   
 
 
 
 
 
 
93 
 
 
MX 40M
1000 10000 100000 1000000
0
5000
10000
15000
20000
25000
30000
B cells
TTCF-B cells
no. of ER-E/T
cp
m
 
soluble TTCF
0.1 1 10 100 1000
0
30000
60000
90000
120000
150000
180000
B cells
TTCF-B cells
0
TTCF titration [nM]
c
p
m
 
Fig. 4.5. B cell acquisition and presentation of relocated ER-E/T following apoptosis induction using 
standard assay. HeLa E/T transfectants were treated with STS (a.), MX (b.) or DX (c.) respectively and 
following washing incubated for 24 h with TTCF-specific B (blue line) or non-specific B cells (red line) 
and with TTCF-specific CD4+ T cells. Panel d. demonstrates presentation of soluble TTCF using  
TTCF-specific B and T cells. These proliferation assays are representative of 2 independent 
experiments.  
a. 
b. 
c. 
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Fig.4.6. MTT test of B and T cell hybridomas treated with low doses of MX for 24 h. TTCF-specific CD4+ 
T cell hybridomas no. 39 and 52, TTCF-specific (A20-3A5) and non-specific (A20) B cells were treated 
with 2 M, 1 M, 0.2 M, 0.1 M and 0.02 M MX for 24 h. This experiment was performed twice in 
independent experiments. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7. Quantitative analysis of MTT test showing absolute values of OD 570 wavelength of B and T 
cell hybridomas treated with low doses of MX. Both T cell hybridomas no. 39 and 52 and B cells: A20 
non-specific B cells and A20-3A5 TTCF-specific B cells were treated with different concentration of MX: 
2 M, 1 M, 0.2 M, 0.1 M and 0.02 M for 24 h. This experiment was performed twice in 
independent experiments. 
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4.2.3. Morphological changes in HeLa E/T transfectants following UVC exposure  
 
As I have previously described, measuring relocated antigens using T cell hybridomas proved to 
be problematic due to the sensitivity of T cells to extremely low doses of anthracyclines, I 
therefore decided to analyse the effect of a different immunogenic apoptotic agent (UVC 
irradiation). The first step was to optimise the dose and time of UVC treatment for HeLa cells. 
HeLa cells were irradiated with a range of different doses of UVC: 100, 200 and 300 J/m2, 
respectively. The optimal time which allowed me to monitor morphological changes in HeLa 
cells was established as 4 h. In Fig. 4.8., it can be seen that UVC induces a dose dependent 
decrease in HeLa cell viability. In particular, 4 h after UVC exposure with 100, 200 and 300 J/m2 
the cell viability dropped to 90%, 80% and 65%, respectively.  
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Fig. 4.8. Quantification of cell viability by MTT test. 4 h after UVC exposure the activity of 
mitochondrial reductase enzymes was measured by production of formazan estimating cells viability. 
Treated cells (blue columns) were compared to untreated cells that represented by 100 % cell viability 
(red columns). Data is representative of 3 independent experiments where the mean optical density 
from triplicate wells was converted to % cell viability (using untreated cells as 100 %). 
 
This initial experiment testing HeLa cell sensitivity to UVC led to examination of the 
morphological changes in these cells. This type of cell death has been well documented and is 
characterised by typical apoptotic hallmarks including loss of membrane asymmetry and 
attachment, condensation of the cytoplasm and nucleus, and inter-nucleosomal cleavage of 
DNA (Nishigaki et al., 1998).  
To test whether HeLa transfectants exhibit those morphological features in response to UVC 
treatment, I decided to visualise changes in cell morphology using microscopy.  
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Relying on my results from ER-E/T HeLa transfectants treated with anthracyclines (Fig. 4.4. 
panel b. and c.), I transfected HeLa with the ER-E/T plasmid. 24 h following transfection HeLa 
cells were exposed to 100, 200 and 300 J/m2 of UVC respectively. 4 h later morphological 
changes were monitored using confocal microscopy.  
In Fig. 4.9. panel b. it can be seen that typical apoptotic changes start to occur even following 
treatment with a 100 J/m2 irradiation. These changes include DNA condensation and 
fragmentation reflected by blue nuclei, stained with Hoechst and punctuate expression of ER-
E/T that differs from control non-irradiated HeLa ER-E/T transfectants. Expectedly, following 
200 J/m2 of UVC irradiation, the morphology of HeLa cells changed even further with 
fragmentation of ER-E/T expression, presumably as a consequence of cytoskeleton breakdown. 
Also nuclei content appears to be released from the cell to the extracellular matrix.  
Maftoum-Cost et. al., described similar changes in HeLa cell morphology following 
photodynamic therapy (PDT). They showed that HeLa cells exposed to PDT undergo changes in 
the ER compartment. This ER damage causes ATP loss and membrane potential dissemination 
that consequently results in the formation of bleb-like structures (Maftoum-Costa et al., 2008). 
 
Fig. 4.9. Morphological changes in ER-E/T HeLa cells induced by different dose of UVC. Confocal 
microscopy of irradiated green transfectants by 100 J/m2 (panel b.), 200 J/m2 (panel c.), 300 J/m2 
(panel d.). Images reflect changes in the cellular morphology after 4 h from UVC irradiation. Panel a. 
represent untreated group of cells transfected with ER-E/T. Cells were also stained with Hoechst 
33342 (5 g/ml) (blue) to visualise nuclei. The images are representative of 2 independent 
experiments. 
a. 
c. d. 
 
97 
In accordance with the previously mentioned results, it can also be seen (Fig. 4.9. panel c.) that 
some ER-E/T-labelled apoptotic bodies contain Hoechst-stained DNA. Finally, the strongest 
dose of 300 J/m2 UVC induced cell shrinkage, complete cytoskeleton damage and chromatin 
fragmentation. This fragmented DNA is also present in fully formed green apoptotic bodies 
containing E/T that originated from the ER.  
These observations using confocal microscopy indicate that HeLa transfectants are undergoing 
apoptotic death. To confirm this treatment was inducing apoptosis, I stained HeLa cells treated 
with 300 J/m2 of UVC with annexin V-FITC (for 40 min RT in Ca2+ containing binding buffer) and 
analysed annexin V binding using flow cytometry. As a positive control for apoptotic cell death, 
I also incubated HeLa cells with STS (1.5 M) for 4 h and compared binding to non-treated 
HeLa cells. As illustrated in Fig. 4.10., more than 80% cells treated with STS or UVC bind 
annexin V indicating that the vast majority of cells treated with both these reagents undergo 
programmed cell death.  
 
Subsequently, I also visualised by confocal microscopy HeLa cells that were transfected with 
the other E/T constructs (cyto-E/T and mito-E/T) following exposure to 300 J/m2 UVC. In Fig. 
4.11., it can be seen that following UVC exposure transfectants expressing the E/T constructs 
exhibited typical apoptotic changes similar to those previously described in ER-E/T 
transfectants. In particular, chromatin condensation, DNA fragmentation and cellular release, 
membrane disruption and bleb formation were visualised.  
Furthermore, I also examined in more detail the morphological changes of HeLa E/T 
transfectants following UVC treatment. For this, I co-stained HeLa transfectants with WGA and 
Hoechst and compared intracellular compartments with organelles from untreated cells. In Fig. 
4.12., 4.13. and 4.14. E/T transfectants exhibited synchronized apoptotic changes. This 
included DNA fragmentation visualised by strong Hoechst staining. In addition, UVC treated 
E/T transfectants showed membrane asymmetry reflected by a diffused pattern of WGA 
staining. In contrast, untreated E/T transfectants showed well organised WGA circular staining 
representing typical cell surface membrane. As expected, the E/T antigen localisation was 
completely disrupted following UVC treatment. Indeed, in E/T transfectants expressing cyto-
E/T (Fig. 4.12.) and ER-E/T (Fig. 4.13.) the blebs containing green fusion protein can be seen. 
This observation demonstrates that cyto-E/T and ER-E/T relocate from cytoplasm and ER, 
respectively to the cell surface. However, mito-E/T expression appears to be maintained in 
intracellular compartments with considerably less localisation at the cell surface.  
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Fig.4.10. Determination of apoptotic cell death by annexin V staining in HeLa cells. 4 h after UVC 
irradiation, HeLa cells were stained with annexin V-FITC antibody and analysed by flow cytometry 
(panel a. blue histogram). As a positive control for surface binding of annexin V, HeLa cells were 
incubated for 4 h with staurosporine (1.5 M) (panel b. blue histogram). Red histograms in both 
panels symbolise untreated HeLa cells. The images are representative of 2 independent experiments. 
 
 
 
 
Fig. 4.11. Visualisation of altered expression of E/T model antigen following UVC-induced apoptosis. 
HeLa cells transfected with cyto-E/T, ER-E/T and mito-E/T panel a., b. and c. respectively, were fixed 
and analysed using confocal microscopy, 4 h following 300 J/m2 UVC exposure. Green represents 
transfected E/T expression. In addition, to visualise plasma membrane and nuclei, HeLa cells were 
stained with WGA (5 g/ml) and Hoechst (5 g/ml) respectively. The images are representative of 3 
independent experiments. 
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Fig. 4.12. Changes in the cellular morphology of cyto-E/T transfectants induced by UVC (300 J/m2). 4 h 
after UVC irradiation HeLa cyto-E/T transfectants were fixed and directly examined using confocal 
microscopy. Green represents cyto-E/T, red shows WGA and blue demonstrates Hoechst, indicating 
the expression pattern of fusion protein, plasma membrane and nuclei respectively, of UVC treated 
HeLa cells (right column) or untreated transfectants (left column). The images are representative of 3 
independent experiments. 
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Fig. 4.13. Changes in the cellular morphology of ER-E/T transfectants induced by UVC (300 J/m2). 4 h 
after UVC irradiation HeLa ER-E/T transfectants were fixed and directly examined using confocal 
microscopy. Green represents ER-E/T, red shows WGA and blue demonstrates Hoechst, indicating the 
expression pattern of fusion protein, plasma membrane and nuclei respectively, of UVC treated HeLa 
cells (right column) or untreated transfectants (left column). The images are representative of 3 
independent experiments. 
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Fig. 4.14. Changes in the cellular morphology of mito-E/T transfectants induced by UVC (300 J/m2). 4 h 
after UVC irradiation HeLa mito-E/T transfectants were fixed and directly examined using confocal 
microscopy. Green represents mito-E/T, red shows WGA and blue demonstrates Hoechst, indicating 
the expression pattern of fusion protein, plasma membrane and nuclei respectively, of UVC treated 
HeLa cells (right column) or untreated transfectants (left column). The images are representative of 3 
independent experiments. 
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This was confirmed by further analysis of UVC treated ER-E/T transfectants. Data acquired 
from single ER-E/T transfectants was analysed both in vertical and horizontal planes to 
produce the images shown in Fig. 4.15. Indeed, the altered ER-E/T location can clearly be seen 
as a circle localised around the edge of apoptotic bodies. The redistributed ER-E/T expression 
present in the apoptotic body highlighted in Fig. 4.15. panel b. as a yellow arrow and is entirely 
overlaid with disrupted cell membrane as visualised by WGA staining. Thus, E/T was 
redistributed to the cell surface following UVC treatment. 
 
 
a. 
   
b. 
 
 
Fig. 4.15. Relocation of ER-E/T construct to the cell surface induced by UVC irradiation (300 J/m2). 
Images captured using confocal microscopy showing a 3D projection of a single HeLa transfectant 
which was sectioned in a vertical and horizontal plane to directly visualise ER-E/T (green) relocated to 
the plasma membrane (red). Hoechst 3342 dye (blue) represents nuclei staining. The images are 
representative of 2 independent experiments. 
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4.3. Discussion 
 
The ability to induce tumour cell apoptosis is an important property of a candidate anti-cancer 
drug (Frankfurt, Krishan 2003). Anthracyclines have recently been investigated as 
chemotherapeutic agents causing immunogenic cell death. However, previous work has 
documented the cytotoxic effect of doxorubicin as one of the most efficient drugs of cancer 
chemotherapy. In particular, this drug is generally related to its interaction with nuclear 
components, such as introduction of double strand breaks in DNA and topoisomerase II 
inhibition. According to Serafino et al. these changes in DNA structure correlate with apoptosis 
induction (Serafino et al., 1999). They observed that in melanoma cell line and 
erythroleukemia human cell line following doxorubicin treatment, both cell lines exhibited 
typical apoptotic morphological changes including condensation of nuclear chromatin, cell 
surface blebbing and cytoplasmic vacuolisation. Similar apoptotic characteristic such as the 
presence of membrane-bound apoptotic bodies and cell shrinkage can be seen in Fig. 4.4., 
when HeLa cells were exposed to DX and MX for 4 h. The green apoptotic bodies might 
indicate that intracellular protein relocation to the cell surface occurs. Such relocated E/T 
might be then recognised by specific-B cells triggering immunogenicity and consequently 
leading to anti-tumour immunity.  
Obeid described that MX has the ability to trigger apoptotic cell death but also to induce 
ERp57 and CRT (both ER chaperone proteins) relocation from ER to the cell surface in CT26 
murine colon cancer cell lines (Obeid, 2008) (Obeid et al., 2007c). Such apoptotic cells were 
then better recognised by DC and tumour cells were rejected in those challenged mice. 
However, cells lacking ERp57 or with low expression of ERp57 could not be efficiently 
eliminated following MX treatment indicating that the activation of anti-tumour immunity was 
driven by surface expression of CRT or ERp57. This data clearly supports my observations that 
MX and DX treated HeLa transfectants relocated ER-E/T fusion protein to the surface of 
apoptotic bodies. In contrast, following STS treatment HeLa transfectants exhibited elongated 
morphology with no evidence of green apoptotic bodies’ formation. In Fig. 4.4. it can be seen 
that E/T remained intracellular indicating that STS is an anti-cancer drug which causes non 
immunogenic cell lethality. This observation is also consistent with data provided by Obeid 
(Obeid et al., 2007b). 
Anthracyclines also have strong effects on mitochondria activity. Tokarska-Schlattner et al. has 
observed numerous mechanisms for the inactivation of the mitochondrial respiratory chain by 
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anthracyclines (Tokarska-Schlattner et al., 2002). They proposed that these effects on 
mitochondria are mediated by the generation of free radicals, interaction with mitochondrial 
DNA, alteration of calcium exchange, lipid peroxidation inducing disturbance of mitochondrial 
membranes and consequently inactivating mitochondrial function. These results are consistent 
with our observations where HeLa cells treated with anthracyclines also decreased 
mitochondria activity. It has been confirmed by MTT test which quantified the metabolic 
dysfunction of mitochondrial reductase following anthracycline treatment (Fig. 4.2.). Inhibition 
of mitochondrial function was dose dependent in HeLa cells incubated with DX and MX. In 
particular, following 4 h incubation with 50 M DX, the viability of HeLa cells was 70%, 50% 
when incubated with 100 M DX and only 25% following 200 M DX treatment. A similar 
pattern was seen following MX treatment. HeLa cells incubated with 20 M MX for 4 h were in 
90% viable, 40 M MX caused 80% viability and only 70% cells were viable after treatment 
with 80 M MX.  
After optimizing apoptotic conditions, I decided to test whether relocated ER-E/T is acquired 
by TTCF-specific B cells and presented to CD4+ T cells. To this end, following 4 h treatment 
with anthracyclines, HeLa ER-E/T transfectants were incubated with specific B and T cells for 
24 h. Before transferring the apoptotic ER-E/T HeLa cells into fresh well containing the TTCF-
specific B and T cells, HeLa cells were extensively washed to exclude possible carryover of any 
remaining anthracycline. Despite this preventative step, I observed inhibition of antigen 
presentation following anthracycline treatment. It was likely, that HeLa cells treated with DX or 
MX accumulate intracellular anthracyclines (data not shown). Fig. 4.5. shows an inverse 
correlation between the number of apoptotic HeLa cells and IL-2 production by T cells. It is 
possible that 24 h after drug treatment, some HeLa cells undergo necrotic death and release 
their intracellular content including anthracyclines when the plasma membrane was ruptured 
resulting in T cell cytotoxicity.  
This hypothesis is consistent with the studies performed by Ferraro et al. demonstrating that 
anthracyclines trigger apoptosis in both non-activated and phytohemagglutinin-activated 
human peripheral blood lymphocytes (Ferraro et al., 2000). In agreement with in vitro data, a 
single intraperitoneal injection of DX or MX in Balb/c mice also induced T cell depletion in 
lymph nodes, and in the thymus. These data indicate that anthracyclines may induce major 
peripheral T cell deletion, a property not shared by many cytotoxic agents and may explain 
why my proliferation assays failed.  
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To test whether anthracyclines have a strong cytotoxic effect on lymphocytes, I performed the 
MTT test measuring cell viability. This experiment clearly showed that similar to T lymphocytes 
(Ferraro et al., 2000), T cell hybridomas are extremely sensitive to anthracyclines as even 20 
nM of MX induced cell death (Fig. 4.7.). Therefore, measurement of antigen redistribution 
following anthracycline treatment using T cell hybridomas was impractical. The solution to this 
problem was to test a different apoptotic-inducing agent which had previously been shown to 
trigger immunogenic cell death and would hopefully have limited effects on co-cultured T and 
B cell hybridomas. The use of UVC has been documented to induce immunogenic cell death, 
interacting with DNA to produce a range of mutations due to genomic instability. Also, UVC 
directly induces damage to intracellular organelles including ER or mitochondria that finally 
leads to cell death (Choi et al., 2000). I therefore optimised the dose of UVC irradiation 
required to induce cell death in HeLa cells using the MTT test. The highest HeLa lethality was 
observed after 300 J/m2 irradiation. Therefore, I analysed the morphological changes seen in 
HeLa transfectants expressing cyto, mito and ER-E/T following 300 J/m2 UVC using confocal 
microscopy. In Fig. 4.11. this can be observed as the appearance of apoptotic green blebs and 
chromatin condensation. Furthermore, to confirm that UVC irradiated HeLa cells are dying by 
apoptosis, I performed annexin V binding and analysis by flow cytometry. Fig. 4.10. 
demonstrates approximately 80% of HeLa cells bind annexin V – FITC either following STS 
treatment or 300 J/m2 UVC treatment. 
Finally the confocal microscopy analysis clearly showed that HeLa cells exposed to 300 J/m2 
UVC exhibited typical apoptotic morphological changes including chromatin condensation and 
fragmentation as indicated by strong Hoechst staining. Also membrane disruption, 
represented by asymmetries diffused pattern of WGA staining, was seen. Importantly, in cyto-
E/T and ER-E/T transfectants, the formation of green apoptotic bodies was also observed (Fig 
4.12. and 4.13.). The E/T present in HeLa apoptotic bodies co-localised with the WGA 
membrane dye (indicated by the orange dots). Furthermore images, which were produced by 
sectioning in vertical and horizontal planes to directly visualise the magnified cell membrane, 
clearly demonstrated ER-E/T antigen redistribution to the plasma membrane by its co-staining 
with the WGA membrane dye (Fig. 4.15.).  
All these observations show that UVC induces E/T relocation to the cell surface. As UVC-
mediated intracellular protein relocation has previously been shown to trigger immunity, my 
observations may indicate that relocated E/T may be acquired by antigen-specific B cells for 
presentation to CD4+ T cells. This novel aspect of antigen relocation will be discussed in 
Chapter 6.  
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In conclusion: 
Both DX and MX anthracyclines were shown to have cytotoxic effect on HeLa cells leading to 
apoptosis. This was observed using light and immunofluorescence microscopy as well as 
confocal microscopy (Fig. 4.1. and Fig. 4.4.). This form of cell death was characterised by cell 
shrinkage and the formation of apoptotic bodies that contained the green fusion protein E/T.  
Nevertheless, in further experiments the ability of anthracycline-induced relocation to trigger 
B cell-mediated antigen acquisition and presentation to CD4+ T cells could not be tested, due 
to high sensitivity of T cell hybridomas to this drug. Therefore, I examined the consequences of 
UVC-treatment as an alternate means of inducing E/T relocation. Following optimisation of the 
dose and time of UVC exposure, HeLa cells were also examined for evidence of apoptosis. Fig. 
4.10. demonstrates annexin V-FITC binding to surface PS in apoptotic cells and Fig. 4.8. shows 
the mitochondrial reductase inhibition as represented by a decreased number of cell viability 
in UVC treated HeLa cells using the MTT test. Also images obtained from confocal microscopy 
showed that following treatment with 300 J/m2 UVC, HeLa transfectants exhibited typical 
apoptotic hallmarks including chromatin condensation, plasma membrane disruption and the 
relocation of intracellular E/T to the cell surface of apoptotic bodies (Fig. 4.12. and 4.13.).  
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-  5. Generation of TTCF-specific T cell hybridomas  - 
 
 
5.1. Introduction 
 
This study aimed to test the hypothesis that antigen expressed by apoptotic tumour cells can 
be recognised by antigen-specific B cells. This recognition, caused by apoptotic modification of 
normal protein localisation, can finally lead to the activation of tumour-specific T cells. To test 
this hypothesis in an in vitro system, Chapters 2, 3 and 4 have described model antigens that 
were targeted to the various subcellular compartments in HeLa cells. In particular, Chapter 4 
describes the relocation of E/T to the cell surface following either anthracycline or UVC 
treatment. In order to establish whether this relocated model antigen is able to induce B cell-
mediated immunity, antigen-specific B and T cell hybridomas are required.  
Our laboratory previously has generated TTCF-specific B cell lines (A20-TTCF). This chapter 
documents the generation of a novel TTCF-specific T cell hybridoma, which can be used to 
study the presentation of TTCF.   
 
Since the original discovery of lymphocyte hybridization by Kohler & Milstein (1975), a number 
of investigators have used this technology to study T cell function. The first T cell hybrids were 
obtained by fusing activated T cells with EL 4 murine lymphoma (Taniguchi and Miller, 1978). 
However, the generated T cell hybridomas from EL 4 cells were very unstable. Since then, a 
major effort has been made to obtain stable populations of antigen-specific T cell hybridomas. 
Therefore, most of the fusions are currently performed with the TCR-/- BW 5147 mouse T cell 
line, because it is more likely to generate stable T cell hybridomas than EL4 cells (White et al., 
2000).  
BW 5147 cells have been characterised to have non-MHC-restricted, non-specific regulatory 
activities in mixed lymphocyte reactions. Therefore, fusion of BW 5147 with antigen-specific T 
cells isolated from immunized mice gives a great opportunity to measure antigen response in a 
long term experiments. In particular, assays detecting T cell hybridoma activation by the 
production of IL-2 production can be used as a very sensitive read out for the recognition of 
peptide/MHC complex formation by APC. There are a number of ways to detect IL-2 secreted 
by activated T cell hybrids. Our laboratory has previously used several of these and has 
selected to use the IL-2 dependent T cell line CTLL-2 based on high IL-2 sensitivity. Incubation 
of CTLL-2 in the presence of IL-2 causes rapid cell division which can be measured by the 
incorporation of radioactive thymidyne added to the culture media. As described in this 
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chapter, I generated and characterised TTCF-specific T cell hybridomas which allowed me to 
study the presentation of E/T following its relocation and acquisition by TTCF-specific B cells 
(Fig. 5.1.).   
 
 
 
 
Fig. 5.1. A schematic representation of proliferation assay of relocated intracellular E/T (1.) following 
UVC treatment (2.) and recognised by TTCF-specific B cells (3.). Antigen acquisition by B cells leads to 
peptide/MHC complex formation that stimulates the activation of TTCF-specific CD4+ T cell 
hybridomas. Consequently, activated TTCF-specific T cell hybridomas produce IL-2 which can be 
measured by the proliferation of the IL-2 dependent T cell line CTLL-2.  
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5.2. Results  
 
 
5.2.1. T cell hybrid generation 
 
Balb/c mice were immunized sub-cutaneously in one hind leg with 50 g of recombinant E/T 
emulsified with the adjuvant TitreMax. After 10 days, mice were killed and cells were isolated 
from the popliteal lymph nodes. Following in vitro re-stimulation with 50 g/ml of E/T, blasts 
were fused with the TCR negative lymphoma fusion partner BW 5147 T cell lymphoma. The 
fusions were selected in hypoxantine-aminopterin-thymidyne (HAT) media.  
Most mammalian cells have two pathways to synthesise DNA (Foung et al., 1982). The first 
one, de novo pathway, is dependent on folic acid as a coenzyme and the second salvage 
pathway relies on the enzyme hypoxanthine phosphoribosyltransferase (HPRT). BW 5147 T cell 
lymphoma has a mutation in the HPRT enzyme and is therefore entirely dependent on de novo 
pathway for its survival.  
The conventional HAT selecting medium contains aminopterin, a drug which blocks de novo 
DNA synthesis leading to lethality of HPRT-deficient BW 5147 T cell lymphoma partners. 
Hence, un-fused BW 5147 cells will die as they cannot produce nucleotides by the de novo 
pathway. Furthermore, un-fused T cells will also die as they have a limited life span in culture. 
Thus, only fused T cell-lymphoma hybrids will survive in long-term cultures.   
After approximately 2 weeks in HAT selecting medium, T cell hybridomas were then gradually 
moved to HT-containing medium. This medium does not contain aminopterin, only 
hypoxantine and thymidyne which help T cell hybridomas to growth. Finally, T cell hybridomas 
were transferred to complete RPMI. Following a 4 week selection process, approximately 50 
HAT resistant hybrids were screened for TTCF specificity using standard antigen presentation 
assays. The murine macrophage cell line (J774) was used as APC. For these assays, 5x104 of 
each candidate hybridomas were co-cultured with two concentrations of recombinant TTCF 
and 5x104 J774 for 24 h in 96 well plates. As a positive control for T cell stimulation, I used 
concanavalin A (ConA) at a concentration of 5 g/ml.  
Antigen specific IL-2 production by hybridomas was measured by transferring the supernatant 
from these assays into fresh wells containing 3x104 of the IL-2 dependent line CTLL-2. To 
determine whether any of the hybrids were specific to EGFP, I also incubated each hybrid with 
two concentrations of recombinant soluble E/T. In Fig. 5.2., the IL-2 dependent proliferation 
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(measured by 3H-thymidine DNA incorporation) of CTLL-2 cells is shown for 12 representative 
hybrids. The vast majority of hybrids show no evidence of TTCF or E/T specificity and also no 
significant response to ConA (for example hybrids 1-8, Fig. 5.2. a.). However, three hybrids (no. 
38, 39, 52) clearly showed TTCF specific proliferation. In particular, hybridomas no. 39 and 52 
respond the strongest to both soluble TTCF and E/T antigens as indicated by the grey and blue 
column respectively (Fig. 5.2. b.). Thus, I further characterised these two hybridomas.  
 
   
    
     
Fig. 5.2. a. A screening of T cells hybridomas specific for TTCF using two concentrations of soluble TTCF 
(1 g/ml and 10 g/ml) and E/T (1 g/ml and 10 g/ml. Shown are 6 representative hybrids (1-6). 
Proliferation assays screening T cell hybridomas were performed once.  
a. 
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Fig. 5.2. b. A screening of T cells hybridomas specific for TTCF using two concentrations of soluble TTCF 
(1 g/ml and 10 g/ml) and E/T (1 g/ml and 10 g/ml. Shown are 6 representative hybrids (7, 8, 19, 
38, 39, 52). Proliferation assays screening T cell hybridomas were performed once. 
b. 
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Following initial selection of two the best responding T cell hybridomas (no. 39 and 52), I re-
tested them again using graded concentrations of TTCF and TTCF-specific B cells as APC (blue 
line in Fig. 5.3. panel a. and b.). In addition, presentation by non-specific B cells (A20) (red line 
in Fig. 5.3. panel a., b.) and macrophages cell lines J774 (purple and green line in Fig. 5.3. 
panel c) were used for comparison. When the TTCF-specific B cells were used as APC, 
presentation was significantly increased, compared to that seen with either J774 or non-
specific B cells with T cell responses being detected at significantly lower concentrations of 
TTCF. This is consistent with other studies using antigen-specific B cell (Ferrari et al., 1997; 
Knight et al., 1997; Lanzavecchia and Bove, 1985). 
 
               a.                                                                            b .  
 
                c.                                                                           d.  
  
 
Fig. 5.3. Proliferation assays of the generated hybrids MC-39 and MC-52 against various doses of 
soluble TTCF. Three types of APC cells were used in this experiment: TTCF-specific B cells A20-3A5, 
non-specific B cells A20 (panel a. and b.) and J774 microphage cell line (panel c.). Panel d. shows 
control proliferation of CTLL-2 lines responding for titration of recombinant IL-2.  
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5.2.2. Characterisation of surface marker and TCR repertoire in MC-39 and MC-52 T 
cell hybridomas  
 
Newly generated hybrids MC-39 and MC-52 were also characterized for expression of T cell 
markers using flow cytometry. Fig. 5.4. (panel from a to d.), represents the histograms for 
CD8, CD4 and TCR staining. Histograms illustrated that both CD4 and TCR were expressed by 
both generated T cell hybridomas MC-39 and MC-52. Control staining were performed using 
murine thymocytes for specificity of anti-TCR, CD4, CD8 antibodies (Fig. 5.4., panel e.).  
              a.                                                                           b. 
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Fig. 5.4. Flow cytometry analysis of the generated T cell hybrids. The expression of TCR, CD4 and CD8 
markers was measured on the cell surface. Histograms overlays show the differential expression of 
TCR, CD4 and CD8 in hybrid no. 39 (panel a. and b.) and 52 (panel c. and d.). Green represents 
unstained cells. Panel e. represents staining of murine thymocytes as a positive control for the anti-
CD4 and anti-CD8 antibodies used in this experiment.  
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In addition, the TCR V gene usage of MC-52 T cell hybrids was also tested. To this end, I used 
a screening panel of 15 specific monoclonal antibodies against different V TCR chains directly 
conjugated with FITC. Following incubation with this panel of antibodies, MC-52 T cell 
hybridomas were analysed by flow cytometry. In Fig. 5.5., it can be seen that MC-52 T cells 
incubated with an anti-V2 antibody gave one log shift (red line) highlighted by a green arrow 
in antibody staining. In contrast, the rest of the 14 antibodies (specific for various other TCR 
Vchains) showed negligible binding compared to the auto-fluorescence seen with unstained 
cells. 
      a. 
 
 
Fig. 5.5. a. Characterization of the TCR structure of MC-52 hybridomas using mouse V TCR screening 
panel. Flow cytometry analysis of MC-52 hybridomas stained with FITC-conjugated monoclonal 
antibodies which recognise mouse V2, 3, 4, 5.2, 6, 7, 8.1 and 8.2 T cell receptor (red histogram) 
respectively. Blue histograms represent unstained MC-52 T cells. Antibody reacting with the V2 
exclusively binds to TCR receptor of MC-52 hybridomas.  
unstained  
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             b. 
 
 
 
Fig. 5.5. b. Characterization of the TCR structure of MC-52 hybridomas using mouse V TCR screening 
panel. Flow cytometry analysis of MC-52 hybridomas stained with FITC-conjugated monoclonal 
antibodies which recognise mouse V 8.3, 9, 10b, 11, 12, 13, 14 and 17a T cell receptor (red histogram) 
respectively. Blue histograms represent unstained MC-52 T cells. Antibody reacting with the V2 
exclusively binds to TCR receptor of MC-52 hybridomas.  
 
This indicated that MC-52 T cell hybridomas are a homogeneous population of CD4+ T cell 
hybridomas expressing the TCR V2 chain. 
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5.2.3. Identification of epitope specificity in MC-52 T cell hybrids  
 
In order to characterise the epitope of TTCF recognised by MC-52 hybridomas, I incubated 
these cells with APC and a panel of overlapping peptides that span the entire sequence of TTCF 
(kind gift from Colin Watts, Dundee University (Antoniou and Watts, 2002)). These 88, 17-mer 
peptides were originally supplied as 22 pools (A to V), each containing 4 individual peptides 
(Fig. 5.6. panel a.). To this end, I measured the response of MC-52 T cells hybridomas when 
incubated with each of these 22 pools. In this experiment, TTCF-specific B cells were used as 
APC. This initial test allowed me to identify pools containing peptides which span the epitope 
recognised by MC-52. In Fig. 5.6. panel b., it can clearly be seen that MC-52 responded to the 
peptides present in pool M (purple column) as indicated by a strong response of approximately 
60 000 cpm. 
 
 
 
Fig. 5.6. Determination of MC-52 fine specificity using a panel of overlapping peptides. Panel a. shows 
schematic representation of overlapping 17-mer peptides pooled into groups (from A to V) that span 
the entire TTCF fragment protein. Panel b. represents proliferation assays of MC-52 hybrids 
responded for above groups of 17-mer peptides (2 g/ml each). TTCF-specific B cells were used as APC 
in this experiment.  
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Consequently, I measured the response of MC-52 to the individual peptides contained in group 
M. As a positive control, pool M was re-used and a negative control was represented by pool 
A. As shown in Fig. 5.7., MC-52 T cells recognised only one 17-mer peptide (52) as indicated by 
a strong response reaching approximately 110 000 cpm (pink column).  
 
 
 
Fig. 5.7. Determination of MC-52 fine specificity using a panel of overlapping peptides. Proliferation 
assays of MC-52 hybrids significantly responded only for peptide 52 (red column) previously pooled in 
group M together with 49, 50 and 51 peptides (2 g/ml each). As negative controls, peptides from 
group A, B and T cells without antigen or medium only were used in this experiment. As a positive 
control pool M were added to the assay (purple column). TTCF-specific B cells were used as APC in this 
experiment.  
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The 3D structure of TTCF and the localisation of the 17-mer peptide 52 are illustrated in  
Fig. 5.8. 
 
 
 
Fig. 5.8. The 3D structure of TTCF including 17-mer sequence of peptide 52 indicated by a yellow line.  
 
 
I have previously shown that TTCF-specific B cells present TTCF protein more efficiently than 
that seen by non-specific B cells (Fig. 4.5.). This is demonstrated in antigen presentation assays 
where TTCF-specific B cells require considerably less antigen than non-specific B cells to induce 
a similar magnitude of response in MC-52. This is consistent with other studies showing that 
processing of TTCF is enhanced by its binding and internalization as part of the TTCF-specific 
BCR complex (Knight et al., 1997). To confirm that peptide 52 was the natural processing 
product recognised by MC-52, I compared the presentation of either peptide 52 or soluble 
TTCF protein by both TTCF-specific and non-specific B cells. As expected, Fig. 5.9. panel a. 
demonstrates that TTCF-specific B cells are more efficient in processing and presentation of 
TTCF to MC-52 T cells. When I incubated B cells with T cells in the presence of TTCF protein 
BCR-mediated processing was evident with 10 M of TTCF only inducing a response when 
TTCF-specific B cells were used. In contrast, when both B cells were incubated with peptide 52 
an identical response was observed (Fig. 5.9. panel b.). 
This experiment clearly demonstrated that MC-52 clones are specific for peptide 52 which 
could be presented by specific and non specific APC equally. However, when T cell hybridomas 
were incubated with soluble protein, TTCF specific-B cell were required for efficient antigen 
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recognition (via specific BCR) and processing of TTCF with peptide/MHC complexes required by 
MC-52 T cell hybridomas.  
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Fig. 5.9. Determination of MC-52 fine specificity. Proliferation assays of MC-52 T cell hybridomas 
responded for titrated dose of soluble TTCF presented only by TTCF-specific B cells (panel a. blue line) 
but not non-specific B cells (panel a. red line). Panel b. shows pooled peptides from group M 
containing peptide 52 (panel b.) presented similarly either by TTCF-specific (blue line) or non-specific 
B cells (red line) in MHC class II pathway to MC-52 T cell hybridomas.  
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5.2.4. Characterisation of the MHC restriction of MC-52 T cell hybridomas  
 
To establish the H-2d class II molecule involved in the presentation of peptide 52 to MC-52, I 
incubated MC-52 T cell hybridomas with murine fibroblasts (gifts from John Robinson), which 
either express H-2Ad or H-2Ed class II molecules. To avoid any deficiency of antigen processing 
which may be present in these cells, I performed these experiments with pre-processed 
peptide 52. Following titration of peptide 52, both H-2Ad and H-2Ed expressing fibroblasts were 
plated with MC-52 into 96 well plates. 24 h later supernatants were transferred into a new 
plate containing both radioactive thymidyne and IL-2 deprived CTLL cells. Subsequently, IL-2 
production was measured as previously described. In Fig. 5.10., it can be seen that peptide 52 
was exclusively presented by the fibroblasts expressing H-2Ad molecules and consequently 
recognised by MC-52 T cell hybridomas (blue line). In contrast, fibroblasts expressing H-2Ed 
molecules did not present peptide 52 (pink line). This experiment clearly demonstrates that 
MC-52 T cell hybridomas are H-2Ad restricted.  
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Fig. 5.10. Proliferation assay of mouse fibroblasts as a antigen presenting cells for MC-52 T cell 
hybridomas. Murine fibroblasts transfected with H-2A
d 
(blue line) or H-2E
d
 (pink line) MHC class II 
molecules were incubated with graded dose of peptide 52 and TTCF-specific T cell hybridomas MC-52 
for 24 h. IL-2 production was measured as described previously.  
H-2Ad 
H-2Ed 
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5.2.5. Detection of surface E/T using antigen-specific B and T cells 
 
To determine whether TTCF-specific B cells are capable of presenting TTCF acquired from 
mem-E/T transiently transfected HeLa cells (as opposed to soluble recombinant TTCF), I 
performed pilot proliferation assays. HeLa cells were transfected with the mem-E/T construct 
and one day later they were harvested and titrated into 96 well plates containing either non 
(A20) or TTCF-specific B cells (A20-3A5) and MC-52 T cell hybrids. As an additional control 
replicate wells containing HeLa cells transfected with the ER-E/T construct were also included. 
The inclusion of these control transfectants allowed me to exclude the possibility that specific 
B cells may acquire and present E/T released from the slightly increased number of cells 
naturally dying in culture following transfection. As can be seen in Fig. 5.11. panel a., when 
HeLa cells transfected with ER-E/T were mixed with various APC (including TTCF-specific B 
cells), MC-52 did not produce IL-2. This indicates that ER-E/T remained intracellular and any 
antigen released was insufficient for acquisition and presentation by antigen-specific B cells. In 
contrast, when HeLa cells expressing mem-E/T were incubated with various APC only antigen-
specific B cells (A20-3A5) were capable of extracting and presenting antigen to MC-52 hybrids 
(Fig. 5.11., panel b.). Thus, membrane located E/T can be recognised, extracted and presented 
to TTCF-specific T cell hybrids by B cells expressing a TTCF-specific BCR. This pilot experiment 
forms the basis of further experiments which I described in more detail in Chapter 6.  
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Fig. 5.11. Antigen presentation assays using newly generated T cell hybrid MC-52 incubated with 
various APC (non-specific B cells (red line), TTCF-specific B cells (blue line) or J774 macrophages (green 
line)) and graded number of HeLa ER-E/T (a.) or mem-E/T (b.) transfectants.  
MC-52 
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5.3. Discussion  
 
In this chapter I described the generation of two TTCF-specific T cell hybrids: MC-39 and MC-52 
according to standard protocols. Balb/c mice were immunized with E/T antigen and 2 weeks 
later antigen specific T cells were isolated from lymph nodes. Subsequently, T cells were fused 
with the BW 5147 lymphoma partner and selected on medium containing HAT in order to 
generate antigen-specific T cell hybridomas. Approximately 50 HAT-resistant hybridomas were 
screened for TTCF specificity. Two hybridomas MC-39 and MC-52 significantly recognised 
TTCFF and E/T antigens (Fig. 5.2., b.). Therefore, I further characterised MC-39 and MC-52 T 
cell hybridomas with respect to expression of several surface marker and responses to titrated 
antigen concentrations.  
As the MC-52 cells responded to antigen more significantly than MC-39, I decided to focus 
further studies on MC-52 T cell hybridomas. These experiments included the identification of 
the TCR V gene usage, characterisation of TCR epitope specificity and identification of the 
MHC epitope restriction of the MC-52. Following the characterisation of MC-52, I decided to 
perform a series of pilot experiments testing whether TTCF-specific B cells are able to extract 
and present surface tethered E/T to MC-52. Fig. 5.11. demonstrates that TTCF-B cells were 
capable of extracting and presenting mem-E/T to MC-52. This figure also shows that this 
antigen presentation is dose dependent as an increase in MC-52 IL-2 production was seen 
following incubation with a fixed number of TTCF-specific B cells with graded numbers of HeLa 
transfectants. In contrast, non-specific B cells and J774 murine macrophages cell lines did not 
acquire and present antigen indicating that surface antigen extraction is BCR-dependent. Also 
HeLa cells transfected with the ER-E/T construct did not allow TTCF-specific B cells extraction 
and presentation confirming the lack of sufficient release following transfectant death.  
 
 
In conclusion: 
In this chapter, I successfully generated and characterised the MC-52 T cell hybridomas. These 
cells appeared to be a homogeneous population derived from the single clone and have been 
characterised as CD4+, TCR+, V2+. In addition, using a panel of overlapping peptides, I 
determined the epitope specificity of MC-52 which was recognised in the context of H-2Ad.  
Using HeLa transfectants, I have also established an assay demonstrating extraction and 
presentation of a plasma membrane-anchored antigen by antigen-specific B cells. These 
findings raise the distinct possibility that antigen specific B cells may be able to extract and 
present only those intracellular ‘neo’ antigens which relocate to the plasma cell surface 
following apoptotic cell death.  
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-  6. Antigen-specific B cells acquire and present E/T that has 
relocated to the cell surface following the induction of apoptosis  - 
 
 
6.1. Introduction 
 
There is a growing body of evidence supporting the beneficial role of radiotherapy as an 
adjuvant enhancing the activation of anti-tumour immunity. In particular, it has been reported 
that both -irradiation and UVC induce immunogenic tumour cell death in colon and breast 
carcinomas (Obeid et al., 2007a) (Tesniere et al., 2009). As previously described, one of the 
principal characteristics of immunogenic cell death is the relocation of the intracellular 
antigens to the cell surface. Indeed, I have shown in Chapter 4 that the model antigen E/T is 
relocated from the ER, cytoplasm and mitochondria following anthracycline or UVC treatment. 
This relocation was shown to lead to E/T expression in the apoptotic blebs in cells transfected 
with cyto and ER-E/T.  
It has been previously reported, that B cells are able to recognise antigens in different forms: 
either in solution (Kim et al., 2006) or tethered to the surface of various cell types (Carrasco 
and Batista, 2007) (Allen and Cyster, 2008). Also in Chapter 5, I presented preliminary data 
that HeLa surface tethered E/T can be acquired and presented to CD4+ T cells by antigen-
specific B cells. Following BCR-mediated antigen internalization, a series of proteolytic and 
other enzymatic events lead to the generation of antigen/MHC class II complexes which 
activate CD4+ T cells.  
 
In this chapter, I have used the reagents and assays that I have previously generated and 
characterised to test the hypothesis that, following UVC induced relocation, intracellular E/T 
can be acquired and presented to CD4+ T cells by TTCF-specific B cells. In particular, I have first 
designed and used a novel assay where TTCF-specific B cells are monitored using flow 
cytometry that has allowed me to analyse the kinetics of E/T acquisition following incubation 
with various HeLa transfectants. Based on the results from this novel assay, I have also 
modified the standard antigen presenting assays previously described, again to give further 
insight into the biological consequences of E/T acquisition by antigen-specific B cells. 
Importantly, these modified antigen presentation assays allowed the ability to control the time 
of interaction between B cells and HeLa cells expressing E/T prior to their incubation with CD4+ 
T cells. In addition, I have also investigated the physical parameters of E/T acquisition by TTCF-
specific B cells. 
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6.2. Results  
 
 
6.2.1. Detection of BCR-mediated E/T acquisition by flow cytometry  
 
In Chapter 4, I have demonstrated that mem-E/T is detected on the surface of transfected 
HeLa cells. In order to establish whether the TTCF component of this chimeric protein is also 
available for B cell acquisition, I stained mem-E/T transfectants with an anti-TTCF monoclonal 
antibody (10G5) (Antoniou and Watts, 2002). Following a 1 h incubation (4oC) with 10G5 
antibodies, HeLa cells were washed and incubated with PerCP conjugated anti-mouse 
secondary antibodies and examined using flow cytometry. Fig. 6.1. shows that 10G5 antibodies 
bound to surface of mem-E/T HeLa transfectants. In addition, it can also be seen that there is a 
direct correlation between the 10G5 staining and the EGFP fluorescence, covering a range of 
expression levels that would be expected in a transient expression system.  
Thus, this confirms that full length E/T chimeric protein is expressed on the surface of HeLa 
cells and future experiments using TTCF-specific B cells will be possible.  
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Fig. 6.1. Surface binding of 10G5 antibody recognizing TTCF epitopes in HeLa mem-E/T transfectants. 
Following 1 h incubation with 2 g/ml of 10G5 antibody recognising TTCF, mem-E/T HeLa cells were 
stained with anti-mouse-PerCP secondary antibody and analysed using flow cytometry. Dot blots (b.) 
represent co-localization between HeLa mem-E/T transfectants (FL-1) and 10G5 antibody (FL-3). Panel 
a. demonstrates untransfected mem-E/T transfectants stained with 10G5 antibody. 
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As the 10G5 monoclonal antibody was capable of detecting mem-E/T, I decided to perform 
flow cytometry analysis to determine whether TTCF-specific-B cells incubated with HeLa E/T 
transfectants could be labelled by the acquisition of the chimeric fluorescent antigen. Prior to 
that, I tested whether flow cytometry would allow detection of soluble E/T binding to TTCF-
specific B cells after incubation for various time periods (1 min, 1 h, and 3 h). TTCF-specific B 
cells were incubated with 2.5 g/ml of soluble E/T at 4oC. Following washing, B cells were then 
stained with a mouse anti-B220 antibody directly conjugated with PerCP fluorochrome and 
analysed by flow cytometry. As the anti-B220 antibodies exclusively recognise the CD45R 
antigen expressed by the B cell lineage, this allowed a gate to be drawn on B cell population. In 
Fig. 6.2., it can be seen that following incubation with soluble E/T for 1 or 3 h, more than 60% 
of the B220 positive cells were also positive for EGFP acquisition and with a significant increase 
in mean fluorescence intensity (MFI) during this time course (from 5.35 following 1h to 5.82 
after 3 h incubation). Interestingly, it can also be seen that incubation with soluble E/T for time 
points as short as 1 min was also sufficient for E/T acquisition (Fig. 6.2. bottom left panel) with 
more than 60% of double positive cells but with lower MFI=4.97.  
 
 
 
Fig. 6.2. Soluble E/T acquisition by TTCF-specific B cells. Flow cytometry analysis of TTCF-specific B 
cells that bind green fluorescent E/T antigen to the cell surface via specific BCR. Fallowing incubation 
with soluble E/T (2.5 g/ml) in a various time periods (1 min, 1 h, 3 h), TTCF-specific B cells were 
washed and incubated with B220-PerCP. After final wash 10 000 events were collected using a 
FACScan Calibur (BD). As a control, TTCF-specific B cells were incubated in medium without any 
antigen (upper dot plot). This flow cytometry analysis is representative of 2 independent experiments.  
soluble E/T  
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Having established a relatively simple assay for an the acquisition of soluble E/T by TTCF-
specific B cells, I then progressed to determine if this assay would allow the detection of 
acquired mem-E/T by these B cells. As previously described for soluble E/T, TTCF specific-B 
cells were incubated at 37oC with mem-E/T HeLa transfectants for the same time points (1 
min, 1 h and 3 h) and following staining with B220 antibody, I quantified B cells fluorescence 
using flow cytometry. Fig. 6.3. demonstrates that, similar to that seen with soluble E/T, 
incubation with TTCF-specific B cells with mem-E/T transfectants for periods of 1 or 3 h 
resulted in 51% and 55% B220/EGFP double positive cells (MFI=3.78 and MFI=3.96 
respectively). In contrast, when these cells were incubated with untransfected HeLa cells there 
is no co-staining (Fig. 6.3. upper right panel). In addition, a 1 min incubation with mem-E/T 
transfectants was sufficient for more than 20% of TTCF-specific B cells to acquire E/T 
(MFI=2.39).  
 
Fig. 6.3. Surface-tethered mem-E/T acquisition by TTCF-specific B cells. Flow cytometry analysis of 
TTCF-specific B cells that bind via specific BCR green fluorescent E/T antigen expressed on the plasma 
cell membrane of HeLa transfectants. Antigen acquisition increases with the time course (lower dot 
plots). Fallowing incubation with mem-E/T HeLa transfectants, TTCF-specific B cells were washed and 
incubated with B220-PerCP. After final wash 10 000 events were collected using a FACScan Calibur 
(BD). As a control, TTCF-specific B cells were incubated in medium without any antigen (upper dot 
plot). This flow cytometry analysis is representative of 2 independent experiments.  
 
HeLa mem-E/T 
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To test whether either soluble or mem-E/T acquisition was BCR-mediated, I also performed 
these experiments using non-specific B cells. Fig. 6.4. indicates that non-specific B cells failed 
to acquire both soluble E/T or mem-E/T from HeLa surface following incubation periods as long 
as 1 h. In can be seen that 0.35% of non-specific B cells incubated with soluble E/T for 1 h were 
double positive, compared to 64% seen in Fig. 6.2. using TTCF-specific B cells. Similarly, 3.7% of 
non-specific B cells incubated with mem-E/T transfectant were double positive, compared to 
54% seen in Fig. 6.3. Finally as a control for E/T release and its acquisition by TTCF-specific B 
cells, I also incubated TTCF-specific B cells for 3 h with HeLa cells transfected with ER-E/T. Fig. 
6.4. (right panel) shows that only 3.7% of TTCF-specific B cells acquire intracellular antigen 
which is similar to the acquisition of mem-E/T by non-specific B cells and significantly less than 
that acquired by TTCF-specific B cells following incubation with mem-E/T transfectants. This 
low level of background acquisition probably reflects the number of naturally dying HeLa cells 
releasing small quantity of E/T into the media. This experiment shows that antigen extraction 
is BCR-mediated and occurs only when E/T antigen is on the cell surface.   
 
In order to quantify the E/T acquisition by TTCF-specific B cells, the median fluorescence 
intensity (MFI) of E/T fluorescence following B cell incubation with various E/T targets was 
examined statistically. Fig. 6.4. panels b., d. and f. shows a summary of the data obtained from 
several replicates of these novel experiments. It can be seen (Fig. 6.5. panel. b.) that there is a 
significant increase in the acquisition of soluble E/T by TTCF-specific versus non-specific B cells. 
Likewise, panel d. shows a similar significant increase in the acquisition of mem-E/T by TTCF-
specific B cells. Panel f. shows that acquisition of E/T by TTCF-specific B cells is dependent on 
expression of E/T at the cells surface as there is a significant difference in the acquisition of 
mem-E/T versus ER-E/T.  
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Fig. 6.4. Flow cytometry and statistical analysis of antigen BCR-mediated E/T acquisition. The dot plots 
shows the non-specific B cells incubated for 1 h with soluble E/T (2.5 g/ml) (panel a.) or for 2 h with 
mem-E/T HeLa transfectants (panel c.). Panel e. demonstrates TTCF- B cells incubated for 3 h with ER-
E/T HeLa transfectants. Statistical analysis significantly quantifies the differences in the E/T 
acquisition between TTCF-specific and non-specific B cells from solution (panel b.) or cell surface of 
mem-E/T HeLa cells. (panel d.) In addition, panel f. demonstrates the differences in antigen 
acquisition from ER-E/T or mem-E/T HeLa transfectants by TTCF-B cells.  
 
b. a. 
c. d. 
e. f. 
B cells + soluble  
E/T for 1h 
 
B cells + mem-E/T 
HeLa cells for 2h 
 
TTCF-B cells + ER-E/T 
HeLa cells for 2h 
 
soluble E/T for 1 h 
indicates p< 0.05             indicates p<0.01                   indicate p<0.001 
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Thus the use of flow cytometry represents a reliable assay for the measurement of the 
acquisition of E/T by antigen-specific B cells. I have previously demonstrated in Chapter 4 that 
intracellular E/T relocates to the cell surface following UVC and anthracycline treatment. 
Therefore, in the next series of experiments I tested whether this flow cytometry-based assay 
would allow me to detect acquisition of relocated E/T by TTCF-specific B cells. To address this 
HeLa cyto-E/T transfectants were exposed to 300 J/m2 of UVC light or left un-treated. After  
4 h TTCF-specific B cells (or non-specific B cells) were added to the transfectants for a period of 
2 h. Following this time the non-adherent B cells were removed, washed, stained with anti-
B220 antibodies and analysed by flow cytometry. Fig. 6.5. summarises this series of 
experiments and shows that when TTCF-specific B cells were incubated with UVC treated cyto-
E/T transfectant a significant number (14.8%) acquired E/T fluorescence as visualised by the 
number of double positive (B220+, E/T+) cells. Importantly, this number of double positive 
cells was significantly reduced when TTCF-specific B cells were incubated with either un-
treated cyto-E/T transfectants (0.7%) or non-transfected HeLa cells (0.18%). It can also be seen 
that non-specific B cells incubated with all transfectants did not show significant E/T 
acquisition. Surprisingly, when TTCF-specific B cells were co-cultured with UVC treated HeLa 
cells expressing ER-E/T, I failed to observe relocated antigen acquisition (Fig. 6.6. panel b.).  
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Fig. 6.5. Relocated E/T antigen extraction by TTCF-specific B cells from cyto-E/T HeLa transfectants 
following UVC treatment. Flow cytometry analysis of TTCF-specific B cell acquisition of relocated 
intracellular antigen from surface of HeLa transfectants via specific BCR. TTCF-specific B cells following 
incubation with cyto-E/T or mem-E/T HeLa transfectants were removed, washed and stained with 
B220-PerCP. Control experiments in which B cells were incubated with untransfected (no antigen) 
HeLa cells (upper dot plot) were also included. This flow cytometry analysis is representative of 2 
independent experiments. 
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In order to quantitate E/T acquisition following incubation of TTCF-specific B cells with 
apoptotic cyto-E/T HeLa transfectants, the E/T MFI of E/T+, B220+ B cells was calculated from 
three independent experiments and these are shown in Fig. 6.6.  
 
 
 
 
 
 
Fig. 6.6. Statistical analysis of the three independent experiments performed by flow cytometry 
demonstrating MFI EGFP acquisition by TTCF-B cells from cyto-E/T (panel a.) and ER-E/T (panel b.) 
HeLa transfectants. B220+ TTCF-specific B cells incubated either with untreated transfectants or with 
transfectants following UVC (300 J/m2) treatment acquire E/T antigen represented as MFI of EGFP.  
 
Thus, these experiments demonstrate for the first time, that intracellular cyto-E/T (but not ER-
E/T) is relocated following UVC treatment and can be acquired by TTCF-specific B cells.  
a. 
b. 
     indicates p< 0.01  
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6.2.2. Detection of E/T presentation by antigen-specific B cells using a novel antigen 
presentation assay 
 
In the previous section, I have demonstrated that TTCF specific B cells were able to extract 
both surface antigens and those relocated from intracellular compartments (cytoplasm), as a 
consequence of immunogenic cell death using flow cytometry. In this section, I have addressed 
whether antigen acquired in this manner is a suitable substrate for BCR-mediated 
internalization and intracellular processing that leads to the generation of peptide/MHC 
complexes that are recognisable by CD4+ T cells. Initially, to test this I performed standard 
antigen presentation assays where various numbers of mem-E/T HeLa transfectants were 
incubated with TTCF-specific (or non-specific) B cells and MC-52 TTCF specific-T cells (described 
in Chapter 5) for 24 h. Fig. 6.7. panel a. extends the analysis of mem-E/T acquisition and 
presentation by TTCF-specific B cells earlier shown in Fig. 5.10. As shown before, Fig. 6.7. 
shows that only TTCF-specific B cells can efficiently acquire and present mem-E/T to MC-52 T 
cells. Maximal T cell stimulation was observed with approximately 6 000 mem-E/T 
transfectants. Paradoxically, when the number of transfectants in each well was increased 
above this number, T cell stimulation was reduced. This may indicate that these standard 
assays may be limited by large number of cells present in each well. This is confirmed by 
control experiments performed simultaneously with soluble TTCF that show significantly more 
MC-52 activation following presentation by TTCF-specific B cells (Fig. 6.7. panel b.).  
Furthermore, I examined whether mem-E/T acquisition is contact dependent. To test this, I 
repeated these assays in the presence of 0.4 m diameter blocking filters. This size of pore 
would be expected to allow free diffusion of soluble antigen, but would introduce a barrier 
between the adherent mem-E/T HeLa transfectants and the co-cultured B cells. Fig. 6.8. 
demonstrates that antigen presentation again was only observed when mem-E/T HeLa cells 
were incubated with specific TTCF-B and T cells. In those wells (panel a. arrow) that contained 
filters, it can be seen that mem-E/T presentation was inhibited. In contrast and as expected 
blocking filters had no effect on the presentation of soluble TTCF by TTCF-specific B cells (panel 
b. arrow).  
This experiment shows that TTCF-specific B cells require direct contact with the surface of 
mem-E/T transfected HeLa cells for E/T acquisition and presentation to MC-52 T cells. This is in 
agreement with previous experiments performed by Batista where immobilized HEL antigen 
was also extracted in a contact dependent manner by HEL-specific B cells (Batista et al., 2001).  
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Fig. 6.7. Antigen recognition from the cell surface or solution and presentation to MC-52 T cell 
hybridomas by specific or not specific B cells using proliferation bio-assay. Both panels demonstrate 
the standard procedure of proliferation bio-assay where B and T cell hybridomas were incubated for 
24 h with mem-E/T HeLa cells (panel a.) or with soluble TTCF (panel b.) and IL-2 was measured. This 
proliferation assay is representative of 6 independent experiments.  
a. 
b. 
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Fig. 6.8. Proliferation bio-assays of TTCF-B cells (blue line) or non specific B cells (red line) co-cultured 
with graded numbers of mem-E/T HeLa cells (panel a.) or graded doses of soluble TTCF (panel b.) and 
MC-52 T cells hybridomas. Green and pink circles represent additional wells containing blocking filters 
separating the HeLa E/T transfectants from the T and B cells. This proliferation assay analysis is 
representative of 4 independent experiments. 
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As these standard antigen presentation assays may be limited by cell number and do not allow 
the process of antigen acquisition and presentation to be physically separated from 
subsequent production of T cell derived IL-2, I decided to establish a novel assay measuring 
antigen recognition by MC-52 T cells. This improved assay was designed to allow B cell antigen 
acquisition over various time points. Following this, B cells were then removed from the target 
cells and re-plated with MC-52 T cells in absence of any further antigen for 24 h to allow IL-2 
production to be detected. Thus, only antigen acquired during the various times of the first 
incubation would be processed by TTCF-specific B cells. Fig. 6.9. panel a., demonstrates that 
when TTCF-specific B cells were incubated with mem-E/T transfectants for periods of 1, 2, 4 
and 6 h and graded numbers transferred to fresh wells containing MC-52, IL-2 production was 
observed. Interestingly, the IL-2 produced by MC-52 following incubation with TTCF-specific B 
cells that had been co-cultured with the HeLa transfectants for 1 or 6 h was similar. 
Furthermore, when MC-52 T cells were co-cultured with TTCF-specific B cells that had been 
incubated with HeLa transfectants for time periods as short as 1 min, levels of IL-2 production 
were also similar (panel b.). Thus, it appears that TTCF-specific B cells acquire sufficient E/T 
following incubation periods as short as 1 min that subsequently leads to maximal MC-52 
stimulation. To exclude the possibility that sufficient mem-E/T was released into the media, I 
also transferred HeLa transfectants supernatant (following the various time points) into fresh 
wells containing MC-52 and TTCF-specific B cells in the absence of any additional antigen. 
Panel c. shows these supernatants were insufficient to stimulate MC-52 IL-2 production.  
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Fig. 6.9. The kinetics of antigen extraction by B cells and presentation to T cell hybridomas from HeLa 
transfectants. Proliferation assay of MC-52 hybridomas responded for E/T antigen presented by 
specific TTCF-specific B cells (blue line) and non-specific B cells (red line). Both B cells (specific and 
non-specific) were previously incubated with mem-E/T HeLa transfectants for a various time points 
(from 1 min to 6 h) before co-culture with T cell hybridomas. In addition, the supernatant from HeLa 
transfectants was examined whether may stimulate B cells to recognition of de-attached antigen. This 
proliferation assay analysis is representative of 2 independent experiments. 
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6.2.3. Detection of intracellular E/T presentation by antigen-specific B cells following 
UVC treatment  
 
Finally to investigate whether intracellular E/T, that has previously been shown that relocate to 
the cell surface after UVC-treatment of HeLa transfectants (Fig. 4.12, 4.14.) was acquired by 
TTCF-specific B cells, I performed the following experiments. Using the previously described 
antigen presentation assay, I exposed HeLa transfectants expressing ER, cyto and mito-E/T to 
300 J/m2 UVC light. 4 h later these transfectants (or non-treated) were incubated with specific-
or non-specific B cells for 2 h. Based on the experiment shown in Fig. 6.5., this time was 
predicted to be sufficient to allow relocated E/T to be extracted by antigen-specific B cells. 
Subsequently, B cells were removed and graded numbers were then transferred to new wells 
containing a constant number of MC-52 T cells for a further 24 h (Fig. 6.10.). Panel a. 
demonstrates that when TTCF-specific B cells were incubated with UVC treated ER-E/T 
transfectants they acquired sufficient relocated E/T for the activation of MC-52 T cells 
Similarly, when TTCF-specific B cells were co-cultured with UVC treated cyto-E/T HeLa 
transfectants (panel b.), relocated E/T antigen from the cytoplasm was sufficient to be 
acquired by TTCF-specific B cells and presented to MC-52 T cell hybridomas. Importantly, in 
both these series of experiments presentation was not seen when either non-specific B cells 
were used (data not shown) or when TTCF-specific B cells were incubated with un-treated 
transfectants (red line). The results from this experiment differ to that seen in Fig. 6.6. where 
statistical analysis of three independent experiments performed by flow cytometry showed 
that TTCF-specific B cells acquired relocated cyto-E/T from UVC treated HeLa cells but did not 
extract relocated antigen from ER compartment. The discrepancy in ER-E/T acquisition by 
TTCF-B cells may be caused by the lower sensitivity of flow cytometry than the bio-assay 
measuring MC-52 activation. It was possible that ER relocated antigen was extracted by TTCF-
specific B cells, despite the levels being insufficient to be detected by flow cytometry. 
However, these levels were clearly sufficient to activate MC-52 T cells to produce IL-2.  
 
In panel c. it can be seen that only limited presentation occurred following incubation of TTCF-
specific B cells with UVC treated mito-E/T transfectants. This is consistent with data shown in 
Fig. 4. 13. panel b. where immunogenic apoptosis did not lead to significant surface expression 
of mito-E/T. 
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Fig. 6.10. TTCF-specific B cells acquired apoptosis-induced relocated E/T. TTCF-specific B cells following 
2 h incubation with UVC treated or untreated cyto-E/T (panel a.), ER-E/T (panel b.) or mito-E/T (panel 
c.) HeLa transfectants, were harvested and washed. Subsequently, the different numbers of such 
stimulated TTCF-specific B cells (blue line) were added to 5*104 MC-52 T cell hybridomas for 24 h. As a 
control, I used TTCF-specific B cells incubated with untreated HeLa transfectants (red line). 24 h later 
the supernatant were added to IL-2 deprived CTLL-2 cells and IL-2 production was measured indirectly 
by 3H-thymidyne incorporation to proliferating CTLL-2 cells. This proliferation assay analysis is 
representative of 5 independent experiments. 
 
a. 
c. 
b. 
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These findings were confirmed by statistical analysis of several independent sets of 
experiments that are shown in Fig. 6.11. It can be seen that while TTCF-specific B cells 
significantly acquired relocated ER (panel a.) and cyto-E/T (panel b.), acquisition of mito-E/T 
was not statistically significant above background levels (data not shown).  
Thus, these findings demonstrate that following the induction of immunogenic apoptosis using 
UVC, intracellular ER and cyto-E/T antigen in HeLa cells is relocated to the cell surface and 
acquired by antigen-specific B cells. This antigen acquisition consequently leads to 
presentation to MC-52 T cell hybridomas.  
 
 
 
Fig 6.11. Statistical analysis of the seven (panel a.) and four (panel b.) independent experiments from 
proliferation assays. Statistical significance between antigen recognition from untreated or UVC 
treated HeLa transfectants by TTCF-specific B cells resulted in IL-2 production by MC-52 hybridomas 
and consequently the proliferation of CTLL-2 IL-2 dependent cell line, was calculated using the 
Student’s t-test for unpaired samples.  
 
a. 
b. 
     indicates p< 0.05  
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6.3. Discussion 
 
Although many studies have shown that B cells recognise soluble antigens in vitro, it is likely 
that in vivo, a proportion of antigens encountered by B cells are membrane–bound. It is well 
documented that FDC that retain native antigens are able to act as target cells for B cells, in 
particularly in specialised areas knows as germinal centres. In these regions, B cells acquire 
tethered antigens and following processing, present peptides fragments to cognate CD4+ T 
cells (MacLennan, 2007).  
Furthermore, evidence also shows that macrophages are able to present intact antigens to B 
cells in the follicle-subcapsular sinus (SCS) boundary of the lymph node (Carrasco and Batista, 
2007). In addition, Wykes et al. showed that DC pulsed with soluble antigen can prime naive B 
cells both in in vivo and in in vitro models (Wykes et al., 1998). Importantly, direct contact 
between live DC and B cells was required to initiate antigen recognition and subsequent 
presentation to T cells. However, lysed DC were ineffective as an antigen source suggesting 
that DC play an active role in antigen priming. Antigen acquisition in an in vitro model by B cells 
was observed during the initial phases before specific antibody production appear. Other 
findings from Batista et. al. surprisingly demonstrated that antigen-specific B cells were also 
able to extract membrane bound antigens from other cells including transfected fibroblasts 
(Batista et al., 2001).  
These described examples of tethered antigen extraction from a variety of different cell types 
led me to establish an in vitro model where the parameters of B cell dependent antigen 
extraction could be studied. Using mem-E/T HeLa transfectants, I performed flow cytometry 
analysis that demonstrated that the anti-TTCF antibody (10G5) was capable of recognising 
chimeric E/T antigen present on the HeLa cell surface. This experiment confirmed that the full 
length fusion protein was expressed on the HeLa cell surface, as the antibody staining entirely 
overlapped with EGFP auto-fluorescence (Fig. 6.1.). I then showed that soluble E/T acquisition 
by TTCF-specific B cells could be detected using flow cytometry. Consequently, I established 
the kinetics of mem-E/T acquisition from HeLa transfectants by TTCF-specific B cells also using 
flow cytometry. Fig. 6.2. and 6.3., demonstrate that TTCF-specific B cells acquired E/T from 
solution or tethered to the surface of HeLa cells very rapidly, in time periods as short as 1 min. 
Incubating TTCF-specific B cells with mem-E/T transfectants for longer time periods led to an 
increase in the percentage of TTCF-B cells that acquired fluorescent antigen (approximately 
64% from solution and 20% from the membrane of HeLa cells). This experiment was repeated 
several times and the EGFP MFI acquired in the various experiments were compared using a 
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Student ‘t’ test. Fig. 6.4. panels b., d. and f. shows a statistical significance (p<0.05, p<0.01 and 
p<0.001, respectively for each panel) in the MFI intensity between non-specific and TTCF-
specific B cells incubated with soluble or membrane bound antigen. Furthermore, in these 
experiments (see Fig. 6.2., 6.3.) the population of cells which were shown to be double 
positive for both B220 and EGFP were contained within the parameters of a forward scatter 
(FSC) and side scatter (SSC) gate which was set on B cells incubated with untransfected HeLa 
cells (Fig. 6.3. top left panel). Therefore, this strongly indicates that the EGFP positive 
population of cells are single B cells and not B-HeLa cell conjugates. The demonstration that 
the B220/EGFP double positive population does not contain B-HeLa cell conjugates is of 
particular importance in subsequent experiments where this population of cells is transferred 
to fresh well containing MC-52 T cell hybridomas in the absence of antigen (Fig. 6.10.). I also 
performed experiments, where TTCF-B cells were incubated with HeLa cells transfected with 
intracellular antigen ER-E/T. This test allowed me to exclude that TTCF-B cells might recognise 
released intracellular antigen. Expectedly, the representative dot plot (Fig. 6.4. panel e.) and 
statistical analysis from four independent experiments (Fig. 6.4. panel f.) demonstrate that 
TTCF-B cells were able to extract only surface tethered E/T antigen. This experiment was 
consistent with Batista data showing that only HEL-specific B cells formed synapse with target 
cell expressing membrane-bound HEL and were able to extract the antigen, in contrast to non 
specific B cells which failed to do so (Batista et al., 2001) .  
Having optimised the parameters of surface antigen uptake, I decided to examine whether 
flow cytometry analysis was able to detect and quantify the acquisition of relocated antigen by 
TTCF-specific B cells from intracellular compartments following UVC treatment. Based on 
previous reports showing that UVC induces immunogenic cell death in cancer cell lines by 
displaying intracellular CRT protein on the cells surface (Obeid et al., 2007a) and my current 
experiments (Fig. 4.12. and Fig. 4.13.), I decided to use UVC treatment on cyto-E/T HeLa 
transfectants. Therefore, UVC treated HeLa transfectants were co-cultured with both TTCF-
specific and non-specific B cells for 2 h. Fig. 6.5. demonstrates that only TTCF-B cells were able 
to acquire E/T expressed by UVC treated cyto-E/T HeLa cells. In contrast to untreated HeLa 
transfectants, E/T was retained in the cytoplasm and antigen acquisition was not observed. In 
these experiments, I also used non-specific B cells which failed to acquire E/T antigen from 
both UVC-treated or control HeLa transfectants. The statistical difference in the MFI of 
acquired E/T between TTCF-B cells incubated with UVC treated cyto-E/T HeLa transfectants or 
untreated cells was assessed using the Student ‘t’ test (Fig. 6.6.).  
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In Chapter 5, I performed pilot experiments indicating that E/T fusion protein expressed on the 
surface of HeLa cells was extracted by TTCF specific-B cells and presented to specific CD4+ T 
cells as shown using an IL-2 dependent proliferation bio-assay (Fig. 5.10.). Therefore, I decided 
to investigate in more detail, whether intracellular antigen relocated to the surface following 
immunogenic apoptosis-induction is acquired by TTCF-specific B cells and presented to CD4+ T 
cells. For these experiments, I established a novel antigen presentation assay that allowed me 
to control the time of B /target cell interaction. B cells were firstly incubated with HeLa 
transfectants previously exposure to UVC light. Subsequently, these B cells were removed and 
incubated with specific CD4+ T cells, in the absence of any additional antigen (see previous 
discussion for exclusion of B/HeLa cell conjugates).  
This novel bio-assay allowed me to confirm that TTCF-specific B cells are indeed able to extract 
membrane tethered E/T antigen in time periods as short as 1 min and to present processed 
peptide to TTCF-specific T cells (Fig. 6.9.). Furthermore, I tested whether direct physical 
contact between target cells and B cells was essential in the process of antigen extraction. 
HeLa cells expressing mem-E/T were co-cultured with TTCF-specific B and T cells in the 
presence of 0.4 m blocking filter. This size of pores was able to inhibit the movement of 
lymphocytes, but not the diffusion of soluble TTCF. Fig. 6.8. panel a. shows that the presence 
of blocking filter completely abrogated mem-E/T recognition by TTCF-specific B cells. In 
contrast, when specific B and T cells were incubated with soluble TTCF for 24 h the presence of 
blocking filters did not affect antigen recognition and presentation (green dot in Fig. 6.8. panel 
b.). This experiment clearly indicates that physical contact between the E/T expressing target 
cell and TTCF-specific B cell was necessary required for antigen extraction from the plasma 
membrane. This is in agreement with data presented by Batista et al. showing the inhibition of 
membrane-anchored HEL extraction by HEL-specific B cells. Again, insertion a mesh separating 
target cells expressing mem-HEL from HEL-specific B cells, prevented antigen extraction, but 
not soluble HEL recognition (Batista et al., 2001). I then examined whether relocated 
intracellular E/T expression by HeLa transfectants can be extracted by TTCF-specific B cells and 
presented to antigen-specific CD4+ T cells using a novel bio-assay, where the process of 
antigen acquisition was physically separated from the process of antigen induced IL-2 
production. Fig. 6.10. shows that HeLa cells transfected with plasmid targeting E/T either to 
the cytoplasm or to the ER were able to provide relocated E/T for TTCF-specific B cell 
acquisition following UVC treatment, compared to non-specific B cells. This experiment was 
repeated several times and the statistical significance of BCR-mediated surface E/T acquisition 
was verified using the Student ‘t’ test. Thus, the proliferation assay to measure acquisition of 
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relocated antigen by B cells seems to be more sensitive than flow cytometry analysis which 
failed to demonstrate ER-E/T acquisition from UVC treated HeLa transfectants (Fig. 6.6 panel 
b.).  
HeLa cells transfected with mito-E/T construct were not examined statistically because I did 
not performed enough experiments allowing me to introduce statistical analysis.  
 
 
In conclusion: 
In this chapter, I have shown that B cells can extract surface-tethered antigen from target cells 
very rapidly, in time period as short as short as 1 min. This extraction was BCR-mediated in a 
contact dependent manner.  
Flow cytometry analysis for the first time allowed me to demonstrate that relocated 
intracellular antigen, as a consequence of immunogenic cell death is extracted by antigen-
specific B cells. Statistical analysis of this data was robust. Furthermore, in this chapter I 
developed a novel bio-assay allowing the detection and quantification of relocated antigen by 
specific B and T cells. This assay indicated that relocated antigen originating from either the 
cytoplasm or the ER, but not from mitochondria was recognised by TTCF-specific B cells and 
presented to cognate CD4+ T cells. Statistical analysis of this data confirmed that UVC treated 
cyto-E/T and ER-E/T HeLa transfectants were able to stimulate MC-52 T cell hybridomas via 
BCR-mediated, B cell antigen presentation.  
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-  7. Discussion  - 
 
 
The immune response to cancer is a dynamic process in which uncontrolled growth of cancer 
cells is countered by various protective mechanisms. The complexity of anti-cancer treatment 
recently has been focused on a positive interaction between conventional therapeutic 
modalities, including chemotherapeutic drugs or radiotherapy inducing the direct death of 
cancer cells and the activation of the host immune system eliciting anti-tumour immunity. 
Therefore, understanding the mechanisms leading to a more efficient collaboration and 
implantation of both these approaches in the clinic, will allow cancer patients to inhibit the 
progression of disease.  
Since the discovery of the first tumour associated antigen TAA, against which T cell immunity 
can be directed, many others still need to be identified. However, one of the main reasons why 
tumours are able to progress and expand is their ability to escape immune recognition. The 
inability to induce tumour anti-immunity is a consequence of down-regulation of many signals, 
including decrease in MHC molecules expression, which are required for antigen presentation. 
Additionally, the induction of regulatory T cells, the alteration of the APC properties of DC and 
macrophages lead to long-term tumour tolerance. This raises the question whether alternate B 
cells may efficiently present TAA. Therefore, there is a great need to perform further studies 
which will clarify the role of B cells as APC of tumour antigens that consequently induce anti-
tumour immunity. The aim of this project was to test this hypothesis.  
 
Although many previous studies have demonstrated that apoptosis appears to be tolerogenic 
rather than immunogenic, recent evidence suggests that following treatment with reagents 
such as UVC irradiation or anthracyclines, apoptotic tumour cells elicit immune responses. In 
particular, DC that engulf these ‘immunogenic’ apoptotic tumour cells are able to cross-
present antigens and prime cytotoxic CD8 T cells extremely vigorously. It has been shown that 
immuno-competent mice, challenged with anthracycline treated EL4, CT26 colon cancer or 
MCA205 fibrosarcoma, inhibited tumour progression more effectively, when compared to 
athymic immune-deficient animals (Apetoh et al., 2007a). Also, locally irradiated immuno-
competent mice rejected tumour tissue, in contrast to immuno-deficient mice which died as a 
consequence of tumour progression. Another study performed by Perez et. al. showed similar 
results; local irradiation of cancer cells can enhance host anti-tumour immune responses in 
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vivo (Perez et al., 2009). They used B16F0 melanoma cell line, as a model to monitor lung 
metastasis. Irradiation of cutaneous melanomas prior to their implementation resulted in 
more than a 20-fold reduction in lung metastases after systemic challenge with untreated 
melanoma cells compared to control mice receiving untreated melanoma cells. This clearly 
demonstrates a positive correlation between chemotherapy and radiotherapy on the host 
immune system as a vaccination strategy eliciting a more effective anti-tumour response. 
Importantly, these independent studies link the findings that CRT is redistributed to the cell 
surface and stimulate maturation of DC and antigen cross-presentation to CD8+ T cells. Many 
studies describe the great potential of tumour antigen recognition by CD8+ T cells, but overall 
such immune responses are generally weak and transient (Wang, 2001). One of the possible 
explanations for a transient effect of CD8+T cell-mediated anti-tumour immunity is the lack of 
CD4 T cell help (Corthay et al., 2005; Hung et al., 1998; Savelyeva et al., 2005). This implies that 
to fully achieve an effective anti-tumour response, well organised and cooperative networking 
between each subset of T cells is required. Therefore, a better understanding of the CD4+ T 
cell function that consequently initiates and maintains the memory response, might be 
essential in long-term clinical treatment against cancer.  
 
Although T cells are the major component of the mononuclear cells infiltrating many solid 
tumours, B cells and plasma cells are also present in the tumour microenvironment. In 
particular, Hansen et al. demonstrated that an increase number of B cells, penetrating MCB 
cancer tissue correlates with a better survival prognosis for patients. This was related to an 
induction of apoptosis in MCB cells by granzyme B released from CTL. Such dying MCB cells 
were shown to expose actin on their cell surface, permitting recognition by the TIB and 
resulting in oligoclonal expansion of B cells. This suggests that a major function of TIB was not 
antibody production but rather acting as a professional APC that prime CD4+ T cells (Hansen et 
al., 2001). Furthermore, Yasuda et. al. investigated the functional significance of TIB in tumour 
sites. They showed that patients with lung cancer have a population of TIB, constituting 4-16 % 
of the total number of infiltrating cells in seven tested lung cancers. These TIB showed up-
regulated expression of molecules involved in antigen presentation inducing CD40, CD80 and 
MHC class II compared with that seen in peripheral blood B cells (Yasuda et al., 2002). 
However, the broader cohort of different clinical stages, histopathology and immune status 
are necessary for a complete clarification of the importance of B cells in anti-tumour immunity.  
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Based on previously described reports documenting novel forms of immunogenic cancer cell 
death and the unclear role of B cells in anti-tumour immunity, I have decided to explore the 
possibility that B cells are able to extract and present to cognate CD4+ T cells tumour antigens 
relocated to the plasma membrane of dying cancer cells. Understanding this process would 
lead to a better understanding of the different components of anti-tumour immunity and 
mutual cooperation and may result in the induction of more effective and persistent anti-
tumour responses. I believe that this might strongly contribute to the future of clinical practice 
for cancer patients. 
 
 
7.1. Generation of a model antigen  
 
The first step of this project involved generation targeting of a model antigen hen egg 
lysozyme (HEL) to various cellular compartments. This would allow me to monitor protein 
relocation following apoptosis.  
The structure of HEL and a number of different anti-HEL antibodies is well characterised 
(Gerwing and Thompson, 1968; Smith-Gill et al., 1984). One of these antibodies, HyHEL10, 
was used to detect HEL expression using immunofluorescence techniques. Additionally, our 
laboratory possesses B cells expressing this antibody as a membrane bound BCR and also 
has a panel of HEL-specific T cell hybridomas (Adorini et al., 1988). Unfortunately, none of 
the plasmids that I generated (cyto-HEL, mito-HEL, nuc-HEL) led to HEL localisation in the 
correct intracellular compartment. Despite additional re-cloning of HEL into GFP-containing 
plasmids resulted in partial GFP expression, the synthesis of the expected fusion protein in 
HeLa cells did not occur. It was likely that the disulphide bonds present in the HEL structure 
negatively affected folding and consequently inhibited expression. Therefore, we decided to 
use another model antigen, EGFP-TTCF (E/T). The N’ terminal region of the E/T fusion protein - 
EGFP has a natural ability to emit green light when excited by blue light. For this reason, 
visualisation of E/T antigen using fluorescence microscopy when expressed in HeLa cells would 
be relatively straightforward. Furthermore, having previously generated and tested TTCF-
specific B cells it was even more encouraging to choose E/T as a model antigen.  
To this end, I generated four different E/T constructs targeting the fusion protein into the 
cytoplasm, mitochondria, ER or to the plasma membrane, respectively and tested their 
expression pattern in HeLa cells. The sub-cellular localization of each construct was detected 
by Western blotting and was also confirmed by immunofluorescence. The microscopic images 
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shown in Chapter 3 demonstrate the correct co-localisation with introduced markers 
characterising particular compartments and the individual E/T expressing constructs. Each co-
localisation chart clearly revealed the correct localisation of E/T antigen in the desired sub-
cellular compartments of HeLa cells. 
 
 
7.2. Establishing the apoptotic parameters required for intracellular 
antigen relocation 
 
Apoptosis is an evolutionarily conserved form of programmed cell death during which dying 
cells acquire a series of morphological and biochemical alterations. These changes include 
cytoplasmic shrinkage, membrane blebbing, chromatin condensation and nuclear DNA 
fragmentation (Wyllie et al., 1980). Importantly, this fundamental biological process is involved 
not only in the maintenance of tissue homeostasis, but also plays a pivotal role in the 
prevention and elimination of cancer cells (Kerr et al., 1994).  
Most cytotoxic drugs kill cancer cells by the induction apoptosis through the p53 pathway and 
by activating effector caspases such as caspases-3 (Kim et al., 2002). Anthracyclines (including 
doxorubicin and mitoxantron), along with oxaliplatine, are a new generation of 
chemotherapeutics which not only induce cancer cell death via inhibition of DNA and RNA 
synthesis, but also activate the immune system to destroy cancer cells. In particular, it has 
been shown in in vivo models, following anthracycline treatment of CT26 colon cancer cells, 
that DC which penetrate the tumour tissue have increased expression of maturation markers 
(CD80, CD83, CD86) and also secrete increased amounts of pro-inflammatory cytokines 
(Apetoh et al., 2008) (Zitvogel et al., 2008). The induction of molecules involved in antigen 
presentation by DC was due to the intracellular relocation of CRT from the ER of dying CT26 
cells to the plasma membrane. Such surface displayed CRT induced DC maturation which led to 
enhanced cross-presentation to CTL and therefore a better anti-tumour response was elicited.  
Based on these findings, I decided to test whether B cells are able to extract relocated antigens 
from an anthracycline treated cancer cell line resulting in CD4+ T cell activation.  
Before studying E/T relocation, I optimised the kinetics of apoptosis in HeLa cells following 
incubation with several anthracyclines. This was performed using the viability MTT test and 
annexin V binding. Based on these results, I subsequently treated HeLa cells for 4 h with 
optimised concentration of drugs (STS, DX and MX respectively). Subsequently, I tested 
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whether the E/T was able to relocate in HeLa transfectants following drug treatment. The 
results from fluorescence microscopy clearly showed that ER-E/T relocated to apoptotic bodies 
of dying cells incubated with DX or MX but not if treated with the non-immunogenic drug STS. 
For this reason, it was possible that ER-E/T expressed in HeLa cells would be a good candidate 
for B cell recognition following apoptosis induction by anthracyclines. Unexpectedly, the pilot 
experiments carried out with anthracycline treated ER-E/T HeLa cells and co-cultured with 
specific-B and T cells did not show the recognition and presentation of relocated E/T antigen. 
Paradoxically, proliferation bio-assays demonstrated a reverse correlation between the 
numbers of drug treated HeLa transfectants and T cell stimulation. Surprisingly, the MTT test 
showed that T cells were extremely sensitive to anthracyclines following incubation with 
extensively washed HeLa transfectants treated with DX or MX. The sensitivity of T cells 
following anthracycline administration is well documented (Kim et al., 2009a). 
Obeid and others showed that local radiotherapy in mice bearing breast cancer was more 
efficient in immune-competent mice then in immune-deficient animals. They showed that 
following UVC treatment, apoptotic tumour cells were engulfed more vigorously by DC leading 
to TAA cross-presentation by MHC class I molecules to CD8+ T cells (Obeid et al., 2007b). Also, 
UVC-treated breast cancer cells released inflammatory mediators including HMGB1, DAMPs 
that induced the upregulation of costimulatory signals on DC. Thus DC were able to act more 
efficiently as APC in CTL-mediated anti-tumour immunity (Green et al., 2009b). Based on these 
observations, I optimised the dose and time required for monitoring the apoptotic changes in 
UVC-treated HeLa cells. Following 100, 200 and 300 J/m2 UVC exposure, I measured HeLa 
viability using the MTT test and visualised using fluorescence and confocal microscopy, how 
ER-E/T intracellular localization was effected. Optimal UVC-induced apoptosis resulted in 40% 
cell death following treatment with 300 J/m2. Additionally, annexin V staining revealed that at 
this dose of UVC more than 80% cells were undergoing apoptosis. This dose was therefore 
used for rest of this study. Subsequently, I monitored changes in cellular morphology following 
300 J/m2 treatment in HeLa transfectants expressing E/T in various subcellular compartments. 
In particular, I focused on changes in the structure of the nuclei, plasma cell membrane and 
intracellular E/T localisation in HeLa transfectants, exposed to 300 J/m2 UVC. UVC-treated HeLa 
cells exhibited typical apoptotic changes such as DNA condensation and fragmentation 
indicated by strong Hoechst 33342 staining and plasma membrane asymmetry visualised by 
WGA dye. Importantly, the expression patterns of cyto-E/T and ER-E/T constructs in UVC-
treated HeLa cells were completely changed. The occurrence of green apoptotic bodies was 
observed. Similar observations have been seen by Maftoum-Cost et. al., in HeLa cells exposed 
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to photodynamic therapy (PDT). They showed that dying PDT-treated HeLa cells underwent 
changes in the ER compartment that tead to formation of bleb-like structures as a 
consequence of ATP loss and membrane potential dissemination (Maftoum-Costa et al., 2008). 
Furthermore, Fuller et al., also observed morphological changes following light exposure 
during PDT in lymphoma cells (Furre et al., 2006). The images from fluorescence microscopy 
demonstrated that PDT treated Jurkat cells exhibited typical apoptotic features such as cell 
shrinkage, chromatin condensation and importantly apoptotic body formation.  
The molecular mechanism of bleb-like structure formation was investigated by the Lane group 
(Lane et al., 2005). They showed the pathway of apoptotic body formation was attenuated if 
actin (LutrunculinA), myosin II (Blebbistatin), or caspace-6 activity (zVEID.fmk) inhibitors were 
added to dying HeLa cells following anisomycin treatment. They presented images of apoptotic 
bodies in HeLa cells that contained ER structures (indicated by strong staining of anti-calnexin 
antibody in membrane layer) and also condensed fragments of chromatin visualised by DAPI 
staining. Prior to apoptosis induction, the pre-incubation of HeLa cells with each inhibitor 
individually reduced the occurrence of apoptotic bodies. They suggested that microtubule 
motors and caspase-6 activity are required for remodelling of chromatin and ER structure that 
is encapsulated by the plasma membrane consequently leading to formation of apoptotic 
bodies. These observations are consistent with my data obtained by confocal microscopy, 
where the condensed chromatin and ER in UVC treated HeLa ER-E/T transfectants were shown 
to undergo inclusion within large plasma membrane blebs. However, in my study, the 
occurrence of green bleb-like structures not only confirms that HeLa transfectants died by 
apoptosis, but more importantly, that the intracellular E/T antigen surface remodelling might 
now be accessible for B cell extraction. This observation was essential for further experiments 
requiring specific-B cells.  
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7.3. Implications for anti-tumour immunity of understanding the 
molecular mechanisms involved in intracellular antigen relocation  
 
Apart from CRT and a few other proteins currently reported to relocate following chemo or 
radiotherapy (Chapter 1), there is a great need to perform more advanced studies identifying 
and classifying novel tumour antigens originally derived from intracellular compartments. In 
particular, understanding the molecular mechanisms of intracellular tumour antigen relocation 
will allow better control and consequently the elimination of growing tumours. Currently, Kepp 
et al. showed that CRT surface exposition following anthracycline or oxaliplatine treatment 
was due to eukaryotic initiation factor 2 (eIF2) phosphorylation by eIF2kinase PERK and 
inhibition of eIF2 phosphatase (composed of the catalytic subunit (PPI) and the regulatory 
subunit (GADD34)) (Kepp et al., 2009). Using a commercially synthesised peptide disrupting of 
PPI/GADD34 complex, they demonstrated that following anthracyclines treatment HeLa cells 
had both reduced enzymatic activity of the PPI subunit and significantly had increased 
phosphorylation of eIF2 that consequently led to CRT surface exposition. Surprisingly, they 
showed that a disruption PPI/GADD34 complex peptide could also stimulate CRT exposure 
without chemotherapeutic inducer. Therefore, these in vitro findings indicate that using a 
protein inhibiting eIF2 phosphatase, CRT-mediated tumour immunogenicity might be elicited 
without cytotoxic side effect and eventually could be beneficial for patients. However, future 
studies which will focus on role of B cells as APC recognising CRT or other relocated tumour 
antigens need to be addressed. Based on the many examples described in Chapters 1, it is 
possible that B cells may prove to be an alter population of APC recognising relocated tumour 
antigens. Furthermore, studies performed by Tesniere et al. demonstrate that colon cancer 
patients who lack functional TLR4 (receptor expressed by DC that mediates the recognition of 
relocated tumour antigen) had a reduced survival rate compare to patients with functional 
TLR4. Therefore, in such situations it is important to look at the role of B cells as an alternative 
population of APC recognising tumour antigen differently (BCR-mediated) rather than via non-
specific TLR4 binding (Tesniere et al.).  
Results obtained during this project represent only an initial analysis of the possible role of B 
cells as APC that need to be explored further. Therefore, in the future, it may be worthwhile to 
generate panel of CRT or TAA-specific B cells recognising relevant antigens and to test it in in 
vivo models of B cell-mediated immunity following UVC or anthracycline treatment.  
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7.4. The physiological consequences of antigen recognition by specific-B 
cells from the surface of target cells 
 
To investigate the immunogenic potential of apoptotic cells monitored by antigen-specific B 
cells, I established several in vitro models. Firstly, I examined whether E/T derived from 
apoptotic HeLa cells will be acquired by antigen-specific B cells and visualised using flow 
cytometry.  
Based on my previous observations using confocal microscopy, that following UVC treatment, 
intracellular E/T expressed by HeLa transfectants relocated to cell surface, I speculated that 
relocated E/T antigen would be acquired by TTCF-specific B cells. Therefore, the detection of 
extracted E/T antigen by specific B cells should be visible using flow cytometry. Indeed, when 
experiments gating on B220 +ve cells were performed, I demonstrated that specific B cells (but 
not non-specific B cells) incubated with apoptotic E/T HeLa transfectants, selectively acquired 
green fluorescence. Such experiments, to my best knowledge, are the first ones to 
demonstrate the acquisition of UVC-induced relocated intracellular antigen by B cells using 
fluorescence cytometry. In addition, to test whether relocated E/T acquired by TTCF-specific B 
cells was subsequently processed and complexed with MHC class II molecules, I performed a 
functional bio-assay measuring TTCF-specific T cell stimulation. This required a generation of 
new H-2d restricted TTCF-specific T cell hybridomas. Therefore, I fused ex-vivo T cells (isolated 
from lymph nodes from E/T immunised mice) with the BW 5417 T cell lymphoma fusion 
partner. Using this new reagent allowed me to establish a novel antigen presentation assay 
that tested the biological consequences of E/T acquisition from apoptotic HeLa cells by B cells. 
In particular, I quantified the IL-2 production by antigen-specific CD4+ T cells following 
incubation with B cells that had been pre-incubated with mem-E/T HeLa transfectants for 
various time periods.  
Somewhat surprisingly, I showed using both techniques (flow cytometry and antigen 
presentation assay) that membrane-tethered antigen acquisition can occur very rapidly. In 
particular, incubation for time periods as short as 1 min was sufficient to detect BCR-mediated 
E/T acquisition by TTCF-specific B cells. Additionally, this level of antigen acquisition was 
sufficient for maximum CD4+ T cell stimulation.  
These findings are consistent with, and extend observations from different groups 
demonstrating BCR-mediated antigen acquisition is very rapid. For example, Batista et al., 
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using confocal microscopy was able to visualise synapse formation between HEL-specific B 
cells and various HEL expressing target cells in times of approximately 10 min. Furthermore, 
serial optical sections of fixed and permeabilized B cells removed from the target cells, 
indicated that HEL-specific B cells internalized extracted HEL antigen (Batista et al., 2001). Flow 
cytometry analysis of these B cells also showed upregulation of CD86 as a result of antigen 
acquisition. However, these studies did not test the physiological aspect of surface tethered 
antigen extraction. This has been successfully demonstrated in this project, that specific-T cell 
hybridomas are able to respond to antigen attached to the surface of other cells – target cell. 
Furthermore, by introducing 0.4 M blocking filters, I confirmed BCR-mediated E/T acquisition 
is a contact-dependent process. In contrast, soluble antigen can be recognised and presented 
by TTCF-B cells to specific CD4+ T cells with or without blocking filters equally, as the soluble 
TTCF is able to penetrate across the 0.4 m blocking filters. These findings extend those of the 
Batista laboratory showing that the incubation of target cells expressing mem-HEL and 
separated by a mesh from HEL-specific B and T cells, abrogated antigen recognition, but not if 
soluble HEL was added to the those B and T cells (Batista et al., 2001). Importantly, Batista’s 
studies did not examine B cell acquisition of antigens relocated from intracellular 
compartments. Therefore, this project demonstrates for the first time that following the 
induction of the previously described immunogenic apoptosis, HeLa transfectants relocate 
intracellular antigens onto the cell surface as integral part of apoptotic bodies. Importantly, I 
have also demonstrated that this form of tethered antigen can be extracted by immuno-
specific B cells and presented to cognate CD4+ T cells.  
The majority of current studies examining the consequences of apoptotic cell death focus on a 
role for DC or macrophages engulfing apoptotic cells leading to cross-presentation and CTL-
mediated immunity (Gregory and Devitt, 2004). However, this project for the first time 
demonstrate that B cells act as APC and stimulate CD4+ T cell-mediated response for antigens 
derived from apoptotic target cells. Therefore, these studies reveal a previously un-described 
aspect of B cell biology. In particular, the ability of B cells to initiate CD4+ T cell responses 
against antigens expressed in intracellular compartments of tumour cells. Furthermore, 
understanding the mechanism of how TIB penetrate tumour sites needs to be clarified. As 
previously described in Chapter 1 (Section 1.2.2.), it is possible for DC to convert (in a tumour 
microenvironment) to become tolerogenic leading to a state of tumour immunosuppression. 
Therefore, identification of the key feature which allows better activation and recruitment of 
tumour-specific B cells before homing at the tumour site may improve tumour antigen 
recognition and consequently may cause more effective anti-tumour immunity. 
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Studies performed by Pages et al. representing a large cohort of patients with colorectal 
tumours (approximately 1000 patients) showed that a high frequency of tumour infiltrating T 
cells had cytotoxic and memory phenotypes, They also showed that the presence of TIB was 
significantly predictive of a favourable clinical outcome (Pages et al.). In particular, they 
demonstrated that tumour infiltration by B and T cells was strongly correlated with DC 
expressing high level of lysosomal-associated membrane protein (Lamp). They suggested that 
Lamp+ DC are involved in tumour antigen presentation by recruitment naive B and T cells in 
adjacent tertiary lymphoid organs (such as GALT, MALT or BALT) as primary sites of tumour-
initiated immune reaction.  
Based on the above mentioned findings and results presented in Chapter 6, it may be likely, 
that following UVC treatment, TIB might be activated in adjacent tertiary lymphoid organs by 
DC resulting in the activation of the adaptive anti-tumour immunity. Therefore, the 
explanation of the role of B cells in recognising relocated tumour antigens may be a very 
promising approach to anti-tumour therapy and requires further investigation.  
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7.5. Summary 
 
The underlying concept behind this project was to examine the possible role of B cells as APC 
in the induction of anti-tumour immunity. In particular, I have examined the ability of B cells to 
recognise intracellular antigens that have relocated following the induction of the apoptosis by 
anthracyclines and UVC. I have shown that these relocated antigens are acquired by antigen-
specific B cells for processing and presentation that consequently can elicit anti-tumour CD4 T 
cell-mediated immunity.  
This was performed by the establishment of several novel in vitro systems. The first was 
engineering a panel of plasmids expressing a model antigen in various sub-cellular 
compartments of HeLa cells. Subsequently, optimisation of the apoptotic conditions inducing 
the intracellular protein relocation to the cell surface was achieved. Finally, using antigen-
specific B and T cells, I was able to demonstrate CD4+ T cell activation following recognition of 
relocated intracellular antigen.  
In conclusion, the in vitro studies described in this thesis demonstrate a ‘proof of principle’ 
that B cells are capable of acting as effective APC leading to a generation of anti-tumour 
immunity. Therefore, better understanding of the molecular mechanisms inducing surface 
antigen relocation may find potential implantation in the clinic. In particular, characterisation 
of the signaling pathways that drive intracellular E/T relocation to the surface needs to be 
understood. Further studies involving organelle fractionation and co-immunoprecipitation to 
allow the identification of proteins essential in the process of E/T relocation should be 
performed. Based on the previous studies by Kepp et al., 2009 (discussed in Chapter 7.3.) 
comparing whether such proteins e.g. ERp57 that co-locate with CRT relocations or eIF2a that 
initiates CRT relocation, also participate in intracellular E/T relocation should be performed. In 
addition, further characterisation of stimuli inducing immunogenic apoptosis with reduced 
harmful side effects needs to be carried out.  
Following these in vitro studies, the next step to understand the role of B cell-mediated anti-
tumour immunity could involve the development of a more physiological in vivo model. 
Indeed, during the final stages of my studies, a report has shown a requirement for B cells in 
the induction in anti-tumour immunity in a mouse model (Dilillo et al.). In this study, B cell 
depleted mice challenged with B16 melanoma were shown to have enhanced tumour growth 
and metastasis compared to control mice. Furthermore, the number of CD4+ memory and 
CD8+ effector T cells were both shown to be reduced in tumour challenged B cell depleted 
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mice. These studies imply that B cells are directly required for cellular response against B16 
melanoma in vivo. However, this study did not address the role of B cell APC-function. This role 
could be addressed in B cell deficient mice challenged with B16 melanoma cells expressing the 
model antigen (E/T) used in my study for example. This would involve analysing E/T specific T 
cell populations from such animals and therefore may provide additional evidence for role of B 
cells as APC in anti-tumour immunity. 
Thus, I envisage that following the induction the immunogenic apoptosis B cell-mediated 
immunotherapy may have an enhanced effect on tumour elimination and consequently may 
improve the quality of life and extend the survival rate of cancer patients in the future. 
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-  8. Materials and methods  - 
 
 
8.1. Materials  
 
8.1.1. Antibodies  
 
The following antibodies were used for both Western blotting (WB), immunofluorescence (IF) 
and flow cytometry (FACS): 
Table 8.1. Primary antibodies. 
Antigen Antibody name Source Dilution and 
application 
hen egg lysozyme 
(HEL) 
HyHEL10 (mouse) 
1mg/ml 
Knight lab 1/100: IF 
HEL HEL (rabbit) Sigma 1/5000: WB 
c-Myc 9E10 (mouse) supernatant Knight lab 1/10: WB 
green fluorescent 
protein (GFP) 
-GFP (rabbit) Sigma 1/2000: WB 
B220 directly labelled -B220-
PerCP (rat) 
BD Pharmingen 1/100: FACS 
CD4, directly labelled CD4–
FITC and PE (rat) 
BD Pharmingen 1/100: FACS 
CD8 directly labelled -CD8-
FITC and PE (rat) 
BD Pharmingen 1/100: FACS 
TCR directly labelled -TCR-
FITC (rat) 
BD Pharmingen 1/200: FACS 
TCR V type 2-17 directly labelled (FITC) 
antibodies from different 
species 
BD Pharmingen TCR V taping : FACS 
 
HRP-conjugated secondary antibodies were from Sigma (anti-rabbit 1/5000) and BD 
Pharmingen (anti-mouse 1/2000, anti-human1/2000) and fluorescently conjugated antibodies 
(FITC or TRITC) were from Molecular Probes, Sigma Aldrich, and ImmunoResearch (1/100 
dilution).  
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8.1.2. Oligonucleotides 
 
PCR primers were designed based on known nucleotide specific sequences of HEL or EGFP-
TTCF. Oligonucleotides were synthesised by MWG Biotech and HPLC purified. Some of the 
primers contain the appropriate restriction enzyme recognition sites (underlined). The forward 
primers specific for the sense DNA strand are donated ‘F’ and reverse primers, specific for anti-
sense DNA strand are donated ‘R’. 
Table 8.2. Primers for recloning HEL and TTCF including the various restriction sites. 
Primer Sequence 
5’Nco1-HEL(cyto) 5’-CCA TGG GGA AAG TCT TTG GAC GAT GT-3’ 
5’Pst1-HEL(mito) 5’-CTG CAG AAA GTC TTT GGA CGA TGT-3’ 
5’Not1-HEL(mitoGFP) 5’-GCG GCC GCA AAA GTC TTT GGA CGA TGT GAG-3’ 
3’Not1-HEL 5’-GCG GCC GCC AGC CGG CAG CCT CTG ATC CA-3” 
5’EGFP Pst1 5’-CTG CAG ATG GTG AGC AAG GGC GAG GAG -3’ 
3’TTCF Not1 5’-GCG GCC GCG TCG TTG GTC CAA CCT TCA TC -3’ 
EGFP Seq 3F 667 5’-CTG AGC ACC CAG TCC GCC CTG-3’ 
TTCF Seq 4F 967 5’-TCT GAA GTT ATC GTG CAC AAG -3’ 
TTCF Seq 5F 1267 5’-TGG GTT TTC ATC ACT ATC ACT -3’ 
TTCF Seq 6F 1567 5’-ATC CCG GTA GCT TCT AGC TCT -3’ 
TTCF Seq 7F 1867 5’-GCT CCG GGT ATC CCG CTG TAC -3’ 
 
 
8.1.3. Bacterial strains 
 
E. coli strain Application Source 
TOPO10 One Shout 50 l Invitrogen 
 
The Invitrogen One Shot® TOP10 chemically competent E.coli (genotype F- mcrA ∆(mrr-
hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆ (ara-leu)7697 galU galK rpsL (StrR) 
endA1 nupG)) were used for cloning and propagating DNA. The chemically competent, 
ampicilin resistant cells were used to amplify the DNA of each generated plasmids. TOPO10 
One Shout E.coli cells used to clone blunt ends (Invitrogen) were kanamycin resistant.  
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8.1.4. Plasmid constructs used for HEL and EGFP-TTCF (E/T) sub-cellular compartment 
expression  
 
The following constructs were used: 
Table 8.3. Constructs used in this study.  
Construct Source 
pCMV-cyto-HEL Gift from S. Ostrand-Rosenberg 
pCMV-mito-HEL Gift from S. Ostrand-Rosenberg 
pCMV-nuc-HEL Gift from S. Ostrand-Rosenberg 
globulin–mem-HEL Gift from F. Batista 
pCMV-mito (-SS)-HEL This study 
pCMV-mito-GFP-HEL This study 
pCMV-cyto-(-SS)-HEL This study 
pCMV-mito-GFP Invitrogen 
pCMV-cyto-EGFP Clontech 
pCMV-cyto-E/T This study 
pCMV-ER-E/T This study 
pCMV-mito-E/T This study 
globulin–mem-E/T This study 
 
Plasmids no. 1, 2 and 3 were kindly received from S. Ostrand-Rosenberg and no. 4 from F. 
Batista. Constructs no. 5 and 6 were re-cloned from the original vector pCMV-mito-GFP (no. 8 
(Invitogen)) by insertion or replacement the GFP part to HEL, thereby I received pCMV-mito-
GFP-HEL or pCMV-mito-HEL. Plasmid pCMV-cyto-HEL (no.7), was generated by replacement 
the EGFP part from cyto-EGFP plasmid (no. 9 (Clontech)) for HEL sequence. Plasmids no. 10.-
cyto-E/T, 11.- ER-E/T, and 12.-mito-E/T, were engineered from the original pShoover plasmids 
(Invitrogen): pCMV-cyto, pCMV-ER and pCMV-mito by introduction into the cloning side 
(N’Pst1 and C’Not1’) the E/T sequence. Constructs no. 13 was made from the commercial 
pCMV-ER (Invitrogen) by inserting E/T sequence and fragment of DNA encoding the 
transmembrane and cytoplasmatic domains of the mouse MHC class I molecule, H-2Kb.
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8.1.5. Cell lines  
 
Cell lines Name Characteristic Reference: 
B cell lines 
A20 - non-specific B 
cells 
mouse IgG2a, B220+, H-2d B cell 
lymphoma 
(Kim et al., 1979) 
A20-TTCF -TTCF-
specific B cells 
mouse IgG2a, B220+, H-2d B cell 
lymphoma expressing TTCF-specific BCR 
Andrew Knight 
T cell lines 
MC-52 TTCF-specific 
T cells 
mouse CD4+, CD8-, H-2d restricted, 
recognizing 17-mer peptide of TTCF in 
position 1120-1137 T cell lymphoma 
expressing TTCF- specific V2 TCR 
This study  
CTLL-2 mouse IL-2 dependent T cell hybridomas 
(Gillis and Smith, 
1977) 
Others 
HeLa human epithelial carcinoma cells line George Otto Gey 
J774 mouse peritoneal macrophage cell line 
(Ralph and Nakoinz, 
1975) 
 
 
8.1.6. Proteins and peptides 
 
A panel of 88 overlapping peptides spanning the TTCF sequence was used to characterize the 
antigen-specific T cell hybridomas MC-52. These 17-mer peptides were a kind gift from Colin 
Watts (Dundee University).  
Recombinant EGFP-TTCF (E/T) protein were isolated by Andrew Knight from transformated 
E.coli K-12 derivative, OrigamiTM (DE3) pLysS (Novabiotech) with previously generated bacterial 
expression plasmid encoding EGFP-TTCF sequence and flanked on N’ terminal end by 10 
histydyne residues. 
 
 
8.1.7. Apoptotic regiments 
 
Doxorubicin (DX) - doxorubicin/adriamycin hydrochloride was parched from Fluka.  
Mitoxantron (MX) - mitoxantrone dichydrochloride was parched from Sigma-Aldrich.  
Staurosporin (STS) - from Streptomyces sp. was parched from Sigma-Aldrich. 
In order to induce UVC light – the special lamp was built in the purpose of this project. The 
lamp was calibrated to delivery 0.2 mJ of UVC /cm2/s.  
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8.2. Methods  
 
 
8.2.1. DNA manipulation  
 
8.2.1.1. Preparation of plasmid DNA  
 
Plasmid purification on a small or large scale was performed with the Qiagen Miniprep or 
Maxiprep kit, respectively. Bacteria were grown over night at 37oC in 2.5 ml or 250 ml cultures 
containing the appropriate selection antibiotic. After centrifugation, plasmid DNA was 
prepared as per manufactures instruction. DNA concentrations/purity were quantified in a 
spectrophotometer at a wavelength of 260/280 nm after dilution in H20.  
 
 
8.2.1.2. Polymerase Chain Reaction (PCR)  
 
PCR reactions were carried out in 50 l reactions containing 100 ng template cDNA, 2 nM 
dNTPs, forward and reverse primers (5 g/ml) and 1 unit Taq or PFX polymerase using the 
following cycles using Thermocycler ‘Alpha Unit Block Assembly for PTC DNA’ (Bio-Rad, Model 
PTC-200) machine: 
              1 cycle          Initial denaturation        94 C, 2min 
                                    Denaturation                   94 C, 15 sec 
                                    Annealing                         55 C, 30 sec 
                                    Extension                         68 C, 1 min 
              1 cycle          Final extension               68 C, 10 min 
 
 
8.2.1.3. Restriction digestion 
 
Restriction digests were carried out in 20 l reactions containing a minimum of 1 g DNA, 5 
units restriction enzyme (New England Biolabs), 2 l 10x restriction buffer supplied and  
100 g/ml BSA. Samples were incubated at 37oC for 1-4 h before the reaction was stopped by 
adding 4x sample buffer (Bromophenol blue in 50% glycine, 1 mM EDTA pH 8.0). 
30 cycles 
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8.2.1.4. DNA agarose gel electrophoresis  
 
Both restriction digests and PCR products were analysed by agarose gel electrophoresis. 
1.2 % agarose was dissolved in TAE buffer (Tris-HCl pH 8.0, 20 mM acetic acid, 1 mM EDTA). 
Ethidium bromide (5 g/ml) was added to a final concentration 0.5 g/ml. Samples were 
mixed with 4x sample buffer and separated in TAE at 110 Volts (V) constant.  
 
 
8.2.1.5. Gel purification of DNA fragments  
 
DNA fragments were cut from agarose and the DNA isolated and purified from the gel slice 
using the QIAquick gel extraction kit (Qiagen) according to manufacturing protocols.  
 
 
8.2.1.6. Ligation  
 
Gel purified cDNA and vectors were mixed at a molar ratio of approximately 5:1. Before 
ligation, vectors were dephosphorylated using calf intestinal phosphatase (CIP) (New England 
Biolabs). Ligation was carried out with T4 ligase (New England Biolabs) in 14 l reactions for 
either 2 hours at room temperature or overnight at 16oC. 1 l or 3 l ligation was transformed 
into E. coli (TOPO10 Invitrigen).  
 
 
8.2.1.7. Bacterial transformation  
 
Cells were transformed chemically, based on manufacturer’s recommended protocols. Briefly, 
after thawing 50 l aliquots of competent TOPO10 cells were mixed with either 3 l or 1 l 
ligation product or 10 ng plasmid and incubated on ice for 15 min. Cells were transformed by 
heat-shock at 42oC for 60 seconds. The 200 l of pre-warmed (to 42oC) SOC medium was 
added and the reaction was incubated at 37oC for a further 1 hour. Bacteria were plated out 
on LB agar plates containing either kanamycin (50 g/ml) or ampicilin (50 g/ml) antibiotics 
and incubated overnight at 37oC to allow colonies to form. 
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8.2.1.8. Screening and expansion of bacterial colonies 
 
Single bacterial colonies were expanded in order to isolate sufficient. A sterile tip was used to 
inoculation individual bacterial colonies for analysis. Inoculated colony with 5 ml of LB 
containing appropriate selective antibiotics were cultured overnight at 37oC with shaking for 
expansion. On the next day 0.5 ml of culture was used to inoculate 250 ml of new LB medium 
and 18 h later the plasmid DNA was isolated using MaxiPrep (Qiagen). Following DNA isolation 
the correctly replicated plasmid was identified by PCR amplification and restriction digestion 
and bi-directionally sequencing (Lark) prior to use.  
 
 
8.2.2. Cell culture  
 
8.2.2.1. Maintenance of mammalian cells  
 
HeLa cells were g
kanamycin and 2mM glutamine, 1mM sodium pyruvate (Invitrogen), non-essential amino acids 
(Invitrogen), and 50 M -mercaptoethanol (Sigma-Aldrich), at 37oC in an atmosphere of 5% 
CO2. For passaging cells were washed once with fresh RPMI and incubated at 37
oC in 5% CO2 in 
0.05% trypsin (Invitrogen) until cells detached from the plastic. They were then either split into 
new flask or seeded into plates at the desired cell number.  
 
 
8.2.2.2. Transient transfection  
 
Transient transfection of HeLa cells expressing HEL was carried out using Lipofectamine 2000 
(Invitrogen) according to manufactures instruction. Approximately 0.8x105 or 2.5x105 cells 
were seeded in either 24 or 6-wells plates respectively containing glass coverslips (for IF). 
Growth medium was changed to growth medium lacking antibiotics one hour before 
transfection. The next day transfectants were either lysed (for WB) or analysed for IF. 
As Lipofectamine 2000 demonstrated high cytotoxic effects of on HeLa transfectants when 
using HEL plasmids, I decided use a different lipolityc cationic polymer TurbofectTM (Fremantes) 
which showed less cell death for the TTCF constructs used subsequently. This polymer forms 
complexes with negatively charged DNA. The transfection efficiency using 2 l of Turbofect 
from 1 g of DNA on 1x105 HeLa cells was routinely more than 80%. The detailed steps of 
transfection were performed according to manufacturer’s protocols. 
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8.2.2.3. Stable transfection 
 
In order to generate stable cells lines 0.8x105 HeLa or J774 cell lines were transfected by 
different constructs expressing HEL or E/T constructs with also curry gene of neomycin (G418) 
resistance. One week later, the single clones’ dilution was made and such single cells were 
then plated out in 96-well plates. Such single cells were cultivated for the next 2weeks in RPMI 
supplemented with G418 1mg/ml allowing selection only the clones, which expressed desired 
construct. Two weeks later selected survived colonies were picked up and divided on the two 
groups: one group which was analysed on microscopy in order to visualised E/T expression and 
second one was expanded and kept as a backup.  
 
 
8.2.3. Analysis of protein expression and sub-cellular localization 
 
8.2.3.1. Indirect immunofluorescence  
 
Following fixation with PFA 3% for 20 min at room temperature, HeLa cells were rinsed three 
times with PBS and incubated for 15 min in 50 mM NH4Cl to neutralize PFA. PBS-washed cells 
were then permeabilized in 0.1%-TX-100/PBS for 4 min at room temperature and washed 
again. Coverslips containing cells were then inverted onto 50 l drops of primary antibody 
(mouse anti-HEL: HyHEL 10; diluted in PBS/2% FCS) and incubated at room temperature for 1 
h. Cells were washed three times and the antibodies were visualised with anti-mouse FITC or 
TRITCI secondary antibodies (ImmunoResearch, Sigma) after incubation at room temperature 
for an additional 1 h. Finally, the cover slips were inverted onto slides containing a drop of the 
mounting/anti-fade medium CitiFluor (Agar Scientific) and analysed using either a Leica 
Microsystems (Heidelberg GmbH) confocal or fluorescence microscope. Three emission 
spectra were used for different dyes: TRITC or MitoTracker Red-excitation 543nm, emission 
580 nm; FITC-excitation 488 nm, emission 510-535nm; Hoechst 33342-excitation 343 nm, 
emission 483 nm, Alexa Fluor 594-excited 594 nm, emission 617 nm. Combined maximum 
intensity of fluorescence was measured by Leica TCS SP2 UV confocal laser scanning 
microscope (LSM) Leica Microsystem using a MCX Plan Apo. Na. software. The 0.85x40 or x60 
magnification lenses were used and images were analysed by LCS 2.61 software with help and 
assistance of Trevor Booth.  
The images from fluorescence microscopy were generated using Laica Microscope Type 020-
919.509 LB 100 TB. and SPOT Advanced Software by permission of Dr. Mark Birch. 
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8.2.3.2. MitoTracker Red labeling 
 
To visualise mitochondria MitoTracker Red (Molecular Probe, 200 nM) was used. This red 
fluorescent dye (tetramethylrhodamine) is selectively concentrated by active mitochondria 
due to its positive charge. Viable cells that have active mitochondria with considerable 
membrane potential will pick up and concentrate the dye in the mitochondria. MitoTracker is 
well-retained even after fixing and permeabilization. MitoTracker Red was added to HeLa cells 
for 20 min at 37oC and cells were then washed extensively with cRPMI and before fixation with 
3% paraformaldehyde (PFA) in phosphate buffer saline (PBS) for 20 min at room temperature 
and performed as previously described to visualise slides on microscopy.  
8.2.3.3. Hoechst and WGA staining 
 
After staining with antibodies cells were treated with 5 g/ml of the DNA dye Bisbenzimide H 
33342 (Hoechst 33342; Sigma). Hoechst 33342 is a cell membrane-permeable dye that 
intercalates in the A-T regions of DNA and produces a blue fluorescence under a UV filter. 
Additionally, in order to distinguish plasma membrane structures in HeLa cells, the red-
fluorescent Alexa Fluor 594 wheat germ agglutinin (WGA) was used. Not-permeabilized HeLa 
cells following 10 min incubation with 5 l/ml of WGA, incorporated dye, which binds 
selectively to N-acetylneuraminic (sialic) acid residues of cell membrane.  
 
8.2.3.4. Preparation of cell lysates and SDS-polyacrylamide gel electrohoreisis 
 
Approximately 1x105 HeLa cells were remove from plates by incubating in 5 mM EDTA/PBS for  
5 min at 37oC. Detached cells were spun down for 5 min at 8000 rcf and lysed for 30 min at 4oC 
in 1% Triton X-100, 1x TBS, plus protease inhibitor cocktail (Sigma P-8340). Nuclei acids and 
insoluble debris was removed from lysates by re-spinning 25 min, 16 000 rcf. Protein 
concentration was determined based on initial number of cells. Samples were mixed with 4x 
SDS-sample buffer (12.5 ml 1M Tris-HCl pH 6.8, 30 ml 20% SDS, 20 g glycerol, 2 ml 1% 
Bromophenol Blue) and 100 mM dTT. Before loading, samples were boiled for 5 min. Equal 
amounts of protein based on the number of cells were loaded per lane and separated on 14% 
SDS-PAGE gels using 100 V constant for 15 min, then 120 V until the dye front reached the 
bottom of the gel.  
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8.2.3.5. Western blot immunodetection  
 
After SDS polyacrylamide gel electrophoresis, proteins were transferred onto nitrocellulose 
(Hybond, Amersham Pharmacia Biotech) at 0.35 Amperes (A) for 90 min. Gel and nitrocellulose 
membranes were embedded in a sandwich of 3 sheets 3mm Whatman paper and two pads on 
each side. The membrane was then blocked in 0.2% Tween 20 in 1x PBS containing 5% dried 
milk for 1 hour and probed with appropriate primary antibodies. Following extensive washing 
(3x10 min., PBS/0.02% Tween), HRP-conjugated antibodies were added and SuperSignal West 
Pico Chemiluminescent were used to detect primary antibodies (Table 8.1.) 
 
 
8.2.4. Determination of cell death 
 
8.2.4.2. Annexin V staining 
 
Annexin V-FITC is a sensitive probe for identifying apoptotic cells, binding to negatively 
charged phospholipid surfaces with high affinity for phosphatidyl-serine (PS). Annexin V 
binding is calcium dependent and defined calcium and salt concentrations are required for 
optimal staining. This reagent was to identify apoptotic cell by: 
 
 microscopy 
Approximately 1x105 treated HeLa cells were grown on a round cover glass of 13mm diameter 
(VWR International) in 24-well plates. Following three times washes in 1X binding buffer (10x 
binding buffer: 0.1 M Hepes/NaOH (pH 7.4) (Invitrogen), 1.4 M NaCl (Sigma-Aldrich), 25 mM 
CaCl2 (Sigma-Aldrich)) and sterilized by 0.2 m filterers, the cover slips with HeLa cells were 
placed onto laboratory film (Parafilm M) containing 5 l drop of Annexin V-Cy5 (BD 
Pharmingen). Following 20 min incubation at RT in dark cover slips were mounted in anti-
fadent solution (CitiFluor) and analysed on confocal microscopy using filters for Cy5 
fluorochrome.  
 
 flow cytometry  
Following various treatments, HeLa cells intensively washed in cold PBS and approximately 
1x106 /ml of HeLa cells were re-suspended in 1X binding buffer (as above). Then, 100 l of 
solution (1x105 of cells) were transferred to round-bottomed 96-wells plate with 5 l of 
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annexin V-FITC (BD Pharmingen). Following incubation at RT in the dark for 15 min, 400 ml of 
1X binding buffer was added and 10 000 cells collected by flow cytometry. 
 
8.2.4.1. MTT test 
 
MTT test is laboratory standard colorimetric assay for measuring cell viability, based on 
reduction of yellow MTT substrate to purple formazan in the mitochondria of living cells. 
Drug or UVC-treated HeLa were cells cultivated on 24 well plates. Cell viability was ascertained 
by adding to dying HeLa cells 30 µl of MTT stock solution (25 mg MTT [3-(4,5-dimethyldiazol-2-
yl)-2,5 diphenyl Tetrazolium Bromid] (Sigma Aldrich), 5 ml PBS (pH 7.4) and sterile filtered) 
diluted in 270 µl of fresh RPMI. Followed 2h incubation in 5% aspirated CO2 incubator, the 
equal volume lysis solution (50% DMF [N,N-dimetyloformamid] (Sigma-Aldrich), 2.5% acetic 
acid (Fisher Scientific), 2.5% HCl (Fisher Scientific), 20% SDS (Sigma-Aldrich)) was added to 
every well. Followed 4h incubation the 100ml of supernatant containing lysed cells was 
transferred into the new 96-well plate in the triplicate wells for each sample. Using 
spectrophotometer at 570 nm wavelength the absorbance of coloured solution was measured 
and quantified in respect un-treated (100% live) HeLa cells.  
 
 
8.2.5. Immunological techniques 
 
8.2.5.1. FASC analysis 
 
Lymphocytes ware harvested from the culture and plated out at 1-5x105/ml to round-
bottomed 96-well plates and wash twice in cold FACS buffer (PBS supplemented with 2% FCS) 
by centrifugation at 400 x g for 1 min. Subsequently, 100ml of appropriately pre-diluted 
antibody was added and incubated for 1 h in dark at 4oC. The cells were washed five times and, 
if necessarily, stained with secondary antibody. Following final washing, the pellet of cells was 
re-suspended in 100 l of FACS buffer and transferred to FACS tubes containing 400 ml of FACS 
buffer. Samples were then analysed using a FACScalibur flow cytometer and CellQuest 
software (Becton Dickinson, Mountain View, CA, USA). 10 000 events were collected. The data 
analysis was carried out using FlowJo software (TreeStar Inc.). 
 
167 
8.2.5.2. T cell hybridomas generation and characterisation 
 
In collaboration with Prof. J. Robinson, and using existing bacterially expressed and purified 
recombinant E/T, Rob Steward immunized mice to generate a panel of new antigen specific T 
cell hybridomas that recognise EGFP or TTCF. The Balb/c mice were maintained in pathogen 
free environment of Medical School of Newcastle University facilities. The 9 week–old female 
were injected sub-cutaneously in the one leg with 50 m of TTCF emulsified in TiterMax 
(Sigma-Aldrich). 7days later a single cell suspension from pooled draining lymph nodes was 
incubated in 24-well plates (Grainger) at 2x106 cell/ml with 50 g/ml TTCF. After 3 days cells 
were purified using density gradient and re-plated at 0.7-1.5x105 cell/ml were re-spun with an 
equal number of similarly washed with serum-free Hanks’ balanced salt solution (Sigma-
Aldrich) over the a period of 90 s with continuous gentle agitation. The cells were diluted into 
20ml of warm Hanks balanced salt solution over 5 min with continues shaking before re-
spanning and re-suspending in 30 ml growth media. Cells were then plated out in 96-well flat 
bottomed plates (Grainger) at various dilutions. 24h later the media was supplemented with 
hypoxanthine, aminopterin, thymidyne (HAT) from Sigma-Aldrich. Two weeks later the 
selective media was removed and 60 surviving clones were tested for TTCF reactivity using 
standard proliferation bio-assay. 0.5x105 of each hybridoma was mixed with 1x105 
macrophage cell lines J774 as APCs and 1 or 10 g/ml of TTCF. The IL-2 produced by TTCF-
depended hybridomas was measured by transferring the supernatant into the fresh wells 
containing 3x104 CTLL-2 cells Those IL-2 dependent CTLL-2 T cell line was 24h prior cultivated 
in the absence of IL-2. CTLL-2 proliferation was quantified by 0.02MBq 3H-thymidyne (GE 
Healthcare) incorporation for 24h at 37oC. Plates were harvested on to printed filters mats fro 
1450 Micro Beta (Wallac Oy, Tutuku) using Harvester 96 (Tomtec).  
 
Only one clone of T cell hybridomas (MC-52) was selected and curried our further the analysis. 
Using a panel of 88 overlapping 17-mer peptides (from Colin Watts’s lab) the characterisation 
of epitope specificity MC-52 hybridomas was able. This experiment shows that MC-52 
recognising the 1120-1137 (NPLRYDTEYYLIPVASS) amino acid sequence of TTCF. Also using 
murine fibroblast expressing either H-2Ad or H-2Ed as APC in standard proliferation assay 
showed that MC-52 T cell hybridomas are H-2Ad restricted.  
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8.2.5.3. Proliferation bio-assays 
 
In the initials experiments the triplicate wells were set up in order to perform the grade dose 
of antigen (TTCF) or different number of HeLa cells which were mixed with B and T cells. In 
some experiments additionally, the blocking filters were introduced between lymphocytes and 
HeLa cells. 
The vast majority of proliferation assays focusing on antigen extraction or relocated antigen 
recognition were performed using modified version of bio-assay. Firstly, 1x105 of B cells were 
stimulated by 1x105 HeLa transfectants growing in 24-well plates. Followed certain period of 
time ranging from 1 min to 6 h, B cells were removed and transferred into new 96-well plate 
containing 0.5x105 of T cells. Assay were then incubated at 37oC for the next 24 h in the 
presence of 5% of C02 and frozen. T cell stimulation was measured as IL-2 release by incubating 
50 l of defrosted supernatant with 5x103 IL-2 dependent CTLL-2 cells, prior starved in medium 
lacking IL-2, for 24h in incubator at 37oC. The proliferation of CTLL-2 cells was assessed by  
0.02 MBq 3H-thymidyne incorporation during 24 h (for details see above).  
 
8.2.6. Statistical analysis 
 
Data analysis was performed using Prisim5 for Mac OS X Version 5.0b (GraphPad Software 
Inc.).  
Values are expressed as +/- SEM. To evaluate the difference in means between two groups, 
the Student‘t’ test was used for parametric date. Significance was defined as P value less than 
0.05.  
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